Estimating modern contraceptive supply shares at national and subnational administration levels using Demographic and Health Survey data, with an application to the calculation of estimated modern contraceptive use.

Hannah Comiskey   Prof. Leontine Alkema   Dr Niamh Cahill

A thesis submitted in fulfillment of the requirements
for the Ph.D. degree in Statistics

at the

Hamilton Institute
Maynooth University
Maynooth, Co. Kildare, Ireland

December 13, 2023

In memory of my Nan Mairita, you would have been so proud.

Declaration

I, Hannah Comiskey, declare that this thesis titled, "Estimating modern contraceptive supply shares at the national and subnational administration level using Demographic and Health Survey data, with an application to the calculation of estimates of modern contraceptive use" , and the work presented in it are my own. I confirm that:

- This work was done wholly or mainly while in candidature for a research degree at this University.
- Where any part of this thesis has previously been submitted for a degree or any other qualification at this University or any other institution, this has been clearly stated.
- Where I have consulted the published work of others, this is always clearly attributed.
- Where I have quoted from the work of others, the source is always given. With the exception of such quotations, this thesis is entirely my own work.
- I have acknowledged all main sources of help.
- Where the thesis is based on work done by myself jointly with others, I have made clear exactly what was done by others and what I have contributed myself.

Signed: Hannah Comiskey

Date: 13-12-2023

Acknowledgements

I would like to thank my supervisor Dr. Niamh Cahill for her unwavering support, patience, and kindness over the past four years. I have enjoyed every moment of this PhD and it can only be down to your truly excellent guidance. You encouraged me everyday, giving me the confidence to trust myself and become the researcher I am today. You are a gifted teacher and researcher, and I am truly grateful for the opportunity to learn from you. I cannot thank you enough for everything.

I would also like to thank my co-supervisor Prof. Leontine Alkema. Your continued support, encouragement, and wealth of knowledge has been incredible. I learned so much from you during my time in Amherst, and I appreciate everything you did for me while I was there. Thank you so much.

I am so grateful to Prof. Ken Duffy, Prof. Claire Gormley and Prof. James Gleeson, Janet Clifford and all the staff involved in the SFI CRT in Foundations of Data Science. The support of the CRT funded my PhD and so many fantastic conferences, master classes, trips and my research visit to the University of Massachusetts Amherst.

Thank you to the Track20 Team. Your expertise and guidance has been invaluable throughout.

To Chloe, Seán, Rebecca, Aoife, and Shauna, thank you for being my biggest cheerleaders and the best friends I could ask for.

To Haydn, thank you for being my rock through-out this whole process. You are truly fantastic. Thank you, I love you.

A big thank you to my brothers Christopher and Daniel, and my wider family for listening to me and encouraging me when I needed it most.

Most importantly, a special thank you to my parents Annette and Paul for supporting me through it all. Your love, strength, wisdom, and support have been unwavering. Without you both, none of this would have been possible and I am eternally grateful.

Funding

This thesis has emanated from research conducted with the financial support of Science Foundation Ireland under Grant number 18/CRT/6049.

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-008441]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

Abstract

Contraceptive method supply shares reflect the contributions of the public and private sectors to the distribution of a given method each year. Quantifying these public/private-sector supply shares of contraceptive methods within countries is vital for effective and sustainable family planning delivery. They are useful to Family Planning officials as they show where contraceptive users have obtained their most recent supplies. Unfortunately due to the cost, many low- and middle-income countries (LMIC) are not in a position to carry out the national-scale surveys necessary to collect this data regularly. Therefore, they evaluate the contraceptive supply market using out-of-date data. Using out-of-date supply share estimates for family planning monitoring has significant knock-on effects. They may lead to inaccurate conclusions on the stability of the contraceptive supply market. In addition, the estimation of other family planning indicators that depend on method supply shares will also be inaccurate and distorted. To date, neither Bayesian nor frequentist methods have been used to estimate this important family planning indicator.

In this thesis, a methodology using Bayesian hierarchical penalised spline models for estimating modern contraceptive method supply shares, at national and subnational administration levels, for LMICs participating in the global Family Planning 2030 (FP2030) initiative is proposed. A series of Bayesian models that evaluate method supply shares using both large multi-country data sets and computationally efficient single-country data sets are described. Lastly, the impact of using national-level annual contraceptive method supply shares with uncertainty in the calculation of another key family planning indicator, estimated modern use (EMU), is evaluated.

To begin, an approach for estimating the proportion of modern contraceptive methods supplied by the public and private sectors at the national administration level using a multi-country dataset is described and evaluated. The proposed approach utilises Bayesian hierarchical modelling techniques, taking advantage of the geographic nature of the data, in combination with penalised splines, capturing the complex shape of the data over time, to produce annual estimates with uncertainty for these supply-share proportions. Global-level correlations between rates of change in method supply shares are

estimated and incorporated into the modelling approach to promote more precise estimation, even in the absence of data. This modelling approach is compared and validated against simpler modelling alternatives.

Next, the mcmsupply R package is presented. This R package combines 4 variations of the multi-country national model. The national modelling approach is extended in two directions. Firstly, the model is extended to estimate method supply shares at the subnational administration level using a multi-country subnational dataset. The motivation for this model extension is an ever-growing interest in subnational family planning indicators due to the decentalisation of family planning services in countries participating in FP2030. Utilising the knowledge gained from modelling the national-level estimates, hierarchical modelling structures of the multi-country national model are incorporated into the multi-country subnational model. Secondly, the model is extended again to estimate the method supply shares (at either national or subnational administration levels) using only the data for a single country. Similarly, informative priors informed by the multi-country model parameter estimates are used to in the single-country modelling approach. This reduces the uncertainty of survey estimates, making the estimates more precise and reliable. The single-country modelling approach is computationally efficient, without a loss of model accuracy.

Lastly, an alternative application of annual method supply share estimates in the calculation of another family planning indicator, estimated modern use (EMU) derived from family planning service statistics is demonstrated. Presently, EMUs are a stand-alone estimate without any associated uncertainty. This chapter considers the calculation process for EMUs. An updated methodology is proposed that calculates EMUs using annual method supply shares with uncertainty, rather than the existing approach that uses the method supply shares observed in the most recent DHS survey for a given country. The impact of this potential update is considered and compared against the existing approach. The benefits and strengths of the proposed update is illustrated using case studies in Country A and Country B.

Publications

The chapters contained in this thesis have been submitted to peer-reviewed journals. Chapter 2 is undergoing the second round of revisions with the *Journal of the Royal Statistical Society: Series A, Statistics in Society.* Chapter 4 has been submitted to *The R Journal* and is currently under review. Chapter 7 is in preparation to be submitted to the journal *BMJ.*

Submitted articles (under review):

- Comiskey, H., Alkema, L. & Cahill, N. Estimating the proportion of modern contraceptives supplied by the public and private sectors using a Bayesian hierarchical penalized spline model (2023). Under review in the *Journal of the Royal Statistical Society: Series A, Statistics in Society. arXiv* preprint: `https://arxiv.org/abs/2212.03844`.
- Comiskey, H. & Cahill, N. Mcmsupply: An R package for estimating contraceptive method market supply shares (2023). Under review in *The R Journal. arXiv* preprint: `https://arxiv.org/abs/2308.09434`.

Articles in prepartion

- Comiskey, H., Alkema, L. & Cahill, N. The inclusion of uncertainty into the estimation process for estimated modern contraceptive use from family planning service statistic data (2023).

Glossary

Family Planning 2030 .... A global movement dedicated to advancing the rights of people everywhere to access reproductive health services safely and on their own terms

Service statistics .... Family planning data that is collected as part of routine family planning (FP) service delivery. Service statistics are collected by the public and private sectors. Service statistics have varying levels of detail. This may include basic information like the number of family planning commodities distributed to facilities each year to more detailed information on individual characteristics of FP users [10]. Service statistics typically collect four types of FP data: contraceptive commodities distributed to FP clients, contraceptive commodities distributed to FP facilities, visits to FP facilities, and FP users.

Track20 Project .... Monitors progress towards achieving the goals of the global FP2030 initiative

Demographic and Health Survey ... "Nationally representative household surveys that provide data for a wide range of monitoring and impact evaluation indicators in the areas of population, health, and nutrition" [87].

mCPR .... Modern contraceptive prevalence rate. Captures the proportion of women aged 15-49 who are currently using any form of modern contraception. mCPR is calculated using large-scale national surveys.

EMU .... Estimates of modern contraceptive use. Captures the proportion of women aged 15-49 who are currently using any form of modern contraception. EMUs are calculated using service statistics.

SS-to-EMU .... The methodology for converting service statistics into estimates of modern use. Created by the Track20 project [80].

LAPM .... Long-acting (intrauterine devices (IUDs) and implants), and permanent methods, (female and male sterilization), of modern contraception [20].

STM .... Short-term methods of contraception (oral contraceptive (OC) pill, injectables, condoms, other modern methods, and emergency contraception).

Historic users .... The number of long-acting and permanent contraception users in existence before service statistic data collection began.

Method continuation rates .... The cumulative probability that a user of a given contraceptive method will still be using the method after one unit of time (e.g.: annually) [19].

Method mix .... The percentage breakdown by method of the distribution of contraception users for each country [21].

Historic user scaling factor .... This factor calibrates the number of historic users estimated to account for the introduction history of an LAPM into the method mix of a given country. If a country has newly introduced an LAPM, then there will be no historic users and the scaling factor will address this issue accordingly.

Couple-years protection factor ..... The average number of years protection provided to a couple by a given contraceptive method.

Family planning commodity .... This is the mode of family planning a user receives from either the public or private sector supplier.

Method-supply shares .... The proportion of each modern contraceptive method in a country supplied by the public and private sectors

Contraceptive method supply shares The proportion of modern contraceptives supplied by the public, private commercial medical and private other sectors over time.

Multi-country national model ...... This model estimates the contraceptive method supply shares at the national administration level over time for many countries simultaneously.

Single-country national model ...... This model estimates the contraceptive method supply shares at the national administration level over time for a single country.

Multi-country subnational model .. This model estimates the contraceptive method supply shares at the subnational administration level over time for many countries simultaneously.

Single-country subnational model .. This model estimates the contraceptive method supply shares at the subnational administration level over time for a single country.

List of Abbreviations

FP2020 .... Family Planning 2020 initiative

LMIC .... Low- and middle-income countries

FP2030 .... Family Planning 2030 initiative

WRA .... Women of reproductive age (15-49 years old)

DHS .... Demographic and Health surveys

OC pills .... Oral contraceptive pills

IUD .... Intra-uterine device

FP .... Family planning

SS .... Service statistics

Track20 .... Track20 project

EMU .... Estimated modern use

mCPR .... Modern contraceptive prevalence rates

FPEM .... Family planning estimation model

FPET .... Family planning estimation tool

STM .... Short term methods of contraception

LAPM .... Long acting and permanent methods of contraception

EAs .... Census enumeration areas

TMMP .... temporal models for multiple populations

MICS .... Multiple Indicator Cluster Surveys

PMA .... Performance Monitoring for Action Surveys

SAE .... Small area estimation

CAR .... Conditional auto-regressive model

ICAR .... Intrinsic conditional auto-regressive model

UNPD .... United Nations Population Division

WHO .... World Health Organisation

UNICEF ...... United Nations Children's Fund

IPUMS .... Integrated Public Use Microdata Series

LMIC .... Low- and middle-income countries

Contents

List of Figures

List of Tables

1 Introduction

1.1 Motivation

In 2012, at the London Summit of Family planning (FP2020), a commitment was made by policy-makers, government officials and the private sector to add 120 million new users of modern contraception from the world's poorest countries by the year 2020. The vision of the summit was to give women of reproductive age (WRA) the freedom to choose exactly when, and how many, children to have in their lifetime [24]. As we move beyond 2020, the goals of this London Summit have not been left behind. In fact, they have been extended to the year 2030. Today, FP2030 is a global initiative, built on the success of FP2020, that aims to advance the rights of women and children worldwide to access reproductive health services safely and on their own terms [26].

For many years, the family planning community relied on large-scale national surveys such as Demographic and Health Surveys (DHS) and the Multiple Indicator Cluster Survey (MICS) [14] [40] [2] [1] [36] to gain insight into key family planning indicators (FP indicators). Using these national surveys, they could track the variation in FP indicators such as the modern contraceptive prevalence rate (mCPR) and unmet need for contraception over time [6]. The "gold standard" of family planning survey data comes from the DHS, which have a census-like methodology and data collection approach. They use a two-stage sampling design, using census information as the sampling frame. Firstly, the country of interest is stratified such that the strata are as homogenous as possible. This homogeneity minimizes the resulting sampling errors of the survey. Within each stratum, the census enumeration areas (EAs) form clusters. The households of each cluster are listed, and a fixed number of households within the selected cluster are chosen by systematic sampling. The sample selection process uses weights to address any differences in the probability of selection. This corrects any over- or under-sampling of different clusters during sample selection. The DHS standard model questionnaires are then utilised to collect data from the selected households [18]. Unfortunately, DHS are extremely expensive to collect, and in low- and middle-income countries regular data collection is not possible. They are typically collected every 5 to 6 years in most countries, with some countries collecting a single DHS over a 30 year period [74].

In addition to monitoring mCPR and assessing unmet need, another noteworthy FP indicator is the origin of contraceptive commodities accessed by FP users. This pertains to whether these commodities are procured from public or private sectors [62]. Within the DHS, valuable data exists concerning this indicator. It manifests as the estimated proportion of women sourcing their contraception methods either from public or private sector outlets. Nonetheless, given the potential time gaps between DHS surveys, there arises a necessity for the capability to generate estimates and projections regarding the distribution of contraceptive supplies between these survey instances. This particular indicator holds significance across diverse contexts, encompassing the evaluation of FP program efficacy. However, within the scope of this thesis, our attention is directed towards leveraging this indicator to estimate modern contraceptive use among women of reproductive age using family planning (FP) services statistics.

Since 2012, the FP2020 (now FP2030) initiative has utilised data to drive decision making processes and monitor the progression of family planning goals [29]. To better manage the analysis and monitoring of data collected for the FP2020 initiative, FP2020 created the Track20 project (Track20). Track20 are a team exclusively devoted to working with, and monitoring the progress of, the participating countries of the FP2020 initiative [77]. A focus for Track20 has been the shifting of countries away from over-reliance on large-scale national surveys, such as the DHS, and towards using all available data sources. As such, Track20 developed a set of FP indicators that evolved from already-established data systems and data sources in the participating countries. One such data source are FP service statistics. FP service statistics are collected in all FP2030 countries and provide varying levels of detail. This may include basic information like the number of family planning commodities distributed to facilities in a given year to more detailed information on individual characteristics of FP users [10]. FP Service statistics are typically comprised of four types of FP data: Contraceptive commodities distributed to FP clients, contraceptive commodities distributed to FP facilities, visits to FP facilities, and FP users. Service statistics are an established but imperfect data source for producing annual estimates of FP indicators, such as modern contraceptive use, at the national and subnational administration levels [77].

Service statistics have many benefits, which make them attractive for FP programs to utilise. These benefits include being inexpensive to collect, regularly collected, and providing high geographic detail. However, as service statistics are not officially collected for the purposes of estimating FP indicators such as contraceptive use, they do not have the same rigorous collection methodologies as DHS surveys. Therefore, service statistics tend not to be standardised across countries. They are error-prone with issues with level-bias, and tend not to capture the contributions of the private sector contraceptive supply. For these reasons, Magnani et al. (2018), recommend that while service statistics are a valuable data source, they should not be used to produce stand-alone estimates of FP indicators.

However, service statistics can still be used to fill in the gaps between national-survey observations of FP indicators to inform a countries true progress towards its family planning commitments [10]. Estimated modern use (EMU) is an FP indicator derived from service statistics that aims to measure the modern contraceptive prevalence rate i.e., the proportion of women, aged 15-49, who are currently using at least one form of modern contraception [75]. As EMUs are derived from service statistics, their purpose is not to be used as a stand-alone mCPR estimate, but rather to act as a supplemental data source to inform estimates and projections of mCPR that are based on more reliable survey data sources [10]. Utilising EMUs together with national surveys to inform country-specific estimates and projections of mCPR and other family planning indicators over time has been made possible by the continued development of the family planning estimation model (FPEM) [2] [11] [33].

To aid FP2030 participating countries in their service statistics data analysis and to calculate EMUs that can be incorporated into FPEM, Track20 developed an innovative tool called the SS-to-EMU tool. It outlines a set of procedures for outputting EMUs from service statistics inputs [80]. The incorporation of EMUs into FPEM for use as a supplemental data source for estimating and projecting modern contraceptive prevalence has given service statistics a renewed purpose. It has also sparked the need to better quantify the uncertainty associated with EMUs, so that they may be incorporated into FPEM to estimate and project mCPR more effectively. The question of EMU uncertainty quantification has motivated many aspects of this thesis. We are interested in examining how the uncertainty associated with EMU point estimates can be captured using Bayesian modelling techniques, and what impact this uncertainty may have on EMU estimates. To quantify the uncertainty associated with EMUs, we must first understand the complex calculation process that is used to derive them from service statistics. The easiest way to do this is to utilise the methodology captured in the SS-to-EMU tool. Further details of the tool and a complete description of the mathematics behind the approach are described later. With the help of Track20, we critically assess the SS-to-EMU tool approach and investigate where it is possible to quantify and incorporate uncertainty into these calculations.

1.2 The SS-to-EMU process

There are four major steps within the SS-to-EMU tool when calculating EMUs from service statistics data (Figure 1.1). Below is a summary of each of the four steps. For further details on the derivation of EMUs from service statistics, please see Chapter 7.

(1) *Set up the SS-to-EMU tool*

This is the first step of the SS-to-EMU tool. It involves providing preliminary information about the service statistics data. The user lists the country of origin for the service statistics data, the administrative level the data was collected at (national or subnational), and the population of women the data reflects (all women or married women only). This information is key when integrating EMUs into FPEM. Classifying the administrative level of the service statistics data allows us to integrate subnational EMUs into FPEM, informing subnational family planning indicators. Not all countries collect data on modern contraceptive use among unmarried women. Therefore, knowing whether the service statistics data reflects the practices of all women or married women informs whether or not there is a population of women missing from the final EMU estimates.

Demographic information is also pre-loaded into the SS-to-EMU tool which the user reviews. This data includes population estimates for the number of women of reproductive age (married or all women, depending on the service statistics data collection approach) in the country. These population estimates are sourced from the most recent United Nations population division World Population Prospects and form the denominator of the final EMU [84]. Therefore, they must reflect the women recorded in the data, i.e., correctly using all women population estimates when the service statistic data reflects both married and unmarried women but using married women population estimates when only married women are collected in the data. Estimates of mCPR from large-scale national surveys including the DHS, MICS, and Performance Monitoring for Action (PMA), are also pre-loaded into the tool. These survey estimates are used to compare annual estimates and average annual growth rates of EMUs and mCPR over time. Lastly, the user provides information about the service statistics data itself. For each type of service statistics collected, the first and most recent years of data collection are listed. This range will make up the years over which the EMUs will be calculated. The source of the service statistics data and the sectors reporting into the data source (public only, public and some private or public and private) are inputted by the user. Establishing the contributions of the private sector into the data is important for the subsequent private sector adjustment step.

(2) *Calculate the number of modern contraceptive users*
To capture the true number of modern contraceptive users in a given year, it is important to account for three groups of women;
(i) Short-term method (STM) users: Women who received their short-term method (injectables, OC pills, condoms, other modern methods and emergency contraception) during the service statistics collection period and are recorded in the data.
(ii) Recorded long-acting and permanent methods (LAPM) users: Women who received their LAPM (female sterilisation, IUDS and implants) during the service statistics collection period and are recorded in the data.
(iii) Historic long-acting and permanent methods (LAPM) users: Women who received their LAPM before service statistic data collection began and are still currently this method in a given year, but are not recorded in the data.
Calculating the total number of modern contraceptive users in a given year requires adding the historic LAPM, recorded LAPM and STM users together to form one total. An estimate for the number of historic users is based on the first year of data observed in the service statistics and back-projected to give estimates for the fifteen years leading up to the first year of data. Adjustments may be made to this historic user calculation that reflects whether the use of a given contraceptive method is newly introduced that year, scaling up from previous years, or is well-established within a country. Short-term methods are also adjusted to reflect their number of users, rather than the number of commodities distributed. For example, the quantities inputted for OC pill service statistics data are divided by 15, as the typical woman uses 15 pill packets a year. The estimated total number of modern contraceptive users often excludes the contributions of condom users. It is difficult to accurately quantify the true impact of condoms as a method of family planning and they are often over-represented in the data [53]. Therefore, excluding condoms from the final estimates tends to improve the accuracy of the final EMU. To note, this total may not include the users who access their contraceptives through the private sector. Therefore, in the next step this total is scaled up to reflect the total contraceptive market.

(3) *Calculate the private sector adjustment*
It is common that when service statistics are collected, they do not capture the contributions of the private sector to family planning in part or at all. To correct

for this issue, the SS-to-EMU tool uses a private sector adjustment step. The private sector adjustment scales up the service statistics data so that it reflects both the captured public sector and the missing private sector contributions. To establish the extent the private sector is captured within the service statistics data, the private sector adjustment step uses the classification of sector's reporting into data from the initial set-up step. This sectors reporting classification controls the magnitude of the adjustment made to the service statistics data. If the private sector is completely absent, the adjustment factor will be at its maximum and if the private sector is completely captured, no adjustment is made to the data. The private sector adjustment step combines reporting rates (user-supplied information capturing the coverage of the data relative to the location it concerns) and the proportion of modern contraceptives (by method) supplied by the public and private sectors. This forms one proportion that reflects the missing private sectors share of each modern contraceptive method. It is the inverse of this proportion that scales up the service statistics data to reflect the complete contraceptive market.

(4) *Calculate the EMU.*
EMUs are calculated using the potentially scaled-up estimated number of modern contraceptive users over the population estimates for the number of women of reproductive age from the initial set-up step. This quantity represents the estimated proportion of women of reproductive age who are using any method of modern contraception in a given year.



Figure 1.1: The SS-to-EMU tool workflow when calculating an EMU from service statistic data.

Reflecting on this SS-to-EMU process, it became clear that the private adjustment factor step was the best place to begin to incorporate uncertainty into the EMUs, as it has a direct impact on the final EMU estimates and the data is readily available from the DHS (Figure 1.1). In addition, while the service statistics data were temporal in nature, the private adjustment factor was fixed over time. The current SS-to-EMU tool approach utilises the most recent DHS survey in a given country to access the contraceptive method supply shares. This is because annual estimates for the proportion of modern contraceptives supplied by the public and private sectors are not available. However as mentioned above, DHS surveys are collected on average every 5 to 6 years in low- and middle-income countries, with some countries having even larger gaps between surveys [74]. Therefore, in some instances the service statistics data and the DHS surveys have significantly different ages, resulting in private adjustment factors that may not reflect the current state of the contraceptive method supply market. This mismatch of temporal data and static adjustments can be remedied using Bayesian time-series modelling, thereby providing the inspiration and motivation for this thesis. Therefore, the focus of this thesis will now be on the statistical model development for estimating and projecting public and private sector contributions to the contraceptive method supply share market over time with uncertainty, at the national and subnational administration levels, for low- and middle-income countries using Demographic and Health Survey data.

1.3 Relevant statistical techniques

We will now describe some of the statistical techniques involved in modelling the probabilistic projections and estimates of the modern contraceptive method supply share market over time. Below is a description of each method. These methods include B-splines, hierarchical modelling, correlation estimation and Bayesian modularization.

1.3.1 B-splines

A spline is a q-order continuous piecewise function that is constructed from sections of smaller polynomials of order (q-1). The points along the x-axis where these piecewise polynomials join together are called "knots". A B-spline, or basis spline, is a set of basis functions that may be added together to give any function in the function space. B-splines are particularly useful when the function space is hard to define. The B-spline may combine many basis functions to manage this issue [95]. In this thesis, the splines used are 3^{rd} order polynomials. A feature of 3^{rd} order polynomials is that at each of the knot points, the first and second derivatives of the piecewise functions must agree with each other. This ensures that the B-spline is continuous over the x-axis. The columns of a design matrix B contain the basis functions. B is of size $n \texttt{ x } k$, where n is the number of observations and k is the number of basis functions (impacted by by the number of knots). The more knots you have in a spline, the closer the fit will be to the data. While too few knots will lead to over-smoothing of the data, too many knots will lead to over-fitting of the data and reduce a model's predictive abilities [32][34].

1.3.2 Hierarchical modelling

Hierarchical modelling takes advantage of any groups present in the data to better estimate related parameters. Usually, these related probabilistic parameters are connected by the structure of the problem. For example, the data may contain geographical information where countries may be related by sub-continental, then continental groups. The aim of hierarchical modelling is to estimate a joint probability model for these parameters that reflects how they are connected to one-another [32]. Hierarchical modelling is particularly useful when a dataset is sparse. It allows us to pool the data together, and produce higher-level well-informed hyper-parameter estimates that go on to inform lower-level parameter estimates where less data is present. In the context of this thesis, we take advantage of the geographic nature of DHS data. We pool across subnational regions, countries, and sub-continents to produce well-informed hyper-parameters even in the absence of data for particular contraceptive methods at lower geographic levels (Figure 1.2).



Figure 1.2: The hierarchical set-up utilised to estimate the proportion of modern contraceptives supplied by the public and private sectors. The data is pooled into one 'world' level parameter that is very well informed. The data is then split recursively into increasingly smaller geographic zones. The higher-order geographic levels have more data available, and as a result their parameter estimates are well-informed. These well-informed higher geographic level parameter estimates inform the priors of the lower geographic levels. When estimating national-level proportions, we do not include the provincial subnational level.

1.3.3 Correlation estimation

Correlation is defined as a measure of the linear association between two quantitative variables and is measured on a scale of -1 to 1 [73]. Complete correlation between two variables is recorded at -1 or 1 and no correlation is recorded at 0. Pearson's correlation coefficient is a common measure of correlation. It is the ratio of the covariance between two variables and the product of their standard deviations [69]. However, using Pearson's correlation estimator for estimating large numbers of pairwise correlations with limited amounts of data can lead to unrealistically strong correlation estimates. In 2018, Azose and Raftery proposed an approach for estimating large correlation matrices for international migration using a maximum *a posteriori* (MAP) estimator. Within the variable ϵ, let the MAP estimator for the correlation matrix (ρ), a matrix of size CxC, between entities i and j over time t $\in (1, .., T)$ be calculated by,

$$\tilde{\rho}_{i,j} = \frac{\sum_{t=1}^{T} \tilde{\epsilon}_{i,t}\tilde{\epsilon}_{j,t}}{\sqrt{\sum_{t=1}^{T} \tilde{\epsilon}_{i,t}^2}\sqrt{\sum_{t=1}^{T} \tilde{\epsilon}_{j,t}^2}} \tag{1.1}$$

Where, $\tilde{\rho}_{i,j}$ is the posterior sample of estimated correlations between entities i and j over time.
ϵ_t is a parameter of interest estimated at time t within a Bayesian framework.
$\tilde{\epsilon}_t$ is the estimated posterior samples of ϵ_t.

To ensure that the correlation matrix (ρ) is positive definite, we let;

$$\hat{\rho}_{i,j} = \overline{\rho}_{i,j} \tag{1.2}$$

Where $\overline{\rho}_{i,j}$ is the posterior mean of $\tilde{\rho}_{i,j}$.

In this thesis, we use this approach to estimate the correlation between the rates of change in method supply shares across time and all countries within a given sector. This allows us to incorporate a dependence structure between the method supply shares, rather than assume that the supply shares of all methods in a given sector act independently of one another. We validated this approach by comparing the out-of-sample results between national and subnational level models with and without correlation estimates.

1.3.4 Bayesian Modularization

Bayesian modularization modifies the influence of the likelihood on the prior during parameter estimation. It is particularly useful in instances when we believe parameter estimates may be 'contaminated' by unreliable data [46][60]. Bayesian modularization acts like a valve, permitting the flow of information downwards from the prior to the likelihood, but not upwards from the likelihood to the prior. This has the effect of restricting the influence of the data on model parameters. In the context of this thesis, we use Bayesian modularization to improve parameter estimation when only using data for a single country. This prevents spurious parameter estimates in instances where countries may have very few surveys available.

1.4 Literature review

The models described in this thesis fall under the classification of temporal models for multiple populations (TMMP) [71]. TMMP can be described as models that are made up of two components, the process model and the data model. The process model captures latent trends of the response variable, while the data model describes the process that generates the observed data. We utilise this approach across all of the models described within this thesis. The Fay-Herriott model is a foundational TMMP [27]. This is an area-level model where the input data is made up of smaller sub-divisions, such as counties, which are accounted for with distinct variation within the model. This model began a trend of using temporal models for small area estimation (SAE) that has continued over time and provides the basis for our proposed approaches to national and subnational contraceptive method supply shares.

Technically, only the subnational-level models would be considered to fall under the SAE model classification, because the national-level data is simply too big to be considered a 'small area'. Nonetheless, the national modelling approaches clearly have a large overlap with SAE. SAE models often use area-level data, which both our national and subnational models also use. Both SAE models and our proposed models account for the spatial dependence within the data. However, they do so in different ways. In SAEs, it is common to account for the small area effects using spatial dependence structures such as a conditional auto-regressive (CAR) or an intrinsic conditional auto-regressive (ICAR) prior [68] [43] [96]. In contrast, while our models do account for spatial dependence within the data, we do not use spatial priors. In this approach, we use Bayesian hierarchical modelling. Hierarchical modelling is a useful tool when dealing with data sparsity at lower geographic levels. It takes advantage of the geographic nature of the dataset, pooling observations together to create precise higher geographic level parameter estimates. These well-informed higher level estimates then inform lower geographic level parameter estimates where less data may be present. Bayesian hierarchical models are also used in SAE models. In Dong and Wakefield (2021), the authors utilised a Bayesian hierarchical space-time model to estimate routine immunization coverage of measels at the subnational administration level. [25]. Bayesian hierarchical modelling techniques are also used by the United Nations Population Division (UNPD) to produce world estimates of modern contraceptive prevalence (mCPR), unmet need and demand satisfied [2] [11].

The use of splines for the estimation of demographic indicators is growing in popularity. Previous studies used SAE models with splines to capture complex shapes of demographic spatio-temporal data [81] [82]. In recent years, many international health organisations have also used splines for the estimation of key demographic indicators. These include the estimation and projection of under-5 mortality for United Nations Children's Fund (UNICEF) [66] and the estimation of excess morality due to Covid-19 for the World Health Organisation (WHO) [41]. We build on these previous studies to use penalised regression splines in our models.

1.5 Thesis outline

This thesis investigates the estimation of modern contraceptive method supply shares at the national and subnational administation levels for countries participating in the global Family Planning 2030 (FP2030) initiative. It considers the application of these estimates within the derivation of estimated modern use (EMUs) from family planning service statistic data.

Chapter 2: Estimating the proportion of modern contraceptives supplied by the public and private sectors using a Bayesian hierarchical penalised spline model

We present the results of a hierarchical penalised spline model that estimates modern contraceptive method supply shares over time for thirty countries involved in the FP2030 global initiative.

Introduction: The motivation for this model is explained and discussed. A literature review classifying the model as a temporal model for multiple populations (TMMP) is discussed as well as a comparison to existing TMMP models [71]. The Demographic and Health survey data used in the analysis is explained in detail [18].
Methods: This section describes the modelling approach for estimating the proportion of modern contraceptive methods supplied by the public and private sectors at the national administration level. We use Demographic and Health survey data from 30 countries across the FP2030 initiative between the years 1990 and 2020. The approach combines Bayesian hierarchical modelling techniques with penalised splines to produce precise estimates with uncertainty for contraceptive method supply-share proportions over time. Correlations capturing the relationship between rates of change in method supply shares are incorporated into the model to promote precise informed estimates even in country-method combinations where little or no data is present.
Results: The results of this model are presented using countries where there are varying amounts of data available. An evaluation of the model estimates for the year 2023 is presented.
Discussion: The findings are discussed and the important results and advantages of using the proposed method are highlighted. The potential applications of these model estimates in the calculation of EMUs and their value as a stand-alone family planning indicator are explored.

Chapter 4: *mcmsupply*: Estimating Public and Private Sector Contraceptive Market Supply Shares

We describe the R package *mcmsupply.* This R package provides a user-friendly approach to modelling contraceptive method supply shares at national and subnational levels.

Introduction: The motivation for estimating modern contraceptive method supply shares is discussed. The reasons for, and explanations of, the extensions made to the model described in Chapter 4 are provided. These extensions include estimating the contraceptive supply share market at the subnational administration level, and adapting the national and subnational modelling approaches to use informative priors to estimate the contraceptive method supply shares for a single country. A summary of how these modelling extensions all link to one another is depicted in a flow diagram. A summary of the *mcmsupply* functions required for each modelling scenario are presented in a flow diagram.
Implementation and operation: The implementation of the *mcmsupply* R package is listed. The operating system of the computer the package was created on is described.
Data: The input data is described. The *mcmsupply* R package contains national and subnational level contraceptive source datasets, generated by IPUMS and Demographic and Health Survey microdata [35] [38]. The functionality for data processing within the *mcmsupply* R package is presented.
Using the Bayesian hierarchical penalised spline models: The functionality used for model fitting and visualising model outputs are presented.
Use cases: Five use cases for the *mcmsupply* R package are presented and discussed. A vigentte for each use case is shown and explained in detail. The plots used to visualise the model estimates in *Case 1: Estimating contraceptive method supply shares at the national administration level for multiple countries simultaneously* and *Case 4: Estimating contraceptive method supply shares at the subnational administration level for a single country* are shown.
Discussion: The benefits and practical applications of the *mcmsupply* R package are presented. Some limitations of the models are discussed and the future directions of the R package are reflected on.
Conclusions: We conclude with closing remarks about the *mcmsupply* R package and highlight how creating and sharing this package aligns with the the findability, accessibility, interoperability, and reusability (FAIR) principles of scientific data [93].

Chapter 7: The inclusion of uncertainty into the estimation process for estimated modern use from service statistic data

We explore the use and impact of estimated modern contraceptive method supply shares within the derivation of estimated modern use (EMU) from service statistics.

Introduction: The motivation for using service statistics with the Family planning estimation model is presented. A brief explanation of service statistics, their limitations, and the derivation of EMUs via the SS-to-EMU tool is discussed.
Terminology: A list of terms used throughout the paper is given.
Method for calculating estimated modern use (EMUs): The methodology used within the SS-to-EMU tool to derive EMUs from service statistics is described in detail.
Comparision to existing approaches: A comparison of the existing methodology and the proposed update is provided with plots highlighting these key differences.
Case studies: Two case studies in countries A and B evaluate the impact of the proposed EMU calculation update, through the comparison of existing EMU estimates with EMUs estimated under the updated methodology.
Discussion: We discuss the impact of this proposed EMU calculation method update on EMUs in the context of the case studies.
Conclusions: We conclude with closing remarks about the proposed EMU update and highlight the strengths of the proposed approach.

2

Estimating the proportion of modern contraceptives supplied by the public and private sectors using a Bayesian hierarchical penalized spline model

This paper is under revision with the Journal of the Royal Statistical Society Series A: Statistics in Society.

2.1 Authors

Hannah Comiskey (a), Leontine Alkema (b), Niamh Cahill (a)

(a) Hamilton Institute and Department of Mathematics & Statistics, Maynooth University, Maynooth, Ireland;
(b) School of Public Health & Health Sciences, University of Massachusetts Amherst, Massachusetts, USA

2.2 Abstract

Quantifying the public/private-sector supply of contraceptive methods within countries is vital for effective and sustainable family-planning delivery. However, many low- and middle-income countries quantify contraceptive supply using out-of-date Demographic Health Surveys. As an alternative, we propose using a Bayesian, hierarchical, penalized-spline model, with survey input, to produce annual estimates and projections of contraceptive supply-share outcomes. Our approach shares information across countries, accounts for survey observational errors and produces probabilistic projections informed by past changes in supply shares, as well as correlations between supply-share changes

across different contraceptive methods. Results may be used to evaluate family-planning program effectiveness and stability.

2.3 Keywords

Bayesian, correlation, family planning, hierarchical, splines, time-series

2.4 Introduction

The Family Planning 2020 Initiative (FP2020) set the target of engaging 120 million new users of modern contraception in sixty-nine of the world's poorest countries by the year 2020. This goal has now been extended to 2030 in line with the UN sustainable development goals [9], [30]. Consequently, there is a heightened need for annual, reliable estimates of family planning (FP) indicators for each country involved in the initiative. One such indicator is the most recent source of contraceptive commodities accessed by FP users. This indicator can be used to highlight where FP users obtain their contraceptives from, as well as to evaluate FP program effectiveness and forecast future commodity procurement [22]. The family planning market is most successful when clients have a variety of methods and sources to choose from [67]. Therefore, annual estimates and projections of the contraceptive method supply share are of particular use to countries who are trying to engage the private sector to re-balance the roles of the public and private sectors [22], meet the needs of all women within a country and enhance efforts to meet family planning goals [63].

In addition to their role as a stand-alone FP indicator, estimates of the contraceptive method supply share can be utilised with FP service statistics in a corrective step to reduce the bias of estimated modern contraceptive use (EMUs) rates [80]. EMUs represent the proportion of women in a particular country using modern contraception based on FP service statistic data [10]. Service statistics data are routinely collected in connection with family planning service delivery. These data provide high geographic detail, are relatively inexpensive to collect but often do not include contributions from the private sector [49]. The private sector is used by women across all socio-economic groups to access their family planning methods9, with 37% to 39% of all family planning users obtaining modern contraceptives through the private sector [12]. Therefore, the private sector makes up a significant portion of the family planning market. Service statistics data that are missing the private sector's contribution must be scaled-up to reflect the complete contraceptive market [80]. This adjustment to the service statistics data has spurred the need for annual estimates of the proportion of modern contraceptives supplied by the public, private commercial medical and private other sectors. Presently, annual estimates and projections with uncertainty for these proportions are not available when they are required for now-casting family planning indicators, such as EMUs. Demographic and Health Surveys (DHS) provide information on the breakdown of public and private sector contributions to the contraceptive supply chain in the form of the percentage of contraceptive methods that are sourced from each sector. In this study, we consider 30 countries involved in the FP2020 initiative, that have DHS data available after 2012. Notably, 54% of the countries considered do not have survey observations of the supply share indicator beyond 2015. In the absence of recent survey observations, we can rely on statistical model-based estimates and projections to bridge the knowledge gap and provide the recent private sector contributions to family planning service delivery with uncertainty.

Our proposed model falls into the class of temporal models for multiple populations (TMMP)[71]. Estimating demographic and health indicators using temporal statistical models with area-level variation is a well-established practice. The foundational 1979 Fay-Herriot model, which first considered estimates of income over time for small places, is an area-level model where the input data is made up of smaller sub-divisions, such as counties [27]. As such, it too would also fall under the class of TMMP. The Fay-Herriot model began a trend of using temporal models for small area estimation (SAE). As time and computing power has increased, so too have the complexity of the TMMP we use today. While our model is not considered a small-area estimation model, by merit of whole countries being too large to be considered small areas and the DHS data being adequately powered to capture observations at the national level, the proposed approach has some similarities to SAE models proposed in previous studies. In 2009, Ugarte et. al combined SAE modelling approaches with penalised splines to analyse trends and forecast dwelling prices in nine Spanish neighbourhoods [82]. Our proposed model also uses penalised splines to capture the complex temporal nature of the data. While in 2013, Marhuenda et al. took advantage of the geographic nature of Spanish EU-SILC data within a spatio-temporal Fay-Herriot model to produce poverty indicators for Spanish provinces [50]. Similarly, in the proposed model we take advantage of the geographic nature of the dataset through Bayesian hierarchical modelling.

In this paper, we describe a Bayesian hierarchical penalised spline model that produces annual, country and method-specific estimates of the proportion of modern contraceptives coming from the public and private sectors. The utility of our model is in the ability to produce short-term projections (with uncertainty) beyond the year of the most recent survey. The model accounts for across method correlations within public and private sector contributions to family planning supply and relies on information sharing across methods and countries via a hierarchical modelling structure. The use of splines for demographic and health indicator estimation is growing in popularity. In recent years, many international health organisations use splines for the estimation of key demographic, health, and family planning indicators. These include the estimation and projection of under-5 mortality for United Nations Children's Fund (UNICEF)[66] and the estimation of excess morality due to Covid-19 for the World Health Organisation (WHO) [41] . We describe our model using two components – a process model and a data model. In the process model, we seek to model the unobserved latent trends over time using a hierarchical systematic element and stochastic temporal smoothing splines. In the data model, we account for the standard errors of the DHS observations.

2.5 Data

Definitions and Data Sources

According to Hubacher and Trussell, a modern contraceptive method is defined as "a product or medical procedure that interferes with reproduction from acts of sexual intercourse" [37]. Modern methods of contraception considered in this study are female sterilisation, oral contraceptive pills (OC pills), implants (including Implanon, Jadelle and Sino-implant), intra-uterine devices (IUD, including Copper- T 380-A IUD and LNG-IUS), and injectables (including Depo Provera (DMPA), Noristerat (NET-En), Lunelle, Sayana Press and other injectables).

The proportion of a modern contraceptive method provided by the public sector is defined as the percent of a modern contraceptive method that is supplied by any public sector outlet relative to all modern methods supplied in each country at a given time. Conversely, the proportion of modern contraceptives provided by the private sector come from the private sector outlets [52]. The public sectors include contraceptives supplied by government health facilities and home/community deliveries. Any supplies that come from sources outside the public sector can be defined as coming from the private sector. These include commercial, for-profit, and non-profit organizations [39]. We consider three sector categories: public, private commercial medical and other private, where the private commercial medical and other private make up the total private sector. In this study, the outcome of interest for a given contraceptive method is the market share breakdown using the three sector categories.

A database of the public and private sector breakdown of modern contraceptive supply with their associated standard errors was created using data from the DHS [87]. The

DHS use a two-stage sampling design, using census information as the sampling frame. First, the country of interest is stratified to have strata as homogeneous as possible. This homogeneity minimizes the resulting sampling errors of the survey. Within each stratum, the census enumeration areas (EAs) form clusters. The households of each cluster are listed, and a fixed number of households within the selected cluster are chosen by systematic sampling. The sample selection process uses weights to address the differences in probability of selection. This corrects any over- or under-sampling of different clusters during sample selection. The DHS standard model questionnaires are then utilised to collect data from the selected households [18]. The cohort of interest for this study was women aged 15-49 years old who are taking a modern contraceptive method. The variable of interest was the current source of their modern contraceptive methods.

In this study we consider countries involved in the FP2030 initiative. Table 2.1 lists the thirty countries used in this study. The total number of surveys carried out and the year of the most recent survey is listed for each country. There are five intermediate world regions considered in this study. Western Africa has the largest number of countries in the dataset with 12 countries, while South-Eastern Asia is the smallest with 2 countries in the dataset. Just under half of the countries included have survey data available after 2015, highlighting the need for annual up-to-date estimates of the contraceptive supply shares.

UNSD intermediate world regions	Country	Total Number of Surveys	Recent Survey Year
Southern Asia	Afghanistan	1	2015
Western Africa	Benin	5	2017
Western Africa	Burkina Faso	4	2010
Middle Africa	Cameroon	5	2018
Middle Africa	Congo	2	2011
Middle Africa	Democratic Republic of Congo	2	2013
Western Africa	Cote d'Ivoire	3	2011
Eastern Africa	Ethiopia	5	2019
Western Africa	Ghana	5	2014
Western Africa	Guinea	4	2018
Southern Asia	India	4	2015
Eastern Africa	Kenya	5	2014
Western Africa	Liberia	3	2019
Eastern Africa	Madagascar	4	2008
Eastern Africa	Malawi	5	2015
Western Africa	Mali	5	2018
Eastern Africa	Mozambique	3	2011
South-Eastern Asia	Myanmar	1	2015
Southern Asia	Nepal	5	2016
Western Africa	Niger	4	2012
Western Africa	Nigeria	5	2018
Southern Asia	Pakistan	4	2017
South-Eastern Asia	Philippines	6	2017
Eastern Africa	Rwanda	6	2019
Western Africa	Senegal	11	2019
Western Africa	Sierra Leone	3	2019
Eastern Africa	Tanzania	6	2015
Western Africa	Togo	2	2013
Eastern Africa	Uganda	5	2016
Eastern Africa	Zimbabwe	5	2015

Table 2.1: Summary of DHS microdata used during the study including the United Nation Statistics Division (UNSD) intermediate world region names, country names, the number of DHS surveys per country available and the year of the most recent DHS survey available. Just over 46% of countries have data available after 2015.

We calculated proportions and associated standard errors from DHS micro-level data. In line with STATcompiler convention [38], we filtered the DHS survey microdata to only include observations for a given method m, at time t in country c where at least one sector (public, private commercial or private other) has a sample size of at least twenty women. This removes sets of observations with large uncertainty due to small sample sizes. Sampling errors were calculated while accounting for the sampling design using a Taylor series linearisation method to approximate the standard error of the calculated proportions [5] [42]. This work was carried out using the 'survey' R package [47]. Any observations where the 95% confidence intervals exceeded zero or one were truncated to maintain boundary of the (0,1) interval.

The final database included 1461 observations for 15 method-sector combinations. An example of the data is shown in Figure 2.1A where the proportion of modern contraceptives coming from each sector are plotted over time for Zimbabwe. Vertical bars indicate standard errors associated with each observation. Zimbabwe is considered a data-rich country as there are between 3 and 5 surveys available for each method. For all five methods, the public sector has the largest market share. However, in recent years, there is an increase in the proportion of OC pills and female sterilization supplied by the private sectors. In Figure 2.1B, the observed method mix for each of the five contraceptive methods is shown for each DHS survey year. We can see that as OC pills declines in the public sector supply share, so too does its popularity in the method mix for Zimbabwe. In the database, standard errors range from 0.015 to 18.2 percentage points. For further details on how the standard errors were calculated and a summary of these errors, please see the accompanying appendix (Chapter 3, section 1).



Figure 2.1: **A**: Contraceptive Supply in Zimbabwe. Observed proportions of the modern contraceptives supplied by each sector over time for Zimbabwe according to the DHS microdata. The sectors are coloured blue for public, grey for commercial medical and gold for other private. The standard errors associated with each observation are used to create the vertical error bars. Zimbabwe is one of the thirty countries included in this study. **B**: Method mix in Zimbabwe. The observed popularity for the 5 contraceptive methods of interest in Zimbabwe according to the DHS microdata. Each method is represented by a different colour. The year of the DHS survey is listed on the x-axis. On the y-axis, the height of each bar captures the proportion of modern contraceptive users utilising each method in a given survey year.

2.6 Methods

The outcome of interest is the components of a compositional vector,

$$\boldsymbol{\phi_{c,t,m}} = (\phi_{c,t,m,1}, \phi_{c,t,m,2}, \phi_{c,t,m,3}), \tag{2.1}$$

where, $\phi_{c,t,m,s}$ the proportion supplied by the public sector (s =1), the private commercial medical sector (s=2) and the other private sector (s=3) of modern contraceptive method m, at time t, in country c.

We break the model specification into two parts, the process model that captures the underlying dynamics of the outcome of interest and the data model which links the observed data to the process model. In the process model, we model the logit-transformed proportion of the public-sector supply share and the ratio of private commercial medical to total private sector supply share using a Bayesian hierarchical penalised spline model. The logit-transformed data is linked to the process in the data model via a Normal distribution.

2.6.1 The process model

We begin by defining a regression model for $\phi_{c,t,m,1}$. Logit-transformed proportion $\psi_{c,t,m,1}$ = logit($\phi_{c,t,m,1}$) is modelled with a penalized basis-spline (P-spline) regression model:

$$\text{logit}\,(\phi_{c,t,m,1}) = \psi_{c,t,m,1} = \sum_{k=1}^{K} \beta_{c,m,1,k} B_{c,k}(t), \tag{2.2}$$

where, $B_{c,k}(t)$ refers to the kth basis function evaluated in country c, at time t. $\beta_{c,m,1,k}$ is the k-th spline coefficient for the public sector supply (s=1) of method m in country c.

The basis functions $B(t)$ are constructed using cubic splines. The basis are fitted over the years 1990 to 2025. We align the knot placement of the basis splines with the most recent survey in each country. As the most recent survey year varies by country, the basis splines $B_{c,k}(t)$ also vary by country. An example of the country-specific basis-functions are shown in Figure 2.2 where the basis are shown as a set of coloured curves plotted over time with the locations of the knots denoted in black dots with dash vertical lines along the x-axis.



Figure 2.2: The set of basis functions plotted over time that are used to fit Afghanistan and Democratic Republic of Congo (DRC). The most recent survey for Afghanistan occurs in 2015 and the most recent survey in DRC occurs in 2013. Thus, the knot point locations, depicted as black dots with vertical dashed lines differ between the two countries.

Similarly, we model the latent variable, $\psi_{c,t,m,2}$, to capture the logit-transformed ratio of the private commercial medical supply share to the total private sector share. The model is specified as follows:

$$\text{logit}\left(\frac{\phi_{c,t,m,2}}{1-\phi_{c,t,m,1}}\right) = \psi_{c,t,m,2} = \sum_{k=1}^{K} \beta_{c,m,2,k} B_{c,k}(t), \tag{2.3}$$

where, $\beta_{c,m,2,k}$ is the k-th spline coefficient for the ratio of private commercial medical sector (s=2) to total private sector for method m in country c.

From the latent variable vector, $\boldsymbol{\psi_{c,t,m}}$, it is possible to infer the compositional vector $\boldsymbol{\phi_{c,t,m}}$,

$$\begin{aligned}\phi_{c,t,m,1} &= \text{logit}^{-1}\left(\psi_{c,t,m,1}\right), \\ \phi_{c,t,m,2} &= \left(1-\phi_{c,t,m,1}\right)\text{logit}^{-1}\left(\psi_{c,t,m,2}\right), \\ \phi_{c,t,m,3} &= 1-\left(\phi_{c,t,m,1}+\phi_{c,t,m,2}\right).\end{aligned} \tag{2.4}$$

Parametrization of the spline regression coefficients

To estimate the spline coefficients, $\beta_{c,m,s,k}$, we use a random walk model of order 1 on spline coefficients such that the first-order differences, $\boldsymbol{\delta_{c,m,s}}$, are penalized. This model choice is motivated by prior work that used constant projections past the most recent data point [79].

The $\boldsymbol{\delta_{c,m,s}}$ vector is of length h where h=K-1 and is defined as

$$\boldsymbol{\delta_{c,m,s}} = (\beta_{c,m,s,2}-\beta_{c,m,s,1}, \beta_{c,m,s,3}-\beta_{c,m,s,2}, ..., \beta_{c,m,s,K}-\beta_{c,m,s,K-1}). \tag{2.5}$$

We assume that in country c, method m and sector s, the value of spline coefficient at knot point k^*, aligning with the year t^* where the most recent survey occurs, is $\alpha_{c,m,s}$. By doing this, we are assuming that the $\alpha_{c,m,s}$ parameter will act as the spline coefficient for the reference spline at k^*. We calculate the remaining spline coefficients by moving away from the reference knot (k^*) to adjacent spline coefficients (k^*+1 and k^*-1) using the estimated $\boldsymbol{\delta_{c,m,s}}$, the first-order rates of change between consecutive spline coefficients. This process is repeated until all spline coefficients are estimated for country c, method m and sector s.

$$\beta_{c,m,s,k} = \begin{cases} \alpha_{c,m,s} & k = k^*, \\ \beta_{c,m,s,k+1}-\delta_{c,m,s,k} & k < k^*, \\ \beta_{c,m,s,k-1}+\delta_{c,m,s,k-1} & k > k^*. \end{cases} \tag{2.6}$$

Hierarchical estimation of the intercept

The parameter $\alpha_{c,m,s}$ acts similarly to an intercept term as it forms the baseline level from which forward and backward projections are based off. A change in $\alpha_{c,m,s}$ can lead to a systematic change on the estimated set of supply-share levels for a particular country. $\alpha_{c,m,s}$ is estimated hierarchically to allow parameter estimates to benefit from cross-method and then cross-country information sharing for each sector. The hierarchical distributions are given by:

$$\begin{gathered}\alpha_{c,m,s} \mid \theta_{r[c],m,s}, \sigma^2_{\alpha,s} \sim N\left(\theta_{r[c],m,s}, \sigma^2_{\alpha,s}\right), \\ \theta_{r,m,s} \mid \theta_{w,m,s}, \sigma^2_{\theta,s} \sim N\left(\theta_{w,m,s}, \sigma^2_{\theta,s}\right).\end{gathered} \tag{2.7}$$

Such that $\alpha_{c,m,s}$. is distributed around a sector, method, region-specific mean $\theta_{r[c],m,s}$. allowing for a cross-method variance $\sigma^2_{\alpha_s}$. for each sector. The geographic regions, r[c], used to group countries together are the UNSD intermediate world regions [86]. The sector, method, region-specific means are distributed around a sector, method-specific world mean $\theta_{m,s}$. allowing for a cross-regional variance $\sigma^2_{\theta_s}$ within each sector. We chose this hierarchical setup as the private sector plays an important role in the supply of contraceptive products, such as OC pill and injectables, whereas the public sector tends to provide higher proportions of clinical contraceptive methods, including female sterilisation, IUDs, and implants [3] [83]. Thus, it made sense for the data to split the prior and hyper-prior mean parameters by method-type to respect these observed differences. Finally, the overall sector-specific mean is given a vague Normal prior and the cross-method and cross-country standard deviation parameters are given half-Cauchy distributions:

$$\begin{aligned} \theta_{w,m,s} &\sim N\left(0,100\right), \\ \sigma_{\alpha_s} &\sim Cauchy\left(0,1\right)_+, \\ \sigma_{\theta_s} &\sim Cauchy\left(0,1\right)_+. \end{aligned} \tag{2.8}$$

Specification of the deviation terms δ

A multivariate normal prior centred on 0 was assigned to the vector of length M of first-order differences of the spline coefficients, $\delta_{c,1:M,s,h}$, for all methods supplied by sector s in country c, at first-order difference h;

$$\delta_{c,1:M,s,h} \mid \Sigma_{\delta,s} \sim MVN(\mathbf{0}, \Sigma_{\delta,s}), \tag{2.9}$$

Where the variance-covariance matrix $\Sigma_{\delta,s}$ is given by,

$$\Sigma_{\delta_s} = \begin{bmatrix} \sigma^2_{\delta_{1,s}} & \hat{\rho}_{1,2,S}\sigma_{\delta_{1,S}}\sigma_{\delta_{2,s}} & \cdots & \cdots & \hat{\rho}_{1,M,S}\sigma_{\delta_{1,s}}\sigma_{\delta_{M,S}} \\ \hat{\rho}_{2,1,s}\sigma_{\delta_{2,s}}\sigma_{\delta_{1,s}} & \sigma^2_{\delta_{2,s}} & \cdots & \cdots & \hat{\rho}_{2,M,S}\sigma_{\delta_{2,s}}\sigma_{\delta_{M,s}} \\ \cdots & \cdots & \cdots & \cdots & \cdots \\ \cdots & \cdots & \cdots & \cdots & \cdots \\ \hat{\rho}_{M,1,s}\sigma_{\delta_{M,s}}\sigma_{\delta_{M,s}} & \cdots & \cdots & \cdots & \sigma^2_{\delta_{M,s}} \end{bmatrix}. \tag{2.10}$$

The variance terms $\sigma^2_{\delta_{m,s}}$ for m=1,..,M and s=1,2 are method-sector specific smoothness parameters that act as a penalization parameter on the first order differences of the spline coefficients. As $\sigma^2_{\delta_{m,s}}$ tends towards 0, deviations away from the sector, method, country-specific mean go to 0. Within each sector, we assume that the first order differences are not independent across methods. This dependency is captured via the covariance, $\hat{\rho}_{i,j,s}\ \sigma_{\delta_{i,s}}\ \sigma_{\delta_{j,s}}$ for s=1,2,i=1,..,M and j=1,..,M and where $\hat{\rho}_{i,j,s}$ is the estimated correlation between first-order differences of spline coefficients for method i and method j supplied by sector s. Σ_{δ_s} plays a pivot role in the estimation process. It influences both the flexibility of the splines to move away from the most recently observed survey level, and the strength of the relationships that occur between the rates of change in contraceptive method supply share estimates.

The deviation terms of the Σ_{δ_s} matrix are given vague uniform distributions,

$$\sigma_{\delta_{m,s}} \sim Uniform\,(0, 10)\,. \tag{2.11}$$

The correlation terms of the covariance matrix, $\rho_{i,j,s}$, were estimated using a maximum *a posteriori* estimator for the correlation matrix as described in Azose and Raftery, 2018 [4]. This approach involves fitting a model where the covariance terms in $\sigma_{\delta_{j,s}}$ are set equal to zero. The resulting estimates are then used to estimate the correlation between methods across time and all countries. Specifically, for sector s, the correlation between method i and method j is calculated as follows,

$$\tilde{\rho}_{i,j,s} = \frac{\sum_{c=1}^{C}\sum_{h=1}^{K-1}\tilde{\delta}_{c,m[i],s,h}\tilde{\delta}_{c,m[j],s,h}}{\sqrt{\sum_{c=1}^{C}\sum_{h=1}^{K-1}\tilde{\delta}^2_{c,m[i],s,h}}\sqrt{\sum_{c=1}^{C}\sum_{h=1}^{K-1}\tilde{\delta}^2_{c,m[j],s,h}}}, \tag{2.12}$$

where, $\tilde{\rho}_{i,j,s}$ is the posterior sample of estimated correlations between method i and method j in sector s.
$\tilde{\delta}_{c,m[i],s,h}$ is the posterior sample of first order differences of the spline coefficients estimated in country c, method i, in sector s at first-order difference h in the zero-covariance model.
C is the total number of countries involved in the study.
h is the number of differences between the K spline coefficients (h=K-1).

To ensure that the correlation matrix (ρ) is positive definite, we let;

$$\hat{\rho}_{i,j,s} = \overline{\rho}_{i,j,s}, \tag{2.13}$$

where $\overline{\rho}_{i,j,s}$ is the posterior mean of $\tilde{\rho}_{i,j,s}$.

Figure 2.3 shows the heat map of the estimated correlations between the first-order differences in the spline coefficients for the five contraceptive methods studied for the public sector and ratio of commercial medical sector to total private sector. In general, both the public and private sectors have weakly positive correlations across all method combinations (Figure 2.3B). In both sectors, OC pills tends to have the strongest correlations with the other methods. The relationships between the other methods tend to be close to zero. In the public sector, injectables and OC pills have a weak-positive correlation at 0.17. This is the strongest average correlation calculated in the public sector. In the private sector, the OC pills-injectables relationship is again the strongest at 0.13 (Figure 2.3A; 0.17. Figure 2.3B; 0.13). In both instances, OC pills have a positive correlation with injectables. This implies that the rates of change in the supply of OC pills tend to increase jointly with the rates of change in the supply of injectables across the public and private sectors.



Figure 2.3: A heatmap of the estimated correlations between the changes in contraceptive supply of contraceptive methods (on the logit scale) present in the public (A) and private (B) sectors. The methods include female sterilization, oral contraceptive pills (OC pills) intrauterine devices (IUD), injectables and implants. Correlation is measured on a scale from -1 (strong negative correlation) to +1 (strong positive correlation). The colours represent the strength of the correlation, blue indicates negative correlations and red indicates positive correlations.

2.6.2 The data model

The likelihood of the logit-transformed observed data, logit(Y_i), the observed logit-transformed proportions of modern contraceptive method supplied by the public and commercial medical sectors (s=1 and s=2) for method m, at time t in country c, are modelled using Multivariate Normal distributions such that,

$$\text{logit}(\boldsymbol{Y_i}) \mid logit(\boldsymbol{\phi}_{c[i],t[i],m[i],s=1:2}) \sim MVN(logit(\boldsymbol{\phi}_{c[i],t[i],m[i],s=1:2}), \Sigma_{Y_i}), \tag{2.14}$$

Where, $logit(\boldsymbol{\phi}_{c[i],t[i],m[i],s=1:2})$ is the vector of logit-transformed public (s=1) and private commercial medical (s=2) supply proportions for the country, time-point, method associated with observation i.
The variance-covariance matrix, Σ_{Y_i}, utilizes the standard errors (SE) and covariances calculated using the DHS survey microdata associated with the logit-transformed observations, $logit(Y_i)$. The calculated variance-covariance matrix is transformed onto the logit scale using the delta-method. Details of the delta-method transformation can be found in the appendix (Chapter 3, section 4).

2.7 Computation

We used R and JAGS (Just Another Gibbs Sampler) to fit the model. JAGS uses Markov Chain Monte Carlo (MCMC) algorithm to produce model estimates for Bayesian Hierarchical models [59]. The number of iterations used was 200,000. The burn-in period was set to 20,000. The samples were thinned to every 90^{th} sample. Consequently, the posterior distribution is made up of 2000 samples. To assess convergence, we considered the convergence diagnostic $\hat{R}$ [88], as well as the individual parameter trace plots. Further details of the computation can be found in the appendix (Chapter 3) section 3.

2.8 Country estimates

We produced estimates and projections of the public and private sector contraceptive supply share from 1990 to 2023 for 5 contraceptive methods in 30 countries involved in FP2030. We used R and JAGS (Just Another Gibbs Sampler) to fit the model. JAGS uses Markov Chain Monte Carlo (MCMC) algorithm to produce model estimates for Bayesian Hierarchical models [59]. The details of how these estimates are created are described in the appendix (Chapter 3), Section 3. Results are presented here for a subset of countries. Results for all countries are included in Chapter 9 (Figures 9.1 - 9.25). We show results for five countries to illustrate the model's response to varying amounts of data available for each country in the data set (Table 2.1). These countries include Afghanistan, Democratic Republic of Congo (DRC), Mozambique, Nepal, and Zimbabwe. Afghanistan has at most a single survey data point for each method and sector. The DRC and Mozambique have at most three survey data points for each method and sector. Finally, Nepal and Zimbabwe have at least three survey data points for each method and sector. To begin, we will look at our model estimates in a data-rich setting. Historically, Nepal appears to distribute the pill supply share equally across the public and private sectors (Figure 2.4A). In contrast to this, Zimbabwe traditionally supplied most OC pills through the public sector (Figure 2.4B). However, in more recent years, Zimbabwe's private medical and private other sectors have been slowly growing in popularity. For other methods the public sector dominates the supply in both countries, however in Nepal the public sector share of IUDs does appear to be decreasing slowly over time. In both Nepal and Zimbabwe, projections beyond the most recent survey are penalised to be as smooth as possible. The models are utilising the most recently observed level ($\alpha_{c,m,s}$) as their baseline for extending estimates out into the future.



Figure 2.4: The projections for the proportion of modern contraceptives supplied by each sector in Nepal (A) and Zimbabwe (B). The median estimates are shown by the continuous line while the 95% credible interval is marked by shaded area. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.

In the DRC, except for the OC pill, the public sector provides the largest share of all contraceptive methods (based on median estimates; Figure 2.5A). More recently, the proportion of OC pill supplied by the private sector seems to be declining (since 2014 approximately). The public sector supply share is increasing over time for female sterilization. Injectables, which in the past projections appeared steady in the public sector supply share, shows an increase in supply from the public sector in more recent years (since 2008 approximately). The private commercial medical sector injectables trend is being impacted by the across-method correlation structure imposed in the model. Changes over time in injectables supply from the private sector have positive correlation with changes in OC pills (correlation=0.13, Figure 2.3B). The behaviour of the OC pill supply share can be explained by the hierarchical structure of the fixed effects term in the model. In the absence of historical data, OC pill estimates begin at the sector, region, method-specific intercept, which is informed by the most recent supply-share level observed, and then the data begins to inform the estimates in more recent years (post-2014 approximately). The extrapolations into the future are steady as the spline coefficients used during estimation are based on the penalised first-order differences which are expected to result in a zero-unit rate of change between coefficients (equation 2.9). In Mozambique, the public sector dominates the supply share for all methods (based on median estimates; Figure 2.5B). The public sector supply share for all methods is mostly steady over time. We see an increase in the public supply share of injectables and OC pills between 1995 and 2010 approximately. For implants, the national estimates are tending towards the sector-specific average of most recently observed supply share levels across the larger geographic region in the absence of data.



Figure 2.5: The projections for the proportion of modern contraceptives supplied by each sector in Democratic Republic of Congo (DR Congo) (A) and Mozambique (B). The median estimates are shown by the continuous line while the 95% credible interval is marked by shaded area. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.

Lastly in Afghanistan (Figure 2.6), there is only one survey available. For all methods except for the OC pill, the public sector provides the largest supply share over the study period (based on median estimates). The supply share median estimates and uncertainty intervals for female sterilization, injectables, IUD and OC pills are influenced by single data points. In the absence of any data for implants, the estimates are centred on the sector, region, method-specific average of the most recently observed supply share levels.



Figure 2.6: Contraceptive Supply in Afghanistan. The projections for the proportion of modern contraceptives supplied by each sector in Afghanistan. The median estimates are shown by the continuous line while the 95% credible interval is marked by shaded coloured area. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.

Table 2.2 shows a summary of the contraceptive supply share for each method in 2023. Overall, the public sector supplies the highest proportion of each contraceptive method, and the private other sector supplies the smallest proportion. Implant supply is dominated by the public sector (approximately 83%). This may be since they require medical assistance for insertion and therefore require medically trained providers. This makes them more expensive to provide and less likely to be accessed through private means [90]. In contrast, the supply of OC pills is close to a 50:50 percentage point split between the public and private sectors. OC pills can be supplied to users without medical assistance making them more popular in the private sector [8].

	Private Commercial Medical		Private Other		Public	
	Mean (%)	**SD (%)**	**Mean (%)**	**SD (%)**	**Mean (%)**	**SD (%)**
Female Sterilization	15.4	9.0	3.8	3.0	81.0	7.05
Implants	15.9	12.0	0.9	1.0	83.2	12.0
Injectables	22.9	14.0	2.6	2.0	75.4	15.0
IUD	25.7	14.0	0.7	0.1	73.7	15.0
OC Pills	40.4	19.0	13.0	10.0	44.5	20.0

Table 2.2: Summary of contraceptive supply share proportions across all countries and in 2023 for each method and sector. The mean estimate for the percentage point supplied and the associated standard deviation (SD) are listed

2.9 Discussion

In this paper we proposed and validated a Bayesian hierarchical model to estimate the country and method specific changes in the contraceptive supply share over time with (sometimes) limited amounts of DHS survey data. The modelling framework uses penalised splines to capture the evolution of the contraceptive method supply from the public and private sectors while imposing a correlation structure to capture correlations between changes in the supply share. The penalised splines provide a flexible fit to the data without over-fitting. The model structure imposes a hierarchy such that the expected sector, country, method-specific supply shares are informed based on the geographical relationships of the countries to promote information sharing across countries where smaller amounts of data are present. The model will produce estimates within the period of available survey data as well as projections beyond the most recent data point.
The model was used to estimate and project the contraceptive supply share from the public, private commercial medical and private other sectors for 30 focus countries of the FP2030 initiative, where relevant data was available. Case study examples illustrated the strength and flexibility of the modelling approach in its ability to capture the evolving nature of the contraceptive supply share over time. The hierarchical setup of the model and the imposed cross-method correlation structure allows the model to produce informed estimates (with uncertainty) even in cases where very limited data are available. Based on a series of validation measures, the proposed model is well calibrated and outperforms various model alternatives (see the supplementary appendix in Chapter 3 for full details).
To show the utility of the proposed approach for producing short-term projections, we use model validations where we leave out the most recent data points and compare the predictive performance of our proposed model to that of alternative simpler approaches,

and check that forecasts are well calibrated. Through the validation exercises, we show that our model provides improved point estimates (as measured in terms of RMSE for predicting left-out observations) and is well calibrated as compared to alternative models.

An application of our model will be in the calculation of Estimated Modern Use (EMU), a proxy for modern contraceptive prevalence derived from service statistics and frequently used in the Family Planning Estimation Model [10] [11]. A short description of how to calculate EMUs can be found in the appendix (Chapter 3), section 'Calculating Estimated Modern Use' and the full mathematical description is found in Chapter 7. Service statistics data include the number of family planning commodities distributed to clients, commodities distributed to health facilities, family planning facility visits, or family planning facility users. Frequently, the raw data reported in a given country does not include the private sector contribution. As such, the raw data may not be fully representative of the country's whole contraceptive market. Currently, to address this issue when calculating EMUs [80], the most recent DHS survey estimate of the country's contraceptive supply share is used to provide a breakdown of the contraceptive market and scale up the raw data accordingly. We instead propose to use our model-based estimates in this important supply-adjustment step of the EMU calculation and to propagate the posterior uncertainty for the contraceptive supply share of sector s, method m, at time t in country c into the EMU calculations. To maximise the engagement of Family Planning community with this model and its application to EMU calculation, we have carefully considered expert opinion and incorporated the current best practice approach to modern contraceptive supply share extrapolations [79]. This is evident in the smooth projections of the model beyond the most recent data points (Figure 2.4). The smooth projections into the future promotes the seamless fusion of the current EMU calculation process and our model-based estimates to produce improved EMUs with uncertainty.

Another potential application of these model estimates could be used in evaluating the security of contraceptive method supply chains. It is well-established that a total-market approach (TMA) is key to both the longevity and sustainability of the family planning market and in achieving equity among family planning users [8]. Understanding and quantifying the supply shares of the private and public sectors in the contraceptive market contributes to a TMA approach to supply chain management [55]. Presently, the latest DHS survey estimates are used to provide the proportion of modern contraceptives supplied by each sector. However, this relies on out-of-date information in relation the private sector supply in the absence recent surveys. The model estimates presented here can provide an essential measure of the private sector's role in modern contraceptive method supplies at a national level. Using the model estimates, it is possible to predict and reflect on overall contraceptive market supply trends. This feeds into indicator 1, “Generating intelligence”, and indicator 6, “Accountability and transparency in health markets”, of the TMA framework which will help to enable evidence-based strategies for resource management within the family planning market and improve the sustainability of future family planning initiatives [15].

The estimates and projections presented here provide important and relevant information on the contraceptive supply share over time, at a national level. The data model allows for the incorporation of survey sampling errors to be included in the modelling process. The use of penalised-splines allows for data driven, flexible model-based estimates and the correlation structure imposed in the estimation of the splines allows the model to draw strength and information from the relationships between supply-shares of different contraceptive methods. Given that data are not necessarily available for all country-periods of interest, we use a smoothing model on the spline coefficients, such that differences between neighbouring spline coefficients are penalized. A similar approach to spline coefficient estimation can be found in Wang et al. (2019), where the authors also model the regression coefficients with a first-order random walk process [89]. The Bayesian hierarchical framework allows for information sharing across methods and regions, which is of particular use for countries where data are limited. It allows us to capture differences between countries, and the similarities of countries within regions. This type of approach follows that used in other global estimation exercises, for example, for family planning use [2] and estimating populations of women of reproductive age [1]. Explorations carried out seem to suggest that there is no spatial auto-correlation in the model estimates. The hierarchical structure within the model, taking advantage of the geographic nature of the dataset, captures any potential spatial residuals within the data. In future work, analyses that focus on using relevant covariates to try to explain or understand differences in supply shares across settings or within settings over time can be considered. Given data limitations and the variety of reasons why supply shares may vary, this falls outside the scope of our current study. Another area of future work will consider speeding up the computational efficiency of this modelling approach using integrated nested Laplace approximations (INLA), a method for approximating Bayesian inference for latent Gaussian models [64], rather than the current approach of MCMC sampling.

This consideration of the public/private sector supply of contraceptive methods within countries is vital for informing family planning programs that seek to improve access to and increase use of modern family planning methods [63]. The private sector can play an important role in the sustainability of family planning markets and therefore the ability, via model-based estimates, to evaluate where countries currently stand in terms of private sector contributions to the contraceptive method supply can help to inform needs for private sector expansion and support the growth of contraceptive use [63].

2.10 Data availability

The code and data used to create these results can be found at `https://github.com/hannahcomiskey/mcmsupply` and the corresponding R package, `mcmsupply` can be found on CRAN [17].

2.11 Acknowledgements

This publication has emanated from research conducted with the financial support of Science Foundation Ireland under Grant number 18/CRT/6049. This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-008441]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

2.12 Disclosure of interest

The authors report there are no competing interests to declare.

3

Appendix A: Estimating the proportion of modern contraceptives supplied by the public and private sectors using a Bayesian hierarchical penalized spline model

3.1 Calculating the variance-covariance matrices of the DHS observations using DHS microdata

Using the 'svymean' function from the 'survey' package in R [47], the proportions of each method supplied the public and privates sectors for the specific surveys in the countries listed above were calculated along with their associated variance-covariance matrices. The 'survey' package uses the Taylor series linearisation method to approximate the standard error of the calculated proportions [5] [42]

Measure	**Range (% over all methods)**	**Median SE size (% over all methods)**	**Largest mean SE (method, %)**		**Smallest mean SE (method, %)**	
Result	0.015 , 18.19	2.23	IUD	4.10	Injectables	2.03

Table 3.1: Summary table for the calculated standard errors of the data observations.

From Table 3.1, the calculated standard errors range from 0.015 to 18.19 percentage points. The median standard error size across all method is 2.23 percentage points. On average, they tend to be largest for IUDs where the mean standard error size is approximately 4 percentage points and smallest in injectables where the mean standard error size is approximately 2 percentage points.

3.2 Imputation of standard errors

In some instances, the calculated standard error was 0, where a particular method came entirely from one sector. In these instances, we needed to impute the standard error of these observations. We did this using a binomial distribution approximation of the variance, with consideration given to the design effect (DEFT) of the individual DHS surveys. For additional caution, we do not impute the standard errors for observations where the sample size is less than 20 women. 20 women is the recommended number of participants per DHS cluster, as per the DHS collection manual [51]. A database of DHS survey design effects for a sample of countries and surveys was collected for illustration purposes. The DHS DEFT can be found in the final DHS report, Appendix B "ESTIMATES OF SAMPLING ERRORS" for each DHS survey in a given country and year [23]. The DHS survey design effects measures the impact of the complex DHS sampling design on the variance of a given estimator, in this case the contraceptive method supply shares in a given country. DEFT are the ratio of the variance of a parameter estimated using a sample collected using the complex design to that estimated from a sample collected using simple random sampling [58]. In this instance, the DEFT will capture the inflation (DEFT > 1) or deflation (DEFT < 1) of our imputed standard error due to the complexity of the DHS sampling process.

The imputed standard error for country c, in year t is given by,

$$\widehat{SE}_{c,t} = \sqrt{\frac{\widehat{v}(1-\widehat{v})}{N_1+1}} \times DEFT_{c,t} \tag{3.1}$$

Where, $\widehat{SE}_{c,t}$ is the imputed standard error for country c, in year t

$$\hat{v} = \frac{N_1+1}{N_{all}+1} \tag{3.2}$$

N_1 is the number of observations in the data where the observed proportion is greater than 0.99.

N_{all} is the total number of observations in the data.

$DEFT_{c,t}$ is the listed DHS survey design effect for country c in year t. If the corresponding $DEFT_{c,t}$ is not in the database, the DEFT is set to 1.5. This is the average of the DEFT values in the database.

3.3 Creating the estimates

We used R and JAGS (Just Another Gibbs Sampler) to fit the model. JAGS uses Markov Chain Monte Carlo (MCMC) algorithm and Gibbs Sampling to produce model estimates for Bayesian Hierarchical models [59]. To evaluate the JAGS output we used 'rjags', an R package that offers cross-platform support from JAGS to the R interface [61]. The number of iterations used was 200,000. The burn-in period was set to 20,000. The samples were thinned to every 90th sample. Consequently, the posterior distribution is made up of 2000 samples. To assess convergence, we considered the R-hats values of the model parameters using the plot function of rjags, as well as the individual parameter trace plots. Consequently, the posterior distribution is made up of 2000 samples. The results were a set of trajectories for the proportion of contraceptive m supplied by each sector over time for each country included in the study. The median of these results was taken to be the model's point estimate. The 95% credible intervals were calculated using the 2.5^{th} and 97.5^{th} percentiles from the posterior distribution for each estimate.

3.4 The Delta Method for the transformation of variance terms onto the logit scale

To transform the variance-covariance matrix onto the logit scale, we use the multivariate delta method such that,

$$g(\Sigma_{Y_i}) = g'(Y_i)\widehat{SE}^2_{Y_i}g'(Y_i)^T \tag{3.3}$$

Where, $g(\Sigma_{Y_i})$ is the variance-covariance matrix associated with the logit-transformed public and private commercial medical sector supplies associated with observation i. $g'(Y_i)$ is the derivative of the associated logit-transformed proportions. $\widehat{SE}^2_{Y_i}$ are the estimated corresponding public and private commercial medical sector standard errors for observed proportions of observation i [45].

3.5 Model validation

3.5.1 Out-of-sample validation

The out-of-sample validation involves training the model on all but the most recent observation for countries that had two or more DHS data points. The withheld data then becomes a test set which we judge our models' projections against. The training set had 350 observations while the test set had 112 observations. We used the model to produce estimates and projections with 95% prediction intervals for all countries contained within the training set for the years 1990 to 2025. We then compared the resulting projections to the test set of most recent observations to check model performance.

3.5.2 Errors and coverage

We calculate sector specific error terms, $e_{j,s}$, to describe the difference between the observed data point j in sector s, $y_{j,s}$, and the median estimate from the posterior predictive distribution, $y_{j,s}$ such that,

$$e_{j,s} = y_{j,s} - \hat{y}_{j,s}. \tag{3.4}$$

We evaluated the results of the validation using different measures of accuracy and prediction interval calibration. To evaluate the accuracy of our model, we considered the root mean square error (RMSE) for each sector's set of estimates.

Let,

$$\text{RMSE}_s = \sqrt{\frac{\sum_{j=1}^{N_s} e_{j,s}^2}{N_s}}, \tag{3.5}$$

where, N_s is the number of observations in the sector s. $e_{j,s}$ is the error for observation j in sector s which is described above. The RMSE can be interpreted as the average error observed across all countries, time points and methods in the test set.

We also evaluated the mean error (eq. 3.6) and the median absolute errors (eq. 3.7). The mean error is the average difference between the observed proportion and true proportion estimated by the model and is an effective measurement of bias within the model. When the mean error is positive, this indicates systematic under-prediction by the model and conversely, a negative mean error indicates that the model is over-estimating the observed data. Median absolute error is the 50^{th} percentile of absolute differences between the observed proportion and true proportion estimated by the model. Median absolute error captures the overall variation within the model estimates.

$$\text{Mean error}_s = \frac{\sum_{j=1}^{N_s} e_{j,s}}{N_s}, \tag{3.6}$$

$$\text{Median absolute error}_s = \text{Median}(|\boldsymbol{e_s}|), \tag{3.7}$$

where, $\boldsymbol{e_s}$ is is a vector of length N_s, containing the complete set of errors estimates for all observations belonging to sector s.

Coverage assumes that if our model is correctly calibrated, then for each sector the model should be able to capture the test set of out-of-sample observations with 95% accuracy, where the remaining 5% of incorrectly estimated observations are approximately evenly distributed above and below the estimated 95% prediction interval. To examine the bias of our models estimates, we examined the location of the incorrectly estimated test set observations. We consider the proportion of test observations located above and below the estimated prediction intervals. By examining the breakdown of locations, we are evaluating the tendency of the model to under- or over-estimate the test set. If a higher proportion of observations are located below the prediction intervals, this indicates that the model is tending to over-estimate the test set. Similarly, if a higher proportion of the incorrectly estimated observations are located above the prediction intervals, the model is tending to under-estimate the test set.

3.5.3 Justification of model complexity

To evaluate whether the complexity of this model is required, we compare the complex model validation results to those of a linear regression model and a P-spline regression model without any cross-method correlation. Details of these models and their set-up can be found in the 'Model Comparison' section of this appendix.

3.6 Results

3.6.1 Out-of-sample model validation

The model described in this paper has been evaluated using various out-of-sample model validation measures to evaluate its effectiveness at estimating the method supply shares at a national level while also considering the prediction intervals it uses to produce these estimates (Table 3.2). It is performing reasonably well considering the complex nature of the data. It has an overall coverage of approximately 92%. The public sector and private commercial medical sector estimates have similar validation results. This model outperforms simpler modelling alternatives, described in the appendix. The results for the out of sample validation are found in Table 3.2. The target coverage is 95%. The model is reasonably well calibrated to the data with the public sector having 89% coverage and the commercial medical sector having 92% coverage. The private other sector has 96% coverage of the test set. The mean error of all sectors is less than 1 percentage point. The median absolute error of the public sector was the largest at 6 percentage points while the median absolute error of the private other sector was the smallest at approximately 0.7 percentage points.

Sector	Coverage (Target 95%)	Mean error (%)	MAE (%)	RMSE (%)	Median Prediction Interval Width (%)	Breakdown of location for the incorrectly estimated observations	
						Above the prediction interval (%)	Below the prediction interval (%)
Private Commercial Medical	97.4	0.51	5.5	10.8	56.9	1.7	0.9
Private Other	99.1	0.52	0.75	5.7	29.5	0.9	0
Public	93.2	1.1	7.79	11.5	55.5	5.1	1.7

Table 3.2: Leave-one-out validation results for the test set using the model described in Chapter 2. MAE is median absolute error. RMSE is root mean square error. Coverage is the proportion of the test set observations that are captured within the 95% prediction interval produced by the model. We consider the median PI width and evaluate the location of the incorrectly estimated leave-one-out validation test set observations.

For the private commercial medical sector, we see that the RMSE of this sector was 10.8% which indicates that the average error across all countries and methods was approximately 11 percentage points (Table 3.2) (For comparison with alternative models, see Tables 3.3 & 3.4). The private other sector has smallest the RMSE at approximately 6 percentage points. This is in line with the magnitude of the proportions found in this sector. In general, the private other makes up a small proportion of the overall sector mix. Finally for the public sector, the RMSE also indicates an average error of approximately 11 percentage points. The RMSE of this sector is larger than the other two sectors (11.5%, Table 3.2) but notably, the proportions supplied by the public sector are often the highest across all methods and countries. The public and private commercial medical sectors have similar median prediction interval widths. The private commercial medical sector is slightly larger at approximately 57 percentage points. The smallest median prediction interval width was produced by the private other sector covering approximately 29 percentage points (Table 3.2). When examining the location of the test observations not captured within the prediction intervals, we expect to see approximately 2.5% of the test observations below and above the prediction interval. An even distribution of the incorrectly estimated observations would indicate unbiased estimation of the test set. Both the private commercial medical and private other sectors see smaller proportions outside the PI than expected, with both sectors having coverage of 97.4% and 99.1% respectively (Table 3.2). This is above the expected 95% mark. All sectors medical sector both have a larger proportion of incorrectly estimated test set observations above the PI. This indicates that the incorrectly estimated test observations are higher than the model estimated. this would indicate a bias within the model for underestimating method supply shares.

3.6.2 Comparison of the model-based estimates to the direct estimates

In Figure 3.1, we consider the observed standard errors observed calculated using the DHS microdata versus the corresponding standard deviations estimated within the full model. From this figure, we can see that in the commercial medical and public sectors, the estimated standard deviation terms are smaller than the observed standard error terms calculated using the DHS microdata. For both sectors, we can see that most of the observations have standard errors between 1 and 12.5% approximately. These same observations when estimated within the model have corresponding standard deviations of approximately 1% to 7.5%. The use of this model results in a considerable reduction in the uncertainty of these observations. In the other sector, the uncertainty estimated within the model is larger than the associated observed standard deviations. Most observations in the private other sector have small observed standard errors (<5%). The estimated standard deviations tend to be approximately 2 percentage points larger than the observed standard errors.



Figure 3.1: A scatter plot across the three sectors comparing the standard error of the direct estimates to the model-based estimates.

In Figure 3.2, we consider the sample size to the ratio of observed to estimated proportions both of which are on the log scale for clarity. From this figure we see that as the sample size increases, the ratio of observed to estimated data point tends towards 1. Therefore, the model's ability to capture the observed data point increases as the sample size associated with each observation increases. This aligns with the same property that is seen in many small area estimation models.



Figure 3.2: A scatterplot of the estimates with log of the sample size on the x-axis and the log ratio of direct to model-based estimates on the y-axis.

3.7 Model comparison

To justify the complexity of our model, we compared it against the performance of two control models – a linear model and a penalized spline model with zero correlation.

3.7.1 Linear model

To justify the complexity of our model, we compared it against the performance of two control models – a linear model and a penalized spline model with zero correlation.

To begin, we evaluated the necessity of using a flexible penalized spline approach by comparing our model to an inflexible linear model. The linear model setting is very similar to the model set up described in Chapter 2, the key difference between the model described in Chapter 2 (we will refer to this as the full model) and this linear model is in the derivation of the latent variables, $\zeta_{c,t,m}$ and $\psi_{c,t,m}$. In the linear model, we describe the latent variables with,

$$logit(\phi_{c,t,m,1}) = \zeta_{c,t,m} = \alpha_{c,m,1} + \delta_{c,m,s} * t, \tag{3.8}$$

$$logit(\frac{\phi_{c,t,m,2}}{1-\phi_{c,t,m,1}}) = \psi_{c,t,m} = \alpha_{c,m,2} + \delta_{c,m,s} * t. \tag{3.9}$$

where,
$\alpha_{c,m,s}$ is a sector, method, country-specific intercept as described by the section 'Hierarchical estimation of the intercept' of Chapter 2
$\delta_{c,m,s}$ is a sector, method, country-specific slope term.

The slope term $\delta_{c,m,s}$ is described using the multivariate normal distribution to utilize the linear correlations between observed rates of change in the supply share for each method on the logit scale for the public sector and ratio of commercial medical sector to total private sector. Such that,

$$\delta_{c,m,s} \sim MVN(\mathbf{0}, \Sigma_{\delta,s}). \tag{3.10}$$

The $\delta_{c,m,s}$ is centered on 0 and the covariance matrix $\Sigma_{\delta,s}$ is of size MxM. $\Sigma_{\delta,s}$ is set up as described in Chapter 2. The components of a compositional vector $\phi_{c,t,m} = \phi_{c,t,m,1}, \phi_{c,t,m,2}, \phi_{c,t,m,3})$ denoting the proportion $\phi_{c,t,m,s}$ supplied by the public sector (s =1), the private commercial medical sector (s=2) and the other private sector (s=3) of modern contraceptive method m, at time t, in country c, are derived as described in Chapter 2.

3.7.2 0-covariance model

To evaluate the impact of using correlated method-specific covariance terms in the variance-covariance matrix of first-order differences of the spline coefficients, $\delta_{c,m,s}$, we considered a model with zero covariance. In this zero-covariance model, the model set up is as described in Chapter 2 with the only difference occurring in the calculation of the variance-covariance matrix $\Sigma_{\delta,s}$. As before, the first-order differences of the spline coefficients, $\delta_{c,m,s}$ are described using a multivariate normal prior centered on 0,

$$\delta_{c,m,s} \sim MVN(\mathbf{0}, \Sigma_{\delta,s}). \tag{3.11}$$

However, in this zero-covariance model the cross-method correlations are set to 0, resulting in zero-covariance on the off-diagonal of the matrix.

Let the variance-covariance matrix of $\delta_{c,m,s}$ in the zero-covariance model be,

$$\Sigma_{\delta,s} = \begin{bmatrix} \sigma^2_{\delta_{s,1}} & 0 & ... & 0 \\ 0 & \sigma^2_{\delta_{s,2}} & ... & 0 \\ . & . & ... & . \\ 0 & . & ... & \sigma^2_{\delta_{s,m}} \end{bmatrix}. \tag{3.12}$$

For both the linear and zero-covariance models, we carried out leave-one-out validation using the same training and test data as described in Chapter 2. The training set was made of 350 training set observations and 112 test set observations. The test set contained the most-recent survey observation for the proportion supplied by the public sector, the private commercial medical sector, and the other private sector of modern contraceptive method m, in country c. We evaluated the models using the same validation measures as those described above in the 'Model Validation' section.

Sector	**Coverage** (Target 95%)	**Mean error** (%)	**MAE** (%)	**RMSE** (%)	**Median Prediction Interval Width** (%)	**Breakdown of location for the incorrectly estimated observations**	
						Above the prediction interval (%)	**Below the prediction interval** (%)
Private Commercial Medical	80.9	-2.27	5.67	10.3	16.5	8.51	10.6
Private Other	95.7	1.36	0.89	6.38	11.3	2.13	2.13
Public	74.5	1.35	6.33	11.1	16.4	17.0	8.51

Table 3.3: Leave-one-out validation results for the test set using linear model. Coverage is the proportion of the test set observations that are captured within the 95% prediction interval (PI) produced by the model. The MAE is the median absolute error. RMSE is root mean square error.

Coverage measures how well a model is calibrated to predict future observations. In this instance, it is the proportion of test observations that are captured in the 95% prediction interval during leave-one-out cross validation. The full model and zero-covariance model perform similarly as both are reasonably well calibrated for all three sectors. The coverage of both the full model (Table 3.3) and the 0-covariance models are the same (Table 3.4) across the three sectors. The coverage of the linear model (Table 3.4) is lower than both the zero-covariance and full models across all sectors. None of the three sectors are optimally fitted in the linear model. As the full model and zero-covariance models have better coverage than the linear model, it justifies the use of complex penalised splines to produce model estimates. To evaluate the bias and variance produced by the three models, we consider the mean errors, median absolute errors (MAE) and root mean

Sector	Coverage (Target 95%)	Mean error (%)	MAE (%)	RMSE (%)	Median Prediction Interval Width (%)	Breakdown of location for the incorrectly estimated observations: Above the prediction interval (%)	Breakdown of location for the incorrectly estimated observations: Below the prediction interval (%)
Private Commercial Medical	97.4	0.79	6.0	10.2	55.5	1.7	0.9
Private Other	99.1	0.55	0.8	5.7	29.4	0.9	0
Public	93.2	1.36	7.05	11.5	54.3	5.0	1.7

Table 3.4: Leave-one-out validation results for the test set using zero-covariance model. Coverage is the proportion of the test set observations that are captured within the 95% prediction interval (PI) produced by the model. The MAE is the median absolute error. RMSE is root mean square error.

square errors (RMSE). Mean error is a measure of model bias (eq. 3.6.). If the mean error for a sector is positive, this indicates systematic under-prediction of test set estimates, conversely a negative mean error indicates potential bias for over-predicting the test set estimates. The median absolute error (eq. 3.7.) highlights the variation within the model. A large MAE would indicate that there exists a large difference between the test set observations and the corresponding model estimates. The root mean square error (RMSE) can be interpreted as the average error produced by the model (eq. 3.5.). Both the full model (Table 3.2) and zero-covariance model (Table 3.4) produce positive mean errors for all three sectors. The public sector test set produce the largest mean errors at 1.12% and 1.36% respectively. This indicates there is a bias for over-predicting these observations in both models, but as these mean errors are approximately 1%, they are still small. Similarly, the linear model (Table 3.3) has a positive mean error of 1.35%. This mean error is larger than that produced by either spline model. This indicates that the linear model has a larger lack of fit and bias when predicting the public sector estimates. The linear model produces the largest mean errors for the public and private other sectors across all three models. This indicates it is the least well-calibrated to the data as it has the largest biases. The zero-covariance and full models are performing similarly in terms of mean error, but the full model has marginally lower mean errors. The median absolute errors (MAE) of the full model (Table 3.2) are slightly smaller than those produced by the zero-covariance model (Table 3.4) for the private sectors. The MAE for the private commercial medical sector is lower in the linear model than those of the spline models (Table 3.3). The MAE of the private commercial medical sector linear model is 5.67% compared to the full model at 5.51% and the zero-covariance model at 5.95%. The MAE of both the full model and the 0-covariance model are very similar, however the full model MAE are slightly smaller. This indicates that they are both similarly approximating the test set proportions across all three sectors. The MAE of the public sector is almost 1 percentage point lower in the zero-covariance model, indicating that the full model tends to have a larger absolute difference between the survey observations and model estimates. The RMSE of the linear model is the largest in all three sectors across the three models (Table 3.3). This indicates that the linear model does not capture the proportions well as the average errors produced are large. The RMSE of the zero-covariance (Table 3.4) and full model (Table 3.2) indicate that the average error produced by these models are similar to one another. When considering this result with the median prediction interval widths, we see that the full model has similar sized prediction interval widths as the zero-covariance model (Table 3.2, Table 3.4). The linear model had the narrowest PI interval widths of all three models for the public (16.4%) and private commercial medical (16.5%) sectors (Table 3.3). However, considering this metric in tangent with the coverage and errors suggests that the linear model is not a good fit for the data. The PI are too tight and are missing the observations. Lastly, when considering the location of the incorrectly estimated test set observations. The full and zero-covariance models tend to under-estimate the method supply shares in all three sectors (Table 3.2) (Table 3.4). The linear model also tends to under-estimate the public sector observations (Table 3.3), as a larger proportion of incorrectly estimated observations are found above the PI boundary (17%), rather than below it (8.5%). In the private commercial medical sector, the linear model (Table 3.3) tends to under-estimate the test set observations. The incorrectly estimated observations of the private other sector are non-biased in both the full model (Table 3.2; above = 2.1%, below = 2.2%) and linear model (Table 3.3: above = 2.13%, below = 2.13%) as there is an equal proportion of observations above and below the PI. Overall, the full model described in Chapter 2 is the most suitable model to describe this data. It captures the complex shape and relationships without over-fitting it or missing the shape. It incorporates information regarding the correlations between the rates of change across the contraceptive methods. The average errors, measures of bias and median 95% prediction intervals widths produced by the model are similar to the zero-covariance models. The strength of the full model is seen in the absence of data for a particular contraceptive method, where model estimates can still be informed by the behaviour of related methods to produce realistic estimates.

3.8 Model results

The model results produced by the national level multi-country model for the 30 countries in the data set can be found in Chapter 9.

4

mcmsupply: Estimating modern contraceptive method supplies

This paper is under revision with The R Journal.

4.1 Authors

Hannah Comiskey and Niamh Cahill

Hamilton Institute and Department of Mathematics & Statistics, Maynooth University, Maynooth, Ireland;

4.2 Abstract

In this chapter, we introduce the R package *mcmsupply* which implements Bayesian hierarchical models for estimating and projecting modern contraceptive method supply shares over time. The package implements four model types. These models vary by the administration level of their outcome estimates (national or subnational estimates) and dataset type utilised in the estimation (multi-country or single-country contraceptive market supply datasets). At the multi-country level, we use Bayesian, hierarchical, penalized-spline models, with survey input, to produce annual estimates and projections of contraceptive supply-share outcomes. At the single-country level, using Bayesian modularization we use an adapted multi-country model to promote precise estimation in data sparse settings. *mcmsupply* contains a compilation of national and subnational level contraceptive source datasets, generated by IPUMS and Demographic and Health Survey microdata. We describe the functions that implement the models through practical examples. The annual estimates and projections with uncertainty of the contraceptive market supply,

produced by mcmcsupply at a national and subnational level, are the first of their kind. These estimates and projections have diverse applications, including acting as an indicator of family planning market stability over time and being utilised in the calculation of estimates of modern contraceptive use.

4.3 Introduction

Family Planning 2030 (FP2030) is a ‘global movement dedicated to advancing the rights of people everywhere to access reproductive health services safely and on their own terms’ [30]. One step towards achieving this goal is to quantify *how* people are accessing their modern contraceptive supplies. To date, obtaining estimates of modern contraceptive supply shares in low- and middle-income countries has relied on large-scale national surveys like the Demographic and Health Surveys (DHS). However, these DHS are not annually available and in practice, most countries carry out DHS every 3 to 5 years approximately, with some countries having fewer surveys than this [74]. In previous work, we described a model that provides probabilistic estimates of the contraceptive supply share over time with uncertainty and examined the model performance at the national administration division for countries that are participating in FP2030 and have varying amounts of DHS data available [16]. The original modern contraceptive supply share model (mcmsupply model) relies on splines, informed by cross-method correlations, to capture temporal variation combined with a hierarchical modelling approach to estimate country-level parameters. Using a multi-country dataset, the original mcmsupply model produces estimates of contraceptive supply market shares at the national level for all countries simultaneously. In this chapter, we extend the model to estimate supply shares using input data from a single-country and to also include estimation at the subnational administrative division.

For the remainder of the chapter, we will refer to the original modern contraceptive supply share model as the multi-country national mcmsupply model. The single-country *mcmsupply* model uses a scaled-down version of the multi-country approach. It borrows strength from the multi-country model using modular model runs with informative priors placed on key parameters to provide precise outcome estimation, even in the absence of data for a particular contraceptive method. Modularization in Bayesian analysis describes the process within a statistical model where information is restricted to flow only from the prior to the likelihood. Thus, preventing the ‘contamination’ of key parameters from suspect data [60] [48]. In the context of our problem, parameters estimated within the multi-country model are used to inform the priors of the single-country (either national or subnational administrative division) models. This approach prevents spurious parameter estimates due to a lack of data for some counties. To summarise how the single-country and multi-country models are connected to each other, Figure 4.1 depicts this modelling relationship at the national administration level. The main differences between the multi-country and single-country approaches is that for a single-country model, we only have data for one country (at the national or subnational administration division) and the country-level (in the national model) or subnational-level (in the subnational model) population parameters are informed by estimates from the corresponding multi-country model. In contrast to this, the multi-country model uses national or subnational level data (depending on your administrative level of interest) from many countries simultaneously to estimate model parameters and the country-level (in the national model) or subnational-level (in the subnational model) population parameters are estimated hierarchically.



Figure 4.1: A flow chart to illustrate the relationship between the multi-country and single-country national estimation approaches. The median estimates of the multi-country national model parameters are used as informative priors in the single-country national model. A legend describing each element of the schematic is located in the blue box.

The need for the single-country version of the mcmsupply model arose for two primary reasons. Firstly, there was a demand for improved computational efficiency while ensuring that model accuracy remains uncompromised when generating projections of modern contraceptive method supply shares for a single-country. Secondly, the option to accommodate custom data, like incorporating a new survey dataset, was sought to be included in the estimation process for users who require a more tailored analysis. The inclusion of the functionality to estimate supply shares at the subnational level in the mcmsupply package was spurred by the growing interest in subnational estimation among the family planning community [57], [54], [44]. The decentralization of family planning services produces a more equitable and efficient service; however, it also shifts the responsibility of service delivery to lower-level organisations that may not have the capacity to carry-out the role [94]. Providing subnational-level estimates can lead to a clearer understanding of localised user preferences, localised user access to family planning commodities and a measure of the true stability contraceptive supply market at a smaller geographic scale [7]. These subnational estimates may also be used as part of a localised temperature check for progress towards the FP2030 goals, which include increasing access to contraceptive methods [56].

This chapter introduces the R package *mcmsupply* for estimating and projecting the contraceptive supply share at the national and subnational administration divisions using multi-country or single-country datasets. Figure 4.2 shows a summary of the different ways users can use the R functions and input data in *mcmsupply* to do model fitting and estimation. The national data contained in the package is derived from the DHS microdata [38] while the subnational data is derived from the IPUMS DHS datasets [35]. In the 'Implementation and Operation' section, we review the operation and implementation requirements of the *mcmsupply* R package. In the 'Data' section, a detailed description of the data used within the *mcmsupply* R package is provided, as well as an explanation of the data pre-processing functions `get_data` and `get_modelinputs`. 'The estimation process' section describes the model fitting and visualisation functions within the *mcmsupply* R package. A basic overview of the process model is provided in 'Overview of the mcmsupply process models' with an explanation of some key modelling parameters. The 'Model fitting' section explains the `run_jagsmodel` function. The `run_jagsmodel` function fits models in a Bayesian framework using the JAGS (Just Another Gibbs Sampler) software and produces estimates with uncertainty for the administration level and dataset type of choice [59]. The 'Model output' section describes the `plot_estimates` function that takes the model estimates and visualises them using the R package ggplot2 [92]. The 'Use cases' section discusses five use cases for modelling modern contraceptive supply shares using the *mcmsupply* R package. Finally, the conclusions are presented.

4.4 Implementation and Operation

mcmsupply contains pre-processing functions to clean and prepare raw input data for model fitting at the administrative level of choice (national or subnational) using the dataset type of choice (multi-country or single-country). This R package includes functions to fit Bayesian hierarchical models using the model inputs. Functionality for post-processing and visualisation of the model estimates are also included. The model fitting process described uses JAGS. JAGS uses Markov Chain Monte Carlo (MCMC) sampling to produce model estimates for Bayesian hierarchical models [59]. For installation, both R ($\geq$3.5.0) and JAGS ($\geq$4.0.0) are required. JAGS can be downloaded at https://sourceforge.net/projects/mcmc-JAGS/files/JAGS/. *mcmsupply* interacts with JAGS using the wrapper functions supplied by the R package *R2jags* [70]. The *mcmsupply* package dependencies are listed in the package `DESCRIPTION` file and will be automatically installed upon installing the main package. There are no minimum RAM, CPU, or HARDDRIVE requirements apart from what is necessary to store model runs, which varies case-by-case. This software was run on a MacBook Air using macOS 13.1 with a 1.6 GHz Dual-Core Intel Core i5 processor and 8GB of memory.

4.5 Data

4.5.1 Input data

The mcmsupply package contains the following input data sources:

(1) Survey data for the national and subnational modern contraceptive supply shares between 1990 and 2020 for a selection of countries participating in the FP2030 initiative.

(2) Estimated correlations between the rates of change in method supply shares in the public and private sectors at both the national and subnational administrative divisions. These are derived based on the method outlined in Comiskey et al., 2023.

(3) Global and subcontinental parameter estimates obtained from the multi-country model run at the national and subnational level.

The inst/data-raw folder of the *mcmsupply* package contains sample R code that was used to create the model inputs in the case of the correlations and parameters. This enables users to recalculate their own single-country model parameters and correlations should they wish to do so. The code for the creation of the main input contraceptive supply source data is provided on the *mcmsupply* github page but the raw data for these datasets cannot be provided. The raw data may be accessed by users through an application to the DHS program for national level data, or the IPUMS program, for subnational level data. Help files for the contraceptive supply source datasets can be accessed by using the command `?mcmsupply::national_FPsource_data` and `?mcmsupply::subnat_FPsource_data`. The national contraceptive supply source data has data for 67 countries (including participants and non-participants of FP2030) between 1990 and 2020. The subnational contraceptive supply source data has data for 246 provinces across 24 countries (all participating in FP2030) between 1990 and 2020. Table 4.1 is a sample of 6 rows of the subnational contraceptive supply source data.

Country	Region	Method	average_year	sector_categories	proportion	SE.proportion	n
Zimbabwe	Midlands	OC Pills	2010.5	Commercial_medical	0.16017376	0.03557217	40
Zimbabwe	Midlands	OC Pills	2010.5	Other	0.10185427	0.02596022	29
Zimbabwe	Midlands	OC Pills	2010.5	Public	0.73797197	0.04498512	194
Zimbabwe	Midlands	OC Pills	2015.5	Commercial_medical	0.19294664	0.03954100	60
Zimbabwe	Midlands	OC Pills	2015.5	Other	0.04282267	0.01660390	13
Zimbabwe	Midlands	OC Pills	2015.5	Public	0.76423069	0.03875660	209

Table 4.1: The subnational contraceptive supply source data used in the subnational estimation models. Country and Region list the name of the country and province the observation relates to. The Method column lists the type of the contraceptive method supplied. The mid-year when the survey was collected is listed in average_year. The supply sector is found in sector_categories. The observed proportion and standard error are found in proportion and SE.proportion. The number of respondent making up each observation are listed in n

Lastly, data on country classification, ISO codes and area groupings is provided in the dataset `Country_and_area_classification` (Table 4.2). The help file for this dataset can be accessed via the R command `?mcmsupply::Country_and_area_classification`.

Country or area	ISO Code	Major area	Region	Developed region	Least developed country	Sub-Saharan Africa	FP2020
Afghanistan	4	Asia	Southern Asia	No	Yes	No	Yes
Albania	8	Europe	Southern Europe	Yes	No	No	No
Algeria	12	Africa	Northern Africa	No	No	No	No
American Samoa	16	Oceania	Polynesia	No	No	No	No

Table 4.2: The Country_and_area_classification dataset is the Track20 project country and area classification data according to the United Nations Statistical Division, standard country or area codes for statistical use (M49). This data set is how we classify each country in subcontinental regions. The name of the country, the International Organization for Standardization (ISO) code for each country, the continent, sub-continent are listed. Details on whether or not a country is defined as a developing, located in Sub-Saharan Africa and the status of it's participation in FP2020 (now FP2030) are also provided.

4.5.2 Data pre-processing

In *mcmsupply*, the data processing occurs in two steps: First, the raw input data is retrieved and preliminary cleaning to the dataset is completed. Secondly, the cleaned data is processed to provide the model inputs for the Bayesian hierarchical model. This two-step process removes any black-box element to the model fitting process and allows the user to review the data at both stages and refer to it later when considering model outputs. The first step involves the `get_data` function. This function retrieves the raw data from the stored contraceptive supply source dataset, does data cleaning and processing to address any issues with missing data and regional naming inconsistencies. Its arguments are summarized in Table 4.3. First, the user defines whether they wish to use national or subnational level administrative data via the `national` argument. National level data is accessed when the `national` argument is set to `TRUE`. When subnational administrative data is required, the user sets national to `FALSE`. Similarly, the user defines whether they want to use multi-country estimation with data from multiple countries or single-country estimation with data from a single-country via the `local` argument. The default setting for the `local` argument is `FALSE`. This induces a multi-country estimation, where the outcomes for all the countries in the contraceptive supply source dataset will be estimated simultaneously. In the event of single-country estimation, the user sets `local` to `TRUE` and indicates their country of interest via the `mycountry` argument. The names of the countries listed in the package data can be found in the `country_names` dataset. The help file for this dataset can be accessed via the R command `?mcmsupply::country_names`. The `fp2030` argument controls whether to include countries that are participating in the FP2030 initiative or not. The default includes only the named FP2030 countries (see `country_names`) in the dataset. There is the optional functionality to include a custom dataset. This allows the user to run the model on data outside of that stored within the package. The `surveydata_filepath` is a character string that denotes the location of the custom dataset. The file must meet a series of internal checks on file type, column names, suitable data ranges and missing data. When a custom dataset is supplied to `get_data`, the function carries out the checks and alerts the user to any differences between what is expected and what has been supplied. If `surveydata_filepath` is left as `NULL`, by default the function uses the stored `national_FPsource_data` or `subnat_FPsource_data`, depending on what administrative level the user has specified via the `national` argument (Table 4.3). The `get_data` function returns a list containing the cleaned data and a list of arguments supplied to the function. Storing the arguments of the `get_data` function allows the set-up information to flow without requiring the user to repeatedly supply the same arguments for each step of the modelling process.

Argument	Data type	Description
national	Character	It indicates whether the user is interested in using data at the national or subnational administration level. This is a binary TRUE or FALSE argument. Default is TRUE which retrieves national level data, while FALSE retrieves subnational data.
local	Character	It indicates whether the user is interested in using data for a single population or not. This is a binary TRUE or FALSE argument. Default is FALSE.
mycountry	Character	This is the name of the country you wish to do single-country estimation for. The data will only be returned for this country. Default is NULL.
fp2030	Character	It indicates whether the user is interested in using only countries participating in FP2030. This is a binary TRUE or FALSE argument. Default is TRUE.
surveydata_filepath	Character	Pathway to the location of the custom dataset. When left as NULL, the function automatically uses the stored datasets. Default is NULL.

Table 4.3: The arguments of the get_data function. The purpose of this function is to retrieve and clean the Demographic and Health Survey (DHS) data or custom user supplied data for use in supply share estimation. The Argument column names the function component. Data type describes the argument. Description explains the purpose of the argument and any default entries.

Step two of the data pre-processing is the `get_modelinputs` function. This function takes the cleaned data from the previous step and repackages it into suitable inputs for the model implementation. The arguments of the function are summarised in Table 4.4. This function uses the arguments set in the `get_data` function as well as additional parameters for the model. These parameters include the year the user wishes to begin their estimation at and the year they finish on. In the *mcmsupply* package, the models use basis splines (B-splines), to capture the complexities in variation of the contraceptive supply source data over time. B-splines use basis-functions to create piece-wise cubic polynomials. The number of basis functions that are fit to the data is determined by the number of knots. Knots are the locations along the x-axis where the piece-wise polynomials of the B-splines join. As you increase the number of knots in the basis functions, the B-splines give a tighter fit to the data. Similarly, if you decrease the number of knots in the basis, you will get a smoother fit to your data. In the *mcmsupply* package, the user may alter the number of knots (`nsegments`) used in the basis functions. The default number of knots is 12, as was used in Comiskey et al., 2023. Like the `get_data` function, this function returns a list containing the model inputs and the function arguments.

Argument	Data type	Description
startyear	Numeric	The year you wish to start your estimation at.
endyear	Numeric	The year you wish to finish your estimation at.
nsegments	Numeric	The number of knots you wish to include in your basis functions. Default is 12.
raw_data	List	The output of the get_data function, which includes a list of the function arguments used and the cleaned contraceptive supply source data.

Table 4.4: The arguments of the get_modelinputs function. The purpose of this function is to get the model inputs for the JAGS model used for supply share estimation. In the table, the argument name and data type of the argument is stated, a description of the argument and any default values is then provided.

4.6 The estimation process

The *mcmsupply* R package contains four Bayesian models, each of which aims to estimate and project contraceptive method supply shares over time with uncertainty. These models vary by the administration level of their outcome estimates (national or subnational estimates) and dataset type utilised in the estimation (multi-country or single-country contraceptive market supply datasets). A full mathematical description of all the models contained within *mcmsupply* is described in Appendix 5 [a]. A summary of each of the parameters and their role within each model can be found in Table 4.5 while a visual summary of the national model, using both multi-country and single-country inputs, can be found in Figure 4.1.

Brief model overview

The outcome of interest is the components of a compositional vector $\boldsymbol{\phi_{q,t,m}}$, which captures the proportion of contraceptive method m, at time t, in population q supplied across the public and private sectors.

$$\boldsymbol{\phi_{q,t,m}} = (\phi_{q,t,m,1}, \phi_{q,t,m,2}, \phi_{q,t,m,3}), \tag{4.1}$$

[a] At the time of publication it is expected that this material will be made available via another open access venue.

where, $\phi_{q,t,m,s}$ is the proportion supplied by the public sector (s =1), the private commercial medical sector (s=2) and the other private sector (s=3) of modern contraceptive method m, at time t, in population q (national or subnational).

Figure 4.1 shows the model set up for the national level models. A similar approach is taken when estimating modern contraceptive method supply at the subnational administration level. For each model within the *mcmsupply* package, the latent variable $\psi_{q,m,t,s}$ relies on a spline to capture the underlying process that generates the data, on the logit scale, for sector s, in year t, for method m and population q (depending on the administration level of interest) .

$$\psi_{q,t,m,1} = \sum_{k=1}^{K} \beta_{q,m,1,k} B_{q,k}(t) \tag{4.2}$$

where, $\beta_{q,m,1,k}$ is the k^{th} spline coefficient for sector s, method m in population q.
$B_{q,k}(t)$ is the k^{th} basis function fit to the data for population q.

We assume that in population q, for method m and sector s, the value of spline coefficient at knot index k^*, aligning with the year t^*, the most recent survey available, is $\alpha_{q,m,s}$. By doing this, we are assuming that the $\alpha_{q,m,s}$ parameter will act as the spline coefficient for the reference spline at k^*. We are then able to calculate the remaining spline coefficients from the reference index (k^*) using the estimated $\boldsymbol{\delta_{q,m,s}}$.

$$\beta_{q,m,s,k} = \begin{cases} \alpha_{q,m,s} & k = k^*, \\ \beta_{q,m,s,k+1} - \delta_{q,m,s,k} & k < k^*, \\ \beta_{q,m,s,k-1} + \delta_{q,m,s,k-1} & k > k^*, \end{cases} \tag{4.3}$$

where, $\alpha_{q,m,s}$ is the most recently observed supply share, on the logit scale, for sector s , method m, in population q. This parameter is estimated hierarchically. The geographical set-up of this estimation process adapts to match the administrative level of interest. For example, the subnational multi-country models contain an additional layer of geography ($world > subcontinent > country > province$) in the hierarchical set-up that the national models don't have, which accounts for the subnational administration levels.
k is the knot index along the set of basis splines $B_{q,k}(t)$
k^* is the index of the knot that corresponds with t^*, the year index where the most recent survey occurred in population q.
$\delta_{q,m,s,k-1}$ is the first order difference between spline coefficients $\beta_{q,m,s,K}$ and $\beta_{q,m,s,K-1}$. These reflect the changes in method supply shares over time. Within each sector, the first-order differences are assumed to be correlated between methods. These correlations

were estimated using a maximum *a posteriori* estimator for the correlation matrix first described in Azose and Raftery, 2018 [4] and adapted for method supply shares in Comiskey et al.,2023. These estimated correlations are available as data for both the national and subnational models. Please see the Data section of this chapter for more details.

Model type	Parameter name	Parameter purpose
Multi-country national	P	The method supply share proportions ($\phi_{c,t,m,s}$) for all countries, methods and sectors.
	beta.k	The set of spline coefficients for ($\beta_{c,m,s,k}$) for all countries, methods and sectors at each knot.
	alpha_cms	The intercept term ($\alpha_{c,m,s}$) for all countries, methods and sectors.
	delta.k	The first order differences between spline coefficients (($\delta_{c,m,s,k}$)) across all knots for all countries, methods and sectors
Single-country national	P	The method supply share proportions ($\phi_{c,t,m,s}$) for all countries, methods and sectors.
	alpha_cms	The intercept term ($\alpha_{c,m,s}$) for the country of interest c, across all methods and sectors.
	inv.sigma_delta	The precision matrix used in the multivariate normal prior of $\delta_{c,1:M,s,k}$
	beta.k	The set of spline coefficients ($\beta_{c,m,s,k}$) for the country of interest c, across all methods and sectors at each knot.
Multi-country subnational	alpha_pms	The intercept term ($\alpha_{p,m,s}$) for all subnational provinces, methods and sectors.
	alpha_cms	The intercept term ($\alpha_{c,m,s}$) for all countries, methods and sectors. $\alpha_{c[p],m,s}$ is the expected value of $\alpha_{p,m,s}$.
	inv.sigma_delta	The precision matrix used in the multivariate normal prior of $\delta_{p,1:M,s,k}$
	tau_alpha_pms	The sector-specific precision associated with $\alpha_{p,m,s}$
	beta.k	The set of spline coefficients ($\beta_{p,m,s,k}$) across all subnational provinces, methods and sectors at each knot.
	delta.k	The first order differences between spline coefficients across all knots ($\delta_{p,m,s,k}$) for all provinces, methods and sectors.
Single-country subnational	P	The method supply share proportions ($\phi_{p,t,m,s}$) for the subnational provinces in the country of interest, for all methods and sectors.
	alpha_pms	The intercept term ($\alpha_{p,m,s}$) for the subnational provinces in the country of interest, for all methods and sectors.
	beta.k	The set of spline coefficients ($\beta_{p,m,s,k}$) for the subnational provinces in the country of interest, across all methods and sectors at each knot

Table 4.5: This table summarises the purpose of each parameter within each of the four models described in the *mcmsupply* R package. The four types of model are listed in the 'Model type' column. For each model, the parameters listed in the 'Parameter name' column are the default parameters monitored when the argument jagsparams=NULL is used within the run_jags_model function. The 'Parameter purpose' column explains the role each parameter plays within the estimation process and the notation can be linked directly to the 'Model overview' section of this chapter.

4.6.1 Model fitting

The `run_jags_model` function fits the selected JAGS model to the supplied data and returns a list of MCMC samples and point summaries for the time-period and locations of interest. Initial set-up arguments (`national`, `local`, `mycountry`) are inherited from the specification of the previous `get_modelinputs` function. The additional inputs of this function are summarised in Table 4.6. The `jagsdata` argument of this function is a list of initial set-up arguments and JAGS model inputs gathered from the `get_modelinputs` function. `jagsparams` is a vector of strings that name the model parameters the user wishes to monitor within the JAGS model. The default is `NULL`. When `jagsparams = NULL`, the function will refer to a stored vector of parameters to monitor (Table 4.5). The JAGS parameters of `n_iter = 80000`, `n_burnin = 10000` and `n_thin = 35` ensure that the model has converged and that the final posterior sample size is 2000 samples. The function `get_point_estimates` takes the chains produced by the JAGS model and estimates the median, 80%, and 95% credible intervals. The `get_point_estimates` function runs automatically inside the `run_jags_model` function and returns the point summaries as part of the `run_jags_model` function output. The `run_jags_model` function returns a list containing the JAGS output of the model and the point summaries for the estimates.

Argument	Data type	Description
jagsdata	List	The output of the get_modelinputs function. A list of the initial set-up arguments and the JAGS inputs required using the data.
jagsparams	Vector	A string vector of model parameters to be monitored. Default is NULL. NULL invokes a standard vector to be used.
n_iter	Numeric	Number of iterations you wish to run your JAGS model for. Default is 80000.
n_burnin	Numeric	Number of burn-in samples you wish to run your JAGS model for. Default is 10000
n_thin	Numeric	Number of samples you wish to thin your JAGS sample by. Default is 35.

Table 4.6: The arguments of the run_jags_model function. The purpose of this function is to run the Bayesian hierarchical models stored within the mcmsupply package for either single- or multi-country datasets at the administration level of interest. The argument name and data type of the argument is stated, a description and any default values of the argument are then provided.

Model output

The user then runs the function `plot_estimates`. This function visualises the point estimates with uncertainty alongside the data using the initial set up inputs of the `get_modelinputs` function and the output of the `run_jags_model` function (Table 4.6). The `plot_estimates` function returns a list of *ggplot2* objects, one for each country (when using the national model) or subnational region (when using the subnational model).

Argument	**Data type**	**Description**
jagsdata	List	A list of the initial set-up arguments and the JAGS inputs required using the data retrieved in the get_modelinputs function.
model_output	List	The object assigned to store the list of MCMC results and estimate summary output from the run_jags_model function.

Table 4.7: The arguments of the plot_estimates function. The purpose of this function is to plot the data alongside the model estimates so that users can visualise their estimated method supply shares. The argument name and data type of the argument is stated, a description of the argument is then provided.



Figure 4.2: A flow chart to illustrate the decision processes that lead to the different estimation types within the mcmsupply package. The first decision is with respect to the administrative level of the estimates you wish to create – they may be either national level or subnational level. An explanation of each division is found on the first row of the figure. The second decision is with respect to the number of countries you wish to estimate – the user may estimate the proportions for all the countries at once or only one country. An explanation of each in the context of the specific administrative division is found on the second row of the figure. A set of sample functions used to estimate and plot the estimates for each modelling option are located on the third row of the figure

4.7 Use cases

4.7.1 Case 1: Estimating contraceptive method supply shares at the national administration level for multiple countries simultaneously

The first use case describes how the user can estimate modern contraceptive method supply shares at the national administrative level over time for multiple countries at once (i.e., using the multi-country national model).

This use case is described in `multi_national_mod` found in the `vignettes` folder. This vignette takes approximately 12 hours to run on a machine with 1.6 GHz Dual-Core Intel Core i5 processor and 8GB of RAM. The `national_FPsource_data` dataset contains observations for 30 countries. The user begins by accessing the `national_FPsource_data` dataset through the `get_data` function with the argument `national=TRUE`, and the remaining arguments sets to their default values, to indicate that they are interested in national-level data for the FP2030 countries present in the data.

```
cleaned_natdata <- get_data(national=TRUE)
```

Next, this data is supplied to the `get_modelinputs` function. This function reshapes the data into a list of inputs for the JAGS model. At this point, the user must indicate the start and end years they wish to estimate between. The `n_segments` argument controls how many knots will be used in the basis functions. The default number of segments is 12. Lastly, the cleaned national data from the `get_data` function is provided to the `get_modelinputs` function via the `raw_data` argument.

```
pkg_data <- get_modelinputs(startyear=1990,
                            endyear=2025.5,
                            nsegments=12,
                            raw_data = cleaned_natdata)
```

This list of data and model inputs is then fed into the JAGS model via the `run_jags_model` function. In this instance, the user wishes to monitor the default set of parameters within the JAGS model. Therefore, they set the 'jagsparams' argument to 'NULL', which invokes the function to use the default list. The parameters for running the JAGS model are set via the `n_iter`, `n_burnin` and `n_thin` arguments. As part of the `run_jags_model` function, the median and 80% and 95% credible intervals for the estimates are calculated.

```
mod <- run_jags_model(jagsdata = pkg_data,
                      jagsparams = NULL,
                      n_iter = 80000,
                      n_burnin = 10000,
                      n_thin = 35)
```

The final JAGS model output and the summary estimates are returned as a list. These summary estimates are visualised via the `plot_estimates` function using the R package *ggplot2* (Figure 4.3).

```
plots <- plot_estimates(jagsdata = pkg_data,
                        model_output = mod)
```

It is also possible to pull out the model estimates for a given country and year that a user may be particularly interested in. In this case, the user utilises the `pull_estimates` function, supplying the model output, country name and year of interest.

```
estimates_2018 <- pull_estimates(model_output = mod, country='Nepal', year=2018)
```



Figure 4.3: The plotted posterior point estimates for each of the three sectors (public in blue, private commercial medical in grey, and private other in gold) for Nepal at the national administrative level over time with the 80% and 95% uncertainty interval denoted as shaded regions. The survey observations are plotted as points with their associated standard error, plotted as vertical lines. This plot was produced using a multi-country set up of the *mcmsupply* functions.

4.7.2 Case 2: Estimating contraceptive method supply shares at the national administration level for a single-country

This case considers when the estimates at the national administration level are required for only one country. Rather than running a multi-country model, which takes several hours, a quicker alternative is the single-country approach, which takes only a few minutes. The main difference between the multi-country and single-country model outputs is that the model estimates of the single-country models have slightly larger uncertainty. This is especially evident where data is absent for a particular method. For example in Figure 4.3, the width of the 95% credible intervals over time for implants estimated by the multi-country national model are smaller than those estimated in the single-country model (Figure 4.4). The arguments `local` and `mycountry` control the single-country estimation models in *mcmsupply*. The user begins as by retrieving the data for Nepal only using the `get_data` function. They set `local=TRUE` and specify which country they are interested in by setting `mycountry=Nepal`.

```
cleaned_natdata <- get_data(national=TRUE,
                            local=TRUE,
                            mycountry="Nepal")
```

These arguments are the only discernible differences in the commands for users, the rest of the workflow is as described above in Case 1. A complete workflow for this use case can be found in `vignettes/local_national_mod`. The single-country model produces model estimates that align with those estimated by the multi-country estimation model.



Figure 4.4: The plotted posterior point estimates for each of the three sectors (public in blue, private commercial medical in grey, and private other in gold) for Nepal at the national administrative level over time with the 80% and 95% uncertainty interval denoted as shaded regions. The survey observations are plotted as points with their associated standard error, plotted as vertical lines. This plot was produced using a single-country set up of the *mcmsupply* functions.

4.7.3 Case 3: Estimating contraceptive method supply shares at the subnational administration level for multiple countries simultaneously

The use case for estimating the contraceptive supply shares via a multi-country model for the subnational administration division is given by the vignette `subnational_multinational _models`. This vignette takes approximately 24 hours to run on a machine with 1.6 GHz Dual-Core Intel Core i5 processor and 8GB of RAM. The dataset contains observations for 225 subnational divisions, across 23 countries. The user begins by calling the multi-country dataset at the subnational administration level via the ‘national‘ argument.

```
cleaned_subnatdata <- get_data(national=FALSE)
```

The remaining workflow is the same as described above in Case 1 and is not shown here. A complete workflow for this use case can be found in `vignettes/subnational_multinational_models`.

4.7.4 Case 4: Estimating contraceptive method supply shares at the subnational administration level for a single-country

This use case is for considering use of the single-country model at the subnational administrative division. The user begins by retrieving the data for Nepal using the `get_data` function by setting the arguments `national=FALSE`, `local=TRUE` and `mycountry="Nepal"`.

```
cleaned_data <- get_data(national=FALSE,
                         local=TRUE,
                         mycountry="Nepal")
```

As in the previous use cases, the JAGS model is run and point summaries are calculated via the `run_jags_model` function. The visualisations for the subnational regions of Nepal are returns as a list via the `plot_estimates` function. An example of these visualisations is given in Figure 4.5, where the estimated median method supply shares for Central region of Nepal are plotted with 80% and 95% credible intervals over time in each of the methods.



Figure 4.5: The plotted posterior point estimates for each of the three sectors (public in blue, private commercial medical in grey, and private other in gold) taken from the subnational single-country population for the Central region of Nepal over time with both 80% and 95% uncertainty denoted as corresponding shaded regions. The survey observations are plotted as points with their associated standard error, plotted as vertical lines.

4.7.5 Case 5: Estimating contraceptive method supply shares at the national/subnational administration level for a single-country using custom data

It is possible to include custom datasets when estimating contraceptive method supply shares at either the national or subnational administration level. The set-up for using custom data is very similar to the above processes, with a small difference in the data retrieval step using the `get_data` function. When using a custom dataset, the user defines the location of the '.xlsx' file containing the custom data.

```
cleaned_data <- get_data(national=FALSE,  local=TRUE,
    surveydata_filepath =  "inst/data-raw/my_custom_data_good.xlsx",
    mycountry="Ethiopia")
```

The file must be in '.xlsx' format and match the layout of either the `national_FPsource_data` or `subnat_FPsource_data`, depending on your desired administration level. The `get_data` function will carry out a series of internal checks to ensure the custom data matches the stored data layout. If the custom data is not suitable, the `get_data` function will return an error and a message to the user describing the issue with the custom data. Once the custom data checks are complete and passed, the regular workflow for fitting an *mcmsupply* model continues. The JAGS model inputs are retrieved using the `get_modelinputs` and the JAGS model is fit using `run_jags_model`. The summary estimates are plotted using the `plot_estimates` function without any further changes to the workflow. A vignette of how to run the subnational model using a custom dataset can be found `vignettes/subnational_local_customdata_models`.

4.8 Discussion

In this chapter we have introduced the package *mcmsupply*. The primary purpose of this package is to estimate and project modern contraceptive method supply shares from the public, private commercial medical and private other sectors with uncertainty, for a selection of countries participating in the FP2030 initiative. The *mcmsupply* package produces estimates within the period of available Demographic and Health Survey data for a given country, as well as projections beyond the most recent data point. The package uses either stored DHS survey data or custom user-supplied survey data as inputs to the modelling process. The package implements four model types. These models vary by the administration level of their outcome estimates (national or subnational administration level) and dataset type utilised in the estimation (multi-country or single-country contraceptive market supply datasets). The modelling framework uses penalised splines to capture temporal nature of the data. These splines utilise correlations between changes in method supply shares that exist within the data. Using splines informed by cross-method correlations allows us to capture the complex shape of the data without over-fitting. Bayesian hierarchical estimation is another key element of this model estimation process. We take advantage of the geographical nature of the data, such that the expected sector, province (subnational level) or country (national level), method-specific supply shares are informed based on the existing geographical structures in the data. This promotes information sharing across locations, and better inform estimates in areas where smaller amounts of data are present. Case studies illustrate how to use the *mcmsupply* for each of the four potential modelling routes, as well as how to estimate contraceptive method supply shares using custom user-supplied data. At the national level, there is no discernible difference between the multi-country model estimates (Figure 4.3) and the single-country model estimates (Figure 4.4). In case study 4, we see that the single-country subnational model estimates are more influenced by the priors than at the national-level. This is evident in the estimation of implants, in Figure 4.5. In this instance, the multi-variate normal prior used to rates of change between spline coefficients is informed by the globally estimated variance-covariance matrix. The globally estimated variance parameter for implants is small, as such the model estimates are more constrained around the expected value (the most recently observed survey level). In addition, the calculated standard error terms for Central Nepal are very large causing the model estimates to be driven more by the prior, than the data. For a complete explanation of all the modelling approaches used in this R package, we direct the reader to Chapter 5, Appendix B.

The *mcmsupply* package has many benefits to users. Firstly, it is the first of it's kind to produce annual estimates with uncertainty for monitoring contraceptive method supply shares over time at the national and subnational levels. On average, most countries carry out DHS surveys every 5-6 years, but in some instances the wait time between surveys may be even longer [74]. The family planning community use contraceptive method supply shares to evaluate the stability and sustainability of a given country's contraceptive market [8]. Contraceptive method supply share estimates are also pivotal in effectively managing contraceptive commodity supply-chains through a 'total market approach' (TMA). A TMA approach to the family planning supply market seeks to engage the public, private commercial, and other sectors in a country to increase family planning users access to vital information, products, and services [55] [72]. Prior to this package, individuals who required contraceptive method supply shares for a given country relied on estimates from the most recent DHS survey in the country, regardless of it's its age. The *mcmsupply* package alleviates this issue and provides the family planning community annual estimates with uncertainty for these contraceptive method supply shares. Secondly, contraceptive method supply shares estimates are not only a stand -alone family planning indicator but are also used in the calculation of an another indicator, estimated modern use (EMU) [79]. EMUs aim to measure the proportion of women, aged 15 to 49 years old , who are currently using any modern method of contraception, and are derived from routinely collected family planning service statistics [79]. Currently, EMU calculations depend on an adjustment that relies on the most recent DHS survey to provide estimates of the contraceptive supply share market in a given country. Now this adjustment can instead rely on the annual estimates and projections with uncertainty produced by the *mcmsupply* package. This can serve to improve the overall accuracy of EMUs with respect to their ability to accurately measure modern contraceptive use. In addition, given the probabilistic nature of the *mcmsupply* estimates the associated uncertainty can be propagated into the EMU calculations.

The last key benefit of the *mcmsupply* package is the speed at which the user is able to access individual countries supply share estimates. Using the single-country models, at either the national or subnational level, provides users with annual estimates of the method supply shares with uncertainty within minutes. This fast estimation approach is computationally efficient while still producing reliable estimates. Using priors informed by multi-country model subcontinental and country-level median parameter estimates, this modelling approach is robust to spurious parameter estimates even when estimating supply shares for countries with fewer surveys available. This computational efficiency without a loss of model accuracy makes the *mcmsupply* package user-friendly and efficient for regular data analysis.

The *mcmsupply* is not without its limitations. We remark that the implementation of these models in JAGS have not been optimised. The multi-country models at the national and subnational levels take hours to run and are intensive on computer memory and CPU. Hence, improvements such as matrix operations rather than for-loops would greatly improve the computation efficiency of this package. Improving the package's computational efficiency would not only make it more appealing to users, but also make it more energy efficient. Given the current climate and energy crisis the world finds itself in, this improvement is of vital importance [65]. Another limitation of this package is that in methods without any survey information, the uncertainty intervals tend to be large. This is especially evident in the single-country models where in the absence of data for a given method, the uncertainty of the associated estimates is even larger than that of the corresponding multi-country model estimates. These limitation inspires our future work, where we seek to improve the computational efficiency of these models. We would also like to investigate the potential for incorporating additional covariates into the models, such as average method pricing for each sector, to improve the uncertainty of model estimates and projections where no DHS survey data is available. Lastly, we wish to design an R-shiny app that promotes the use of these model estimates among statistical non-experts within the family planning community.

4.9 Conclusions

mcmsupply is an R package that estimates the modern contraceptive method supply shares at the national and subnational administrative divisions over time for countries participating in the Family Planning 2030 initiative. The package provides the user an easy and accessible way to produce annual estimates with uncertainty using Bayesian hierarchical penalised spline models with cross-method correlations at the national and subnational administration levels. These annual estimates with uncertainty may act as a stand-alone family planning indicator of the stability of the modern contraceptive supply market or be used to produce alternative family planning indicators, such as estimated modern use (EMUs) using service statistics [79]. To the best of our knowledge, the package is the first of its kind to estimate these supply shares at both administrative levels. Using an R package to disseminate this work aligns with the findability, accessibility, interoperability, and reusability (FAIR) principles of scientific data [93]. The data used in the package is cited and explained thoroughly, the code is commented and easy to understand should a user wish to tweak or review any functionalities, and finally it is reusable by the very nature of the R package.

5

Appendix B: Mathematical description of process to estimate and project contraceptive method supply shares at national and subnational administration levels over time using Bayesian hierarchical penalised splines

5.1 Introduction

This document is a summary of the extensions made to the model described in Comiskey et al., (2023) [16]. Described below are the statistical models used to estimate national and subnational contraceptive method supply shares over time using Bayesian hierarchical penalised spline models with multi-country and single-country datasets. These models are utilised in the mcmsupply R package [17].

5.2 Terminology

Contraceptive method supply shares: The proportion of modern contraceptives supplied by the public, private commercial medical and private other sectors over time.

Multi-country national model: This model estimates the contraceptive method supply shares at the national administration level over time for many countries simultaneously.

Single-country national model: This model estimates the contraceptive method supply shares at the national administration level over time for a single country.

Multi-country subnational model: This model estimates the contraceptive method supply shares at the subnational administration level over time for many countries simultaneously.

Single-country subnational model: This model estimates the contraceptive method supply shares at the subnational administration level over time for a single country.

5.3 Overall set-up

The outcome of interest is the components of a compositional vector

$$\boldsymbol{\phi_{q,t,m}} = (\phi_{q,t,m,s=1}, \phi_{q,t,m,s=2}, \phi_{q,t,m,s=3})$$

where, $\phi_{q,t,m,s}$ is the proportion supplied by the public sector (s =1), the private commercial medical sector (s=2) and the other private sector (s=3) of modern contraceptive method m, at time t, in population q (national or subnational).

We begin by defining a regression model for $\phi_{q,t,m,1}$. The logit-transformed proportion, logit($\phi_{q,t,m,1}$), is modelled through a latent variable $\psi_{q,t,m,1}$, with a penalized basis-spline (P-spline) regression model:

$$\text{logit}\,(\phi_{q,t,m,1}) = \psi_{q,t,m,1} = \sum_{k=1}^{K} \beta_{q,m,1,k} B_{q,k}(t), \tag{5.1}$$

where,
$\psi_{q,t,m,1}$ is the latent variable capturing the logit proportions of the public sector (s=1) supply share of method m, at time t, in population q. $B_{q,k}(t)$ refers to the k^{th} basis function evaluated in population q, at time t . $\beta_{q,m,1,k}$ is the k^{th} spline coefficient for the public sector supply (s=1) of method m in population q.

Similarly, we model the latent variable, $\psi_{q,t,m,2}$, to capture the logit-transformed ratio of the private commercial medical supply share to the total private sector share. The model is specified as follows:

$$\text{logit}\left(\frac{\phi_{q,t,m,2}}{1-\phi_{q,t,m,1}}\right) = \psi_{q,t,m,2} = \sum_{k=1}^{K} \beta_{q,m,2,k} B_{q,k}(t), \tag{5.2}$$

where, $\beta_{q,m,2,k}$ is the k^{th} spline coefficient for the ratio of private commercial medical sector (s=2) to total private sector for method m in population q.

The basis functions $B_k(t)$ are constructed using cubic splines. The basis are fitted over the years 1990 to 2025. We align the knot placement of the basis splines with the most recent survey year in each country. As the most recent survey year varies by country (in the case of national-level data) or province (in the case of subnational data), the basis splines $B_{q,k}(t)$ also vary by location.

To estimate the spline coefficients, $\beta_{q,m,s,k}$, we use a random walk model of order 1 on spline coefficients such that the first-order differences, $\boldsymbol{\delta_{q,m,s}}$, are penalized. This model choice is motivated by prior work that used constant projections past the most recent data point [79]. The $\boldsymbol{\delta_{q,m,s}}$ vector is of length h where h=K-1, and K is the total number of knots used in the set of basis functions. It is defined as,

$$\boldsymbol{\delta_{q,m,s}} = (\beta_{q,m,s,2} - \beta_{q,m,s,1}, \beta_{q,m,s,3} - \beta_{m,s,2}, ..., \beta_{m,s,K} - \beta_{q,m,s,K-1}). \tag{5.3}$$

We assume that in population q, for method m and sector s, the value of spline coefficient at knot index k*, aligning with the year t*, the most recent survey available, is $\alpha_{q,m,s}$. By doing this, we are assuming that the $\alpha_{q,m,s}$ parameter will act as the spline coefficient for the reference spline at k*. We are then able to calculate the remaining spline coefficients from the reference index (k*) using the estimated $\boldsymbol{\delta_{q,m,s}}$.

$$\beta_{q,m,s,k} = \begin{cases} \alpha_{q,m,s} \quad k = k^*, \\ \beta_{q,m,s,k+1} - \delta_{q,m,s,k} \quad k < k^*, \\ \beta_{q,m,s,k-1} + \delta_{q,m,s,k-1} \quad k > k^*. \end{cases} \tag{5.4}$$

Where,
$\alpha_{q,m,s}$ is the most recently observed supply share on the logit scale for sector s , method m, in population q. This proxies as an intercept in the model.
k is the knot index along the set of basis splines $B_{q,k}(t)$
k^* is the index of the knot that corresponds with t^*, the year index where the most recent survey occurred in population q.
$\delta_{q,m,s,k-1}$ is the first order difference between spline coefficients $\beta_{q,m,s,K}$ and $\beta_{q,m,s,K-1}$

We assume a smooth transition between spline coefficients. Thus, we centre our rates of change, $\delta_{q,1:M,s,k}$, on 0, with a variance-covariance matrix, Σ_{δ_s}, that captures the correlations that exist between the rates of change in supply shares for each pair of methods.

$$\delta_{q,1:M,s,h} \mid \Sigma_{\delta_s} \sim MVN(\mathbf{0}, \Sigma_{\delta_s}), \tag{5.5}$$

From the latent variable vector, $\boldsymbol{\psi_{q,t,m}}$, it is possible to infer the compositional vector

$\boldsymbol{\phi_{q,t,m}}$, such that,

$$\begin{aligned}\phi_{q,t,m,1} &= \text{logit}^{-1}\left(\psi_{q,t,m,1}\right), \\ \phi_{q,t,m,2} &= \left(1-\phi_{q,t,m,1}\right)\text{logit}^{-1}\left(\psi_{q,t,m,2}\right), \\ \phi_{q,t,m,3} &= 1-\left(\phi_{q,t,m,1}+\phi_{q,t,m,2}\right).\end{aligned} \tag{5.6}$$

At the national level, the likelihood of the logit-transformed observed data, logit(Y_i), the observed logit-transformed proportions of modern contraceptive method supplied by the public and commercial medical sectors (s=1 and s=2) for method m, at time t in country c, are modelled using Multivariate Normal distributions such that,

$$\text{logit}(\boldsymbol{Y_i}) \mid logit(\boldsymbol{\phi}_{c[i],t[i],m[i],s=1:2}) \sim MVN(logit(\boldsymbol{\phi}_{c[i],t[i],m[i],s=1:2}), \Sigma_{Y_i}), \tag{5.7}$$

Where, $logit(\boldsymbol{\phi}_{c[i],t[i],m[i],s=1:2})$ is the vector of logit-transformed public (s=1) and private commercial medical (s=2) supply proportions for the country, time-point, method associated with observation i.
The variance-covariance matrix, Σ_{Y_i}, utilizes the standard errors (SE) and covariances calculated using the DHS survey microdata associated with the logit-transformed observations, $logit(Y_i)$. Details of the delta-method transformation can be found in the appendix (Chapter 3, section 4).

At the subnational level, the likelihood of the logit-transformed observed data, logit(y_i), the observed logit-transformed proportion of modern contraceptive method supplied by the public and commercial medical sectors (s=1 or s=2) for method m, at time t are modelled using Normal distributions, such that,

$$\text{logit}(y_i) \mid logit(\phi_{q[i],t[i],m[i],s[i]}) \sim N(logit(\phi_{q[i],t[i],m[i],s[i]}), SE_i^2). \tag{5.8}$$

Where,
$logit(\phi_{q[i],t[i],m[i],s[i]})$ is the logit-transformed supply proportion for the population q, time t, method m, and sector s associated with observation i.
The variance, SE_i^2, utilizes the standard error (SE) calculated using the DHS survey microdata associated with logit-transformed observation y_i. The variance is transformed onto the logit scale using the delta-method [13].

5.4 Estimating parameters for national and subnational models using multi-country and single-country datasets

Summaries of the national and subnational-level models can be found in Figure 5.1 and Figure 5.2. A table of parameters and their interpretations can be found in Table 5.1.

5.4.1 Modelling $\alpha_{q,m,s}$ hierarchically with a multi-country dataset

In this approach, we take advantage of the geographic nature of the dataset. We pool data to estimate precise intercepts at higher geographic levels that then go on to inform more granular level intercepts, until we reach our geographic level of interest (national or subnational), where less data is present.

National-level model

At the national-level, the hierarchical distributions to capture the most recently observed DHS level in country c, for method m, supplied by sector s, are given by:

$$\begin{aligned}
\alpha^{country}_{c,m,s} \mid \theta^{subcon.}_{r[c],m,s}, \sigma^2_{\alpha,s} &\sim N\left(\theta^{subcon.}_{r[c],m,s}, \sigma^2_{\alpha,s}\right), \\
\theta^{subcon.}_{r,m,s} \mid \theta^{world}_{w,m,s}, \sigma^2_{\theta,s} &\sim N\left(\theta^{world}_{w,m,s}, \sigma^2_{\theta,s}\right), \\
\theta^{world}_{w,m,s} &\sim N\left(0, 10^2\right), \\
\sigma_{\alpha,s} &\sim Cauchy\,(0,1)_+\,, \\
\sigma_{\theta,s} &\sim Cauchy\,(0,1)_+\,.
\end{aligned} \tag{5.9}$$

Where, the geographic hierarchy begins at the world level $\theta^{world}_{w,m,s}$, which informs the subcontinental intercepts, $\theta^{subcon.}_{r,m,s}$, which in turn inform individual country intercepts, $\alpha^{country}_{c,m,s}$. Vaguely informative Cauchy priors are given to the standard deviation terms of the country- and subcontinental- terms [31]. The standard deviation terms capture the cross-country ($\sigma_{\alpha,s}$) and cross-subcontinent ($\sigma_{\theta,s}$) variation within the data.

Subnational-level model

At the subnational-level, we include an additional layer of geographic intercepts to capture the most recently observed DHS level in subnational province p, for method m,supplied by sector s. While, we use the same notation to explain the hierarchical set up of this approach, the estimates of the country-level and above parameters will be different from the national-level model to the subnational-level model. In the subnational instance, the hierarchical distributions are given by:

$$
\begin{aligned}
\alpha^{prov.}_{p,m,s} \mid \alpha^{country}_{c[p],m,s}, \sigma^2_{\alpha_p,s} &\sim N\left(\alpha^{country}_{c[p],m,s}, \sigma^2_{\alpha_p,s}\right), \\
\alpha^{country}_{c,m,s} \mid \theta^{subcon.}_{r[c],m,s}, \sigma^2_{\alpha_c,s} &\sim N\left(\theta^{subcon.}_{r[c],m,s}, \sigma^2_{\alpha_c,s}\right), \\
\theta^{subcon.}_{r,m,s} \mid \theta^{world}_{w,m,s}, \sigma^2_{\theta,s} &\sim N\left(\theta^{world}_{w,m,s}, \sigma^2_{\theta,s}\right), \\
\theta^{world}_{w,m,s} &\sim N\left(0, 10^2\right), \\
\sigma_{\alpha_p,s} &\sim Cauchy\,(0,1)_+\,, \\
\sigma_{\alpha_c,s} &\sim Cauchy\,(0,1)_+\,, \\
\sigma_{\theta_s} &\sim Cauchy\,(0,1)_+\,.
\end{aligned}
\tag{5.10}
$$

In this instance, we mirror the geographic hierarchy of the national model, and add an additional layer to reflect the province-level intercepts, $\alpha^{prov.}_{p,m,s}$, of the subnational level model, and cross-provincial variation ($\sigma_{\alpha_p,s}$).

5.4.2 Modelling $\alpha_{q,m,s}$ using informative priors with a single-country dataset

In this approach, priors for higher-population level intercept parameters are informed from the multi-country national- or subnational-level models (i.e., the models that used multi-country datasets).

National-level model

$\alpha^{country}_{c,m,s}$ is the national-level intercept for country c, method m and sector s, informed by the posterior median estimates of the subcontinental level model interceptand the associated variance parameter estimated from the multi-country national model, such that

$$
\alpha^{country}_{c,m,s} \mid \hat{\theta}^{subcon.}_{r[c],m,s}, \hat{\sigma}^2_{\alpha_c,s} \sim N\left(\hat{\theta}^{subcon.}_{r[c],m,s}, \hat{\sigma}_{\alpha_c,s}\right), \tag{5.11}
$$

where, $\hat{\theta}^{subcon.}_{r[c],m,s}$ is the posterior median UNSD subcontinental population intercept for region r, method m, sector s, associated with country c estimated from the national-level multi-country model and $\hat{\sigma}^2_{\alpha_c,s}$ is the posterior median of the sector specific cross-country variation associated with the $\alpha_{c,m,s}$ intercept estimated from the national-level multi-country model.

Subnational-level model

$\alpha^{prov.}_{p,m,s}$ is the subnational-level intercept for subnational province p, method m, sector s, informed by the posterior median estimates of the country-level model interceptand the associated variance parameter estimated from the multi-country subnational model, such that

$$\alpha^{prov.}_{p,m,s} \mid \hat{\alpha}^{country}_{c,m,s}, \hat{\sigma}^2_{\alpha_p,s} \sim N\left(\hat{\alpha}^{country}_{c,m,s}, \hat{\sigma}^2_{\alpha_p,s}\right), \tag{5.12}$$

where, $\hat{\alpha}^{country}_{c[p],m,s}$ is the posterior median national-level population intercept for country c, method m, sector s, associated with the subnational province p, estimated from the subnational-level multi-country model and $\hat{\sigma}^2_{\alpha_p,s}$ is the posterior median of the cross-province variation associated with the $\alpha_{p,m,s}$ intercept estimated from the subnational-level multi-country model.

5.4.3 Modelling Σ_{δ_s} using cross-method correlations with a multi-country dataset

In this approach, we decompose the Σ_{δ_s} into its variance and correlation matrices and estimate the components separately. This is a two-model run approach which involves estimating the correlations using a model run with correlations set to 0.

For both the national and subnational models, a multivariate normal prior centred on 0 was assigned to the vector of length M of first-order differences of the spline coefficients, $\delta_{q,1:M,s,h}$, for population q (national or subnational), using all methods supplied by sector s at first-order difference h,

$$\delta_{q,1:M,s,h} \mid \Sigma_{\delta_s} \sim MVN(\mathbf{0}, \Sigma_{\delta_s}), \tag{5.13}$$

where,

$$\Sigma_{\delta_s} = \begin{bmatrix} \sigma^2_{\delta_{1,s}} & \hat{\rho}_{1,2,S}\sigma_{\delta_{1,S}}\sigma_{\delta_{2,s}} & \cdots & \cdots & \hat{\rho}_{1,M,S}\sigma_{\delta_{1,s}}\sigma_{\delta_{M,S}} \\ \hat{\rho}_{2,1,s}\sigma_{\delta_{2,s}}\sigma_{\delta_{1,s}} & \sigma^2_{\delta_{2,s}} & \cdots & \cdots & \hat{\rho}_{2,M,S}\sigma_{\delta_{2,s}}\sigma_{\delta_{M,s}} \\ \cdots & \cdots & \cdots & \cdots & \cdots \\ \cdots & \cdots & \cdots & \cdots & \cdots \\ \hat{\rho}_{M,1,s}\sigma_{\delta_{M,s}}\sigma_{\delta_{M,s}} & \cdots & \cdots & \cdots & \sigma^2_{\delta_{M,s}} \end{bmatrix}. \tag{5.14}$$

The correlation terms of the covariance matrix, $\rho_{i,j,s}$, were estimated using a maximum a posteriori estimator for the correlation matrix as described in Azose and Raftery, 2018 [4]. This approach involves fitting a model where the covariance terms in $\sigma_{\delta_{j,s}}$ are set equal to zero. The national and subnational models deviate in terms of the geographic level that they estimate these correlations at. For the national model, we estimate the correlations based on country-level rates of change, $\delta_{c,1:M,s,h}$, terms. This captures the correlations across all countries. While in the subnational model, we estimate the correlations using provincial-level rates of change, $\delta_{p,1:M,s,h}$. In this instance, the correlations captured are across the subnational provinces of all countries.

National-level model

In the national model, the deviation terms of the Σ_{δ_s} matrix are given vague uniform priors,

$$\sigma_{\delta_{m,s}} \sim Uniform\,(0, 10)\,. \tag{5.15}$$

The 0-covariance model estimates are used to estimate the correlation between methods across time and all countries at the national-level. Specifically, for sector s, the correlation between method i and method j is calculated as follows,

$$\hat{\rho}_{i,j,s} = \frac{\sum_{c=1}^{C}\sum_{h=1}^{K-1}\tilde{\delta}_{c,m[i],s,h}\tilde{\delta}_{c,m[j],s,h}}{\sqrt{\sum_{c=1}^{C}\sum_{h=1}^{K-1}\tilde{\delta}^2_{c,m[i],s,h}}\sqrt{\sum_{c=1}^{C}\sum_{h=1}^{K-1}\tilde{\delta}^2_{c,m[j],s,h}}}, \tag{5.16}$$

Where, $\tilde{\delta}_{c,m[j],s,h}$ are the estimated first order differences of the spline coefficients for country c, method m, sector s, at the h-th difference between spline coefficients. They are given by the posterior medians of $\delta_{c,m,s,h}$ from the zero-covariance run, after subsetting the period considered to periods with data within a country. C represents the total number of countries involved in the study. K is the number of knots in the basis functions. h represents the number of differences (h=K-1) between the spline coefficients.

Subnational model

In the subnational model, the deviation terms of the Σ_{δ_s} matrix are given vague Cauchy priors. This prior is suggested as a weakly informative prior in the paper titled Prior distributions for variance parameters in hierarchical models by Gelman, Bayesian Analysis (2006) [31].

$$\sigma_{\delta_{m,s}} \sim Cauchy\,(0, 1)_{+}\,. \tag{5.17}$$

The 0-covariance model estimates are used to estimate the strength of the correlations between methods across time and all provinces in all countries at the subnational-level. Specifically, for sector s, the correlation between method i and method j is calculated as follows,

$$\hat{\rho}_{i,j,s} = \frac{\sum_{p=1}^{P}\sum_{h=1}^{K-1}\tilde{\delta}_{p,m[i],s,h}\tilde{\delta}_{p,m[j],s,h}}{\sqrt{\sum_{p=1}^{P}\sum_{h=1}^{K-1}\tilde{\delta}^2_{p,m[i],s,h}}\sqrt{\sum_{p=1}^{P}\sum_{h=1}^{K-1}\tilde{\delta}^2_{p,m[j],s,h}}}, \tag{5.18}$$

Where, $\tilde{\delta}_{p,m[j],s,h}$ are the estimated first order differences of the spline coefficients for province p, method m, sector s, at the h-th difference between spline coefficients. They are given by the posterior medians of $\delta_{p,m,s,h}$ from the zero-covariance run, after subsetting the period considered to periods with data within each province. P represents the total number of subnational provinces across all countries involved in the study. K is the number of knots in the basis functions. h represents the number of differences (h=K-1) between the spline coefficients.

5.4.4 Modelling Σ_{δ_s} using informative priors with a single-country dataset

For estimation of the method supply shares using a single-country national or subnational dataset, we set Σ_{δ_s} as the median estimate of the MxM variance-covariance matrix from the corresponding (national or subnational) multi-country model, $\Sigma_{\delta_s}^{\mathbf{global}}$ and we estimate the first-order difference spline coefficients using a Multivariate Normal prior centred on zero such that,

$$\delta_{1:M,s,h} \mid \hat{\Sigma}_{\delta_s}^{\mathbf{global}} \sim MVN(\mathbf{0}, \hat{\Sigma}_{\delta_s}^{\mathbf{global}}). \tag{5.19}$$

Model Parameter	Interpretation
$\phi_{q,t,m,s}$	The proportion supplied by sector s, of modern contraceptive method m, at time t, in population q (national or subnational).
$\psi_{q,t,m,s}$	The latent variable used to model $\phi_{q,t,m,s}$ on the logit scale
$\beta_{q,m,s,k}$	The k^{th} spline coefficient for sector s, method m in population q
$B_{q,k}(t)$	The set of basis functions for population q, evaluated at knot k for time t.
$\alpha^{pop.}_{q,m,s}$	The most recently observed supply share on the logit scale for sector s , method m, in population q. This proxies as an intercept in the model.
$\delta_{q,m,s,k-1}$	The first order difference between spline coefficients $\beta_{q,m,s,K}$ and $\beta_{q,m,s,K-1}$
Σ_{δ_s}	Variance-covariance matrix used in the MVN prior of $\delta_{q,1:M,s,h}$
$\sigma_{X,s}$	Standard deviation terms relating to the intercept parameter X for sector s. X may be at the provincial-, country-, or subcontinental-level.
$\rho_{i,j,s}$	Correlation between the rates of change in supply shares for method[i] and method[j] in sector s.

Table 5.1: A table of parameters names and their interpretations across the national and subnational models. The indexing refers to sector s, of modern contraceptive method m, at time t, in population q (national or subnational).



Figure 5.1: Schematic linking the multi-country and single-country national-level modelling approaches.



Figure 5.2: Schematic linking the multi-country and single-country subnational-level modelling approaches.

6

Appendix C: Validation of the subnational Bayesian hierarchical penalised splines model for estimating and projecting contraceptive method supply shares over time

6.1 Data

Data source

In this study we consider countries involved in the FP2030 initiative. A database of administration-1 level Demographic and Health Survey (DHS) data observations for the supply of modern contraceptive methods by the public and private sectors and their associated standard errors was created using the Integrated Public Use Microdata Series (IPUMS) project, IPUMS-DHS [35]. Like the national-level study (Chapter 2), the modern methods of contraception considered in this study are female sterilisation, oral contraceptive pills (OC pills), implants (including Implanon, Jadelle and Sino-implant), intra-uterine devices (IUD, including Copper- T 380-A IUD and LNG-IUS), and injectables (including Depo Provera (DMPA), Noristerat (NET-En), Lunelle, Sayana Press and other injectables). The variables contained within the IPUMS-DHS database are consistent over time and space. IPUMS-DHS uses integrated geography variables for a country across sample years to address issues with subnational boundaries changing over time and enable comparisons over time. Table 6.1 lists the 23 countries used in this study. The total number of administration level 1 (admin-1) subnational regions, the number of DHS surveys each country has in the database, and the year of the most recent survey in the database is listed for each country. Just under half of the countries included have survey data available after 2015, highlighting the need for annual up-to-date estimates of the contraceptive supply shares.

Country	Number of admin-1 level subnational provinces	Number of IPUMS-DHS surveys	Recent survey year
Benin	6	4	2017
Burkina Faso	13	4	2010
Cameroon	3	3	2004
Congo Democratic Republic	5	2	2013
Cote d'Ivoire	15	3	2011
Ethiopia	10	4	2016
Ghana	8	5	2014
Guinea	3	4	2018
India	27	4	2015
Kenya	8	5	2014
Liberia	5	2	2013
Madagascar	6	4	2008
Malawi	3	5	2016
Mali	4	5	2018
Mozambique	11	3	2011
Nepal	5	5	2016
Niger	6	4	2012
Pakistan	6	4	2017
Rwanda	7	6	2014
Senegal	4	9	2017
Tanzania	6	6	2015
Uganda	4	4	2016
Zimbabwe	10	5	2015

Table 6.1: Summary information regarding the countries considered for subnational modelling. The name, number of subnational administration level 1 (admin-1) regions, the total number of DHS surveys present in the data, and the year of the most recent DHS survey in the data for each country are listed.

Standard error calculation

Like the standard errors of the national-level method supply share model - the standard errors for the subnational method supply share observations were calculated using the 'svyciprop' function from the 'survey' package in R [47]. The same technique, using DHS design factors to impute calculated standard errors when the calculated standard error is 0, used in the national-level modelling approach is applied to the subnational model. A full description of how the standard errors are calculated and the imputation technique used to estimate standard errors can be found in chapter 3, sections 3.1 and 3.2.

Measure	Range (% over all methods)	Median SE size (% over all methods)	Largest mean SE (method, %)		Smallest mean SE (method, %)	
Result	0.0 , 22.0	3.84	OC pills	5.3	Implants	3.6

Table 6.2: Summary table for the calculated standard errors of the IPUMS-DHS subnational-level data observations.

From Table 6.2, the calculated standard errors range from 0 to 22 percentage points. The median standard error size across all method is 3.8 percentage points approximately.

On average, they tend to be largest for OC pills where the mean standard error size is approximately 5 percentage points and smallest in implants where the mean standard error size is approximately 4 percentage points. The calculated standard errors of the subnational IPUMS-DHS data are larger than those calculated using the DHS national-level data (Table 3.1) . At the national level, the median standard error (across all methods) is 2.23%. This is almost half the size of the subnational median. Similarly, at the national-level IUDs have the largest mean standard error (4.10%). This is almost 1% smaller than the 5.3% observed for OC pills at the subnational level.

6.2 Out-of-sample validation results

6.2.1 Multi-country model with cross-method correlations

Sector	**95% coverage (%)**	**Root mean square error (RMSE) (%)**	**Proportion of incorrectly estimated observations located above and below the prediction interval (PI) boundary (%)**		**95% PI width (%)**	**Mean error (%)**	**Median absolute error (%)**
Commercial medical	95.3	15.5	**Above**	2.84	68.4	-2.32	7.25
			Below	1.90			
Other	98.1	6.13	**Above**	1.18	33.3	-0.17	1.0
			Below	0.71			
Public	97.2	15.4	**Above**	0.71	72.2	2.49	7.08
			Below	2.13			

Table 6.3: Out-of-sample validation results for the test set using multi-country subnational model with cross-method correlations. Coverage is the proportion of the test set observations that are captured within the 95% prediction interval (PI) produced by the model. RMSE is root mean square error. The 95% PI width reflects the median PI width for each observation estimated by the model.

The multi-country subnational model described Chapter 5 has been evaluated using various out-of-sample model validation measures to gauge its effectiveness at estimating the method supply shares at a subnational level, while also considering the prediction intervals it uses to produce these estimates. It is performing reasonably well considering the complex nature of the data. It has an overall coverage of approximately 97%. The results for the out-of-sample validation are found in Table 6.3. The target coverage is 95%. The model is reasonably well calibrated to the data with the public sector having 97% coverage and the commercial medical sector having 95% coverage. The private other sector has 98% coverage of the test set. The public and private other sectors have coverage of that test set that is slightly higher than expected. The private commercial medical is showing optimal coverage at 95%. The root mean square error (RMSE) for the private commercial medical sector and the public sector are both at approximately 15 percentage points. The private other sector has an RMSE of approximately 6 percentage points. We also considered where the incorrectly estimated test set observations lie with respect to the prediction interval bounds to assess the bias of the model. In theory, if the model is unbiased and well calibrated then we would expect an equal proportion of incorrectly estimated observations above and below the prediction interval boundaries. Both the commercial medical and other sector has a higher proportion of observations above the prediction interval boundary. This would imply that the model tends to under-estimate the observations in these sectors. In the public sector, there is a higher proportion of incorrectly estimated test set observations below the prediction interval. This implies that for this sector, the model tends to over-estimate the public sector. The median width of the 95% prediction intervals is largest in the public sector at 72 percentage points. The private other sector has the smallest median 95% prediction interval width at 33 percentage points. The mean error for the private commercial medical is approximately -2 percentage points. The mean error for the public sector is the absolute largest of all three sectors at approximately 2.5 percentage points. The private other sector has a mean error of less than 1 percentage point. The median absolute error of the private commercial medical sector is the largest at approximately 7 percentage points while the median absolute error of the private other sector was the smallest at approximately 1 percentage point.

6.2.2 Comparison of the model-based estimates to the direct estimates

In Figure 6.1, we consider the observed standard errors calculated using the IPUMS-DHS microdata versus the corresponding standard deviations of the model-based estimates for the proportions. From this figure, we can see that in the commercial medical and public sectors, the estimated standard deviation terms are smaller than the observed standard error terms calculated using the DHS microdata. For both sectors, we can see that most of the observations have standard errors up to 15 percentage points approximately. These same observations when estimated within the model have corresponding standard deviations of approximately up to 10 percentage points. The use of this model results in a considerable reduction in the uncertainty of these observations. The observed SEs of approximately 3 percentage points correspond to the observations where the standard errors were imputed. The outlier observation at 25 percentage points in both the commercial medical and public sector corresponds to IUDs in Maputo City, Mozambique. IUDs in Maputo only has one observation in 1997, whereas the other methods have more recent survey observations to inform model estimates. The lack of data for IUDs in this instance causes the model estimates to have larger uncertainty.



Figure 6.1: A scatter plot across the three sectors comparing the observed standard errors calculated using the IPUMS-DHS microdata versus the corresponding standard deviations of the model-based estimates for the proportions

In Figure 6.2, we consider the sample size with respect to the ratio of observed to estimated proportions, both of which are on the log scale for clarity. From this figure we see that as the sample size increases, the ratio of observed to estimated data point tends towards 1 after approximately log(5), which corresponds approximately to a sample size of 148. Therefore, the model's ability to capture the observed data point increases as the sample size associated with each observation increases. This aligns with the same property that is seen in many small area estimation models.



Figure 6.2: A scatter plot of the estimates with log of the sample size associated with each of the IPUMS-DHS microdata observations on the x-axis and the log ratio of direct to model-based estimates for the same observations on the y-axis.

6.2.3 Model comparison

Multi-country subnational model with 0-covariance

For the subnational multi-country model, we used a 0-covariance model to validate the use of the cross-method correlations within the estimation of $\delta_{q,1:M,s,h}$, the first-order differences between spline coefficients. This approach is similar to that described in Chapter 3. In this instance, the off-diagonal elements of Σ_{δ_s} are set to 0. The variance-covariance matrix Σ_{δ_s} informs the multi-variate normal prior of $\delta_{q,1:M,s,h}$.

As before, we describe the first-order differences between spline coefficients, $\delta_{q,1:M,s,h}$, using a Multi-variate Normal prior centred on 0 with variance-covariance matrix Σ_{δ_s}.

$$\delta_{q,1:M,s,h} \mid \Sigma_{\delta_s} \sim MVN(\mathbf{0}, \Sigma_{\delta_s}), \tag{6.1}$$

such that, Σ_{δ_s} is a diagonal matrix with 0 on the off-diagonal elements;

$$\Sigma_{\delta_s} = \begin{bmatrix} \sigma^2_{\delta_{1,s}} & 0 & \dots & \dots & 0 \\ 0 & \sigma^2_{\delta_{2,s}} & \dots & \dots & 0 \\ 0 & \dots & \dots & \dots & 0 \\ \dots & \dots & \dots & \dots & \dots \\ 0 & \dots & \dots & \dots & \sigma^2_{\delta_{M,s}} \end{bmatrix}. \tag{6.2}$$

Having 0-covariance between the variance terms of Σ_{δ_s} implies that the rates of change in method supplies act independently of one another. We compare the validation results for this simpler 0-covariance model with the model using cross-method correlations to investigate the impact of including cross-method correlations in the model estimation process.

Sector	**95% coverage (%)**	**Root mean square error (RMSE) (%)**	**Proportion of incorrectly estimated observations located above and below the prediction interval (PI) boundary (%)**		**95% PI width (%)**	**Mean error (%)**	**Median absolute error (%)**
Commercial medical	96.4	17.4	**Above**	2.37	68.9	-3.02	7.35
			Below	1.18			
Other	98.1	6.77	**Above**	1.42	33.4	0.768	0.976
			Below	0.474			
Public	97.9	14.8	**Above**	0.474	72.8	2.30	7.21
			Below	1.66			

Table 6.4: Out-of-sample validation results for the test set using multi-country subnational 0-covariance model. Coverage is the proportion of the test set observations that are captured within the 95% prediction interval (PI) produced by the model. The MAE is the median absolute error. RMSE is root mean square error

The coverage of the 0-covariance model (Table 6.4) is higher than that of the cross-method correlation model (Table 6.3). The 0-covariance model has 98% coverage in both the public and private other sectors. The commercial medical sector has 96% coverage (Table 6.4). The coverage of the model with cross-method correlations is Commercial medical = 95%, Other = 98%, Public = 97% (Table 6.3).

To evaluate the bias and variance produced by the 0-covariance and cross-method correlation models, we consider the mean errors (eq. 3.6), median absolute errors (MAE) (eq. 3.7) and root mean square errors (RMSE) (eq. 3.5). Across all three sectors, the RMSE of the 0-covariance model is larger than the cross-method correlation model. The private commercial medical sector has the largest RMSE with an average error of approximately 17 percentage points(Table 6.4). The RMSE of the private commercial medical sector in the cross-method correlation model is approximately 2 percentage points smaller at 15 percentage points (Table 6.3). In both models, the private other sector has the smallest RMSE. In the 0-covariance model, it is approximately 7 percentage points whereas in the cross-method correlation model it is approximately 6 percentage points. Overall, the cross-method correlation model performs better in this model validation measure than the 0-covariance model. In both models the mean error on the private commercial medical sector is negative (-3.02 percentage points in the 0-covariance model and -2.32 percentage points in the cross-method correlation model) and the mean error of the private other and public sectors are positive. This implies that both models over-predict the test set of the commercial medical sector and under-predict the remaining two sectors. The median absolute errors (MAE) of both models are very similar. Both the 0-covariance and cross-method correlation models see the largest MAE in the private commercial medical sector (7.35 percentage points in the 0-covariance model and 7.25 percentage points in the cross-method correlation model). In both models, the private other sector has an MAE of less than 1 percentage point (0.1 percentage points in the 0-covariance model and 0.1 percentage points in the cross-method correlation model).

When considering the median prediction interval widths, we see that the cross-method correlation model has slightly smaller sized prediction interval widths as compared to the 0-covariance model for the commercial medical and public sectors (68 percentage points and 72 percentage points Table 6.3; 69 percentage points and 73 percentage points Table 6.4). The median prediction interval width of the private other sector is the same in both models at 33 percentage points.

Lastly, when considering the location of the incorrectly estimated test set observations, the cross-method correlation model and 0-covariance models both tend to over-estimate the public sector (as there is higher proportion of incorrectly estimated observations below the prediction interval) and under-estimate the private commercial medical and private other sectors (as there is higher proportion of incorrectly estimated observations above the prediction interval) (Table 6.3) (Table 6.4).

Overall, the multi-country subnational model with cross-method correlations is the most suitable model to describe this complex data. It captures the complex shape and relationships without over-fitting it or missing the shape. It incorporates information regarding the correlations between the rates of change across the contraceptive methods. The coverage, RMSE and median 95% prediction intervals widths produced by the cross-method correlation model are similar but slightly better than those of the 0-covariance model. The strength of the full model is seen in the absence of data for a particular contraceptive method, where model estimates can still be informed by the behaviour of related methods to produce realistic estimates.

6.3 Subnational multi-country model results

The model results produced by the subnational level multi-country model for the 23 countries in the data set can be found in Chapter 9.

6.4 Single-country national and subnational model validation results

We validate the single country models indirectly using the multi-country model estimates. The idea here is that, by comparing the median estimates of the single-country model to the validated multi-country model estimates when can get a gauge of the reliability of our single-country model estimates. If the single-country model estimates align with the multi-country model estimates, then they too are validated.

6.4.1 Single-country national model validation

In Figure 6.3, it is clear that the single-country national model median estimates align approximately with the multi-country national median estimates. Therefore, we can conclude that the single-country national model estimates are as valid and reliable as those estimated by the multi-country national model (for national multi-country model validation results, see Chapter 3). The estimated prediction intervals of the multi-country national and single-country national models are very similar (Figure 6.4). This is indicated by their alignment along the 1:1 line.



Figure 6.3: A scatterplot comparing the median estimates of each country, method, sector, and time point estimated by the single-country model (x-axis) and the multi-country model (y-axis). Each panel represents a different method and each colour represents a country. The diagonal line captures the 1:1 agreement between the two modelling approaches.



Figure 6.4: A scatterplot comparing the predicted prediction intervals of each country, method, sector, and time point estimated by the single-country national model (x-axis) and the multi-country national model (y-axis). Each panel represents a different method and each colour represents a country. The diagonal line captures the 1:1 agreement between the two modelling approaches.

6.4.2 Single-country subnational model validation

In Figure 6.5, we can see that when comparing the single-country estimates to the multi-country estimates, the majority of observations fall inside the ±5% boundary. This means that the estimates and projections produced by both models have a difference of up to ±5%. There are few observations in IUDs that are outliers to this. These belong to Mozambique, where there is only one survey in 1997 taken in the City of Maputo. Therefore, we can conclude that the single-country subnational model median estimates are as valid and reliable as those estimated by the multi-country subnational model (for multi-country subnational model validation results, see Section 6.0.2 Model Summary). The prediction interval widths of the single-country subnational model tend to be similar to the multi-country subnational model for all methods, except implants (Figure 6.6). In the case of implants, the estimated median global variance associated with implants is quite small, resulting in the single country model estimates tending towards the estimated intercept. Over all methods, implants have the fewest number of observations at both the national and subnational level. Again, in IUDs the blue cluster of observations that have a higher estimated prediction interval in the multi-country model are associated with the single observation in the City of Maputo, Mozambique.



Figure 6.5: A scatterplot comparing the median estimates of each country, method, sector, and time point estimated by the single-country subnational model (x-axis) and the multi-country subnational model (y-axis). Each panel represents a different method and each colour represents a country. The outer dashed lines represent the +5% and -5% from complete agreement between the two models. The diagonal solid line capture the 1:1 agreement between the two modelling approaches.



Figure 6.6: A scatterplot comparing the predicted prediction intervals of each country, method, sector, and time point estimated by the single-country subnational model (x-axis) and the multi-country subnational model (y-axis). Each panel represents a different method and each colour represents a country. The diagonal line captures the 1:1 agreement between the two modelling approaches.

7

The inclusion of uncertainty into the estimation process for estimated modern contraceptive use from service statistics data

7.1 Authors

Hannah Comiskey (a), Leontine Alkema (b), Niamh Cahill (a)

(a) Hamilton Institute and Department of Mathematics & Statistics, Maynooth University, Maynooth, Ireland;
(b) School of Public Health & Health Sciences, University of Massachusetts Amherst, Massachusetts, USA

7.2 Abstract

The Family Planning 2030 (FP2030) global initiative strongly advocates for data- and evidence-based decision making within each of the participating countries. Expanding the use of family planning data at the country-level to annually assess family planning indicators, such as the modern contraceptive prevalence rate (mCPR), improves reporting processes, policies, and programs. It also enables countries to better track their progress towards their individual family planning goals. The Family Planning Estimation Model (FPEM) was developed to produce estimates and projections of key family planning indicators, such as mCPR, over time, with uncertainty. However, the large-scale national surveys that are used to inform FPEM estimates are carried out on average every 5 to 6 years, with some countries having even longer gaps between surveys. Consequently, FPEM projections beyond a country's most recent survey have larger uncertainty than data-informed estimates. The irregularity of national survey collection and the importance of regular family planning indicator measurement has created a need for more

readily available annual family planning data to inform FPEM estimates in the absence of larger surveys. Estimated Modern Use (EMU) is a family planning indicator derived from routinely collected family planning service statistics and aims to track mCPR levels. Unfortunately, service statistics are an imperfect data source. They tend to be error-prone and as a result, EMUs tend to have issues with variance and level-bias when compared to estimates of mCPR. In addition, EMUs are only calculated as a point-estimate with no associated uncertainty. In a bid to reduce the issues with level-bias and variance, the EMU calculation process involves adjustments being made to the data. One such adjustment, the private sector adjustment factor, accounts for potentially missing private sector contributions to service statistics data. It relies on the most recent Demographic and Health Survey to provide estimates of the contraceptive supply share market for a given country. In this chapter, we propose an update to the EMU calculation process, whereby we incorporate annual estimates and projections with uncertainty of contraceptive method supply shares, estimated by a Bayesian hierarchical model, into the private sector adjustment factor calculation process. We first describe in detail the mathematics of the EMU calculation process and our proposed update to this process. We highlight how this update can serve to improve the overall accuracy of EMUs with respect to their ability to accurately measure mCPR. An additional benefit of this proposed update is that given the probabilistic nature of the Bayesian model estimates, the associated uncertainty can now be propagated into the EMU calculations. We illustrate these benefits through a case study in two countries, A and B. The names of these countries are withheld for data confidentiality.

7.3 Introduction

FP2030 is a global initiative that is dedicated to advancing the rights of people everywhere to access reproductive health services safely and on their own terms [29]. Evaluating the success of the FP2030 initiative within a country often involves measuring the country's modern contraceptive prevalence rate (mCPR). mCPR is defined as the proportion of women aged 15-49, or their partners, who are using any modern method of contraception [28]. Typically, mCPR is measured using large-scale national surveys such as the Demographic and Health surveys (DHS) or Multiple Indicator Cluster Surveys (MICS). However, due to rigorous collection methodologies associated with these surveys, they are very expensive to carry out and as a result, are only collected approximately every 5 years in most low- and middle-income countries [74]. The United Nations Population Division uses the Family Planning Estimation Model (FPEM) to produce annual estimates with uncertainty for mCPR and other key indicators using these large-scale national surveys [85]. However, in some cases large gaps between survey observations can result in FP indicator estimates that are not data-driven [2].

The irregularity of national survey collection and the importance of regular family planning indicator measurement has created a need for more readily available annual family planning data. Service statistics are a readily available annual data source that is collected as a by-product of carrying out family planning services. The data collected contains information on family planning users, family planning facility visitors, and the numbers of contraceptive commodities distributed to facilities and users. Service statistics have high geographic detail, low collection costs and are frequently reported, making them a desirable data source for family planning programs. However, service statistics are an imperfect data source. Since they are not intentionally planned and designed for directly estimating FP indicators, such as in a national survey, they are susceptible to errors when used to measure indicators of interest. In addition, service statistics can have limited coverage of the private sector's contribution to family planning service delivery. Consequently, they do not have complete coverage of the contraceptive users population. As a result, estimates derived from service statistics have issues with level bias when tracking family planning indicators estimated using national surveys, and tracking mCPR using service statistics is no exception to this issue [49].

Estimated modern use (EMU) is a family planning indicator, derived from service statistics, that measures modern contraceptive use in a given country [79]. EMUs are not a stand-alone family planning indicator, instead they are designed to enable countries to approximate and track changes in mCPR over time and between survey years. Organisations such as the Track20 project (www.track20.org), and researchers committed to monitoring the progression of countries towards their FP2030 goals are now focusing on using EMUs to inform mCPR estimates [79]. The Family Planning Estimation Tool (FPET) is a user-friendly web application for the country-specific implementation of FPEM, and the Track20 project uses FPET to monitor the progress of individual countries. In recent years, EMUs have been integrated into FPET to better inform mCPR estimates in the absence of large-scale national survey data [78] [11] [10]. Specifically, the observed annual changes in EMU level estimates inform changes in FPET estimates of mCPR [10].

To estimate EMUs, the Track20 project has created a tool that converts service statistics to EMUS, called the 'SS-to-EMU Tool' [80]. The 'SS-to-EMU' tool captures service statistics data for 22 contraceptive methods. Namely, sterilization (including female tubal ligation and male vasectomy), intra-uterine devices (including Copper- T 380-A IUD and LNG-IUS), implants (including Implanon, Jadelle and Sino-Implant), injectables (including Depo Provera (DMPA), Noristerat (NET-En), Lunelle, Sayana Press, and other injectables), oral contraceptive (OC) pills (including Combined Oral (COC), Progestin only (POP), and other OC pills), male condoms, female condoms, Lactation amenorrhea method (LAM), standard days method (SDM), vaginal barrier, spermicides and emergency contraception. The primary purpose of the 'SS-to-EMU' tool is to account for some of the issues that can arise when using service statistics to estimate modern contraceptive use, including accounting for missing private sector contributions within the service statistics database, and minimising the level bias of the EMUs when tracking mCPR levels. The 'SS-to-EMU' tool provides the foundation for how EMUs are calculated. The EMU calculation process is discussed in detail in subsequent sections. However, as a brief overview there are three main adjustments made to the service statistics data during the SS-to-EMU process. They are: accounting for long-acting or permanent method (LAPM) users in years after they first receive the LAPM method, accounting for LAPM users who received their methods prior to the first year of service statistics data collection, and scaling up the total number of users of each modern contraceptive method to account for a potentially missing private sector contribution. These adjustments serve to make EMUs a better proxy for mCPR.

While being an innovative use of service statistics, the SS-to-EMU tool approach does have its limitations. Each adjustment in the SS-to-EMU tool makes key assumptions about the data, which all have a significant impact on the resulting EMUs. The current EMU calculation process uses large-scale national surveys observations, such as the DHS, MICS and PMA, to inform adjustment calculations. However currently, the EMU adjustment calculations do not account for, or reflect, the standard errors associated with the survey observations. As a result, EMUs are point estimates with no associated uncertainty. We seek to remedy this issue by propagating uncertainty into the EMU calculation via the private sector adjustment step. Presently, a key assumption in the SS-to-EMU tool is that the annual private sector adjustment being made to service statistics remains constant over time and relies only on the most recently observed DHS observation for contraceptive method supply shares. We propose an update to this approach that utilises probabilistic estimates and projections of the contraceptive method supply shares and allows for the incorporation of annual variation into the adjustment [16]. We will demonstrate how we integrate the model-based estimates and projections of the contraceptive supply share into the existing SS-to-EMU calculations to produce temporally-varying private sector adjustment factors with uncertainty, which then contribute to an uncertainty quantification for EMUs.

7.4 Terminology

Service statistics: Family planning (FP) data that is collected as part of routine FP service delivery. Service statistics are collected by the public and private sectors. Service statistics have varying levels of detail. This may include basic information such as the number of family planning commodities distributed to facilities each year in addition to more detailed information on individual characteristics of FP users [10]. FP service statistics are typically comprised of four data types: contraceptive commodities distributed to FP clients, contraceptive commodities distributed to FP facilities, the number of visits to FP facilities, and the number of FP users.

Demographic and Health Survey: "Nationally representative household surveys that provide data for a wide range of monitoring and impact evaluation indicators in the areas of population, health, and nutrition" [87].

mCPR: Modern contraceptive prevalence rate. Captures the proportion of women aged 15-49 who are currently using any form of modern contraception. mCPR observations are obtained from large-scale surveys.

EMU: Estimated modern use. Aims to capture the proportion of women aged 15-49 who are currently using any form of modern contraception. EMUs are calculated using service statistics and typically provide a biased estimate of mCPR.

LAPM: Long-acting (intrauterine devices (IUDs) and implants), and permanent methods, (female and male sterilization), of modern contraception [20].

STM: Short-term methods of contraception (oral contraceptive (OC) pill, injectables, condoms, other modern methods, and emergency contraception).

Historic users: The number of long-acting and permanent contraception methods supplied to users before service statistics data collection began.

Method continuation rates: The cumulative probability that a user of a given contraceptive method will still be using the method after one unit of time (e.g., annually) [19].

Method mix: The percentage breakdown by method of the distribution of contraception users for each country [21].

Historic user scaling factor: This factor calibrates the number of historic users estimated to account for the introduction history of an LAPM into the method mix of a given country. If a country has newly introduced an LAPM, then there will be no historic users and the scaling factor will address this issue accordingly.

Couple-years protection factor: The average number of years protection provided to a couple by a given contraceptive method.

Family planning commodity: This is the mode of family planning a user receives from either the public or private sector supplier.

7.5 Method for calculating estimated modern use (EMU)

The EMU estimation process can be divided into 4 main steps.

Step 1: Calculate numbers of continuing users captured by service statistics data

Note that this step does not adjust for any users that may have accessed their contraceptives through the private sector, and therefore may be missing from service statistics. This issue will be addressed later. For now, we calculate the total number of users in country c, for method m, in year t, recorded by service statistics data type s.

Short-term contraceptive methods are named so because of their short-term efficacies. For instance, an OC pill user is only covered for the duration of their pill packet (typically 1 month) and no longer. Typically for a given STM, the service statistics data recorded reflects the number of contraceptive commodities distributed, rather than the number of method users. Therefore, we must adjust these STM quantities to reflect the number of users of each method. This is achieved by adjusting $y_{c,m,t,s}$, the quantity recorded in service statistics data type s, in time t, for STM m, and country c, by the couple-years protection factor (CYP), $\frac{1}{i_m}$ (Table 7.1). CYP is the average number of years protection provided to a couple by one unit of a given contraceptive method [91] [76].

Let $\eta_{c,m,t,s}$ represent the estimated number of women in country c, using method m, in year t, captured by service statistics data type s, before adjusting for the private sector. Such that if method m is classified as an STM,

$$\eta_{c,m,t,s} = y_{c,m,t,s} \frac{1}{i_m} \text{ for m } \in \text{ STM methods.} \tag{7.1}$$

Where,
i_m is the number of FP units utilised per person per year for a given method m used across all service statistics data types. i_m is time- and service statistics type invariant (Table 7.1).
$\frac{1}{i_m}$ is the couple-years protection factor, the average number of years protection provided to a couple using method m.

Example 1: Short-term methods
If average woman uses 4 units of Depo Provera (DMPA) injections a year. The CYP factor for DMPA injections is $\frac{1}{4}$. As a result, if 400 units of DMPA injections are distributed in a given year and location, this would imply that there are 100 ($\frac{400}{4}$) users of DMPA injections that year.

Short-term Methods		i_m	Units
Injectable	Depo Provera (DMPA)	4	per user per year
	Noristerat (NET-En)	6	per user per year
	Lunelle	13	per user per year
	Sayana Press	4	per user per year
	Other Injectable	4	per user per year
Pill	Combined Oral (COC)	15	per user per year
	Progestin only (POP)	15	per user per year
	Other OC Pill	15	per user per year
Condom	Male Condom	120	per user per year
	Female Condom	120	per user per year
Other Modern Methods	LAM	4	per user per year
	SDM (Standard Days)	1.5	years of protection
	Vaginal barrier	1	per user per year
	Spermicides	120	per user per year
Emergency contraception	EC	20	per user per year

Table 7.1: The number of units used per person for each short-term contraceptive method. Each short-term method is first named, then broken by the method sub-type, i_m denotes how many units of each FP method is used per person per year, and Units indicates the units of i_m. For short term methods, the units of i_m are the number of FP commodities used per person per year.

Unlike STMS, LAPMs provide multiple years of protection to their users. Consequently, women continue using their LAPM beyond the year they first acquire it. When using service statistics data to estimate total numbers of contraceptive method users, we must account for the women who acquired their LAPM in a given year (recorded in the SS-to-EMU tool) and the women from previous years who are continuing to use their LAPM in subsequent years (not recorded in the service statistics data for a given year). This helps to capture the true number of LAPM users per year more accurately. Therefore, the purpose of this step is to estimate the number of LAPM users in year t. This number includes those users that were recorded for year t, as well as those who continued using their method from previous years $t-1, t-2$..... One issue to overcome with this calculation is estimating historic users, i.e., numbers prior to the first year of data collection. If method m is an LAPM, we include the cumulative contributions of historic users and recorded users, such that,

$$\eta_{c,m,t,s} = \sum_{k=0}^{15} x_{c,m,t-k,s}\alpha_{m,k} \text{ for m} \in \text{LAPM methods, for } t \geq t_0. \tag{7.2}$$

Where, $\eta_{c,m,t,s}$ are the total number of users (historical and recorded) in country c, of method m, in year t, estimated by service statistics type s.
$x_{c,m,t,s}$ is the estimated number of new users in country c, of method m, in year t, estimated by service statistics type s.
$\alpha_{m,t}$ are the method continuation rates over a 16 year time period used across all countries and service statistics data types (Table 7.2).

Method continuation rates represent the average proportion of women that will continue to use a given LAPM each year after receiving the method [19]. For long-acting methods of contraception the set of associated method continuation rates, $\alpha_{m,j}$, tend to decrease over time (Table 7.2). This is because the likelihood of a woman continuing to use a contraceptive method m, j years after first receiving it decreases as j increases from 1 to 16. For permanent methods of contraception, e.g. female and male sterilization, the method continuation rates remain constant at 1 for all j (Table 7.2). This reflects the fact that these methods of contraception are irreversible, and therefore no drop-out will occur. The same set of method continuation rates are used across all service statistics data types (s = 1,2,3,4) and countries (c = 1,....,C).

To illustrate the calculation of historic users, let $x_{c,m,t_0,s}$ represent the number of new users recorded by service statistics data of type s, in the first year of data collection ($t_0 = 0$), for method m, in country c and let $x_{c,m,-j,s}$ be the number of new users in the years prior to $t_0, j = 1, ...16$. $x_{c,m,-j,s}$ is calculated by scaling $x_{c,m,t_0,s}$ by a country-, method-, service statistics type specific scaling factor, $\theta_{c,m,s}$. Such that,

$$x_{c,m,-j,s} = x_{c,m,t_0,s} * \theta_{c,m,s} \tag{7.3}$$

The value of $\theta_{c,m,s}$ is chosen based on 1 of 3 scenarios (Figure 7.1A). Scenario 1 is where where method m has been introduced for the first time into country c, in which case it can be assumed that there are no users of the method back in time and $\theta_{c,m,s} = 0$. Scenario 2 aims to reflect a situation where a method m has been scaling up to the current numbers, $\theta_{c,m,s} = 0.5$ and the users projected back in time are assumed to be half of $x_{c,m,t_0,s}$. Finally, scenario 3 assumes method use is established and constant in country c, in which case $\theta_{c,m,s} = 1$.

Example 2: Long-acting and permanent methods

Figure 7.1 is an example of the LAPM adjustment when an estimated 10,000 users of Copper-T 380-A IUD users are recorded in the first year of data (t_0). In this scenario, we first calculate the number of new users for each of the 15 years prior to t_0 (Figure 7.1A). In Figure 7.1B, we consider the method continuation rates for Copper-T 380-A IUDs. These can be found in Table 7.2. We apply the method continuation rates to the year of service statistics data we are interested in (year t_0) and the previous years t_0-1 to t_0-15. By doing this, we are able to account for the number of continuing users coming from each of the previous years. In Figure 7.1C, we calculate the total number of users in year 0. The total number of users in a given year is the sum of all continuing users from year t_0-15 to year t_0. In this example, we include the continuing historic users from year t_0-15 up to the recorded users in year t_0 to get a final estimate of the total number of Copper-T 380-A IUD users in year t_0. To estimate the total number of users for the next year (t_0+1), we can shift the observation window across the timeline to include the year of interest (year t_0+1) and the previous 15 years (years t_0, t_0-1, t_0-2, ...t_0-14). After the first year of service statistics data, the users continuing from previous years will include a mixture of historic and recorded users.

Example 2 continued: Long-acting and permanent methods



Figure 7.1: This plot shows an example when calculating the total number of Copper-T 380-A IUD users for the first year of service statistics data (t=0). In this example, we assume that $x_{c,IUD,t_0,s}$ is 10000. The users who are recorded in the service statistics are shown in red and the estimated historic users are shown in green. **A**: The number of historic users, not captured in the service statistics data but who received their Copper- T 380-A IUDs in the years previous to Year 0 are first calculated. Each panel shows a different setting of θ. This plot represents the calculation of step 1. **B**: This plot shows the method continuation rates (in %) for Copper- T 380-A IUDs (Table 7.2). The year index t is on the x-axis. The time axis shows the years before the first year of data (t=0). The y-axis captures percentage of women in their t^{th} using Copper-T 380-A IUDs that continue into year t+1. **C**: This plot shows the total number of Copper- T 380-A IUD users in Year 0. These numbers are made up of users recorded in the service statistics (green) and historical users estimated in step 1 (red).

	Year of method acceptance	0 to 1	1 to 2	2 to 3	3 to 4	4 to 5	5 to 6	6 to 7	7 to 8	8 to 9	9 to 10	10 to 11	11 to 12	12 to 13	13 to 14	14 to 15	15 to 16
Sterilization	Tubal Ligation (F)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
	Vasectomy (M)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
IUD	Copper- T 380-A IUD	0.92	0.77	0.65	0.54	0.46	0.38	0.32	0.27	0.23	0.19	0.00	0.00	0.00	0.00	0.00	0.00
	LNG-IUS	0.92	0.77	0.65	0.54	0.46	0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Implant	Implanon	0.94	0.82	0.71	0.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Jadelle	0.94	0.82	0.71	0.62	0.54	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Sino-Implant	0.94	0.82	0.71	0.62	0.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Table 7.2: The long-acting and permanent contraceptive method continuation rates utilised within the EMU calculation. The type, brand, and set of method continuation rates for the first 16 years are listed for each contraceptive method.

Step 2: Scale up the number of users using a private sector adjustment

Often, service statistics data do not capture the complete contraceptive market. They tend to have very high or complete coverage of the public sector, but limited coverage of the private sector. The purpose of this step in the EMU calculation process is to capture the users who access their contraceptives through the private sector but are not recorded by service statistics. Using a private sector adjustment factor, the number of modern contraceptive users estimated using service statistics data must be scaled up to reflect the complete contraceptive market. Let $\lambda_{c,m,t,s}$ represent the proportion of users across the public and private sectors, in country c, using method m, in year t, captured by service statistics data type s. We calculate $\lambda_{c,m,t,s}$ using,

$$\lambda_{c,m,t,s} = \sum_{d=1}^{3} \tau_{c,d,s}\beta_{c,m,t,d}. \tag{7.4}$$

Where, $\tau_{c,d,s}$ is the proportion in country c, of sector d, reporting into the service statistics data type s. The contribution of each sector into the service statistics is quantified using 3 potential ordinal responses (Yes, No and Partially) which are translated into contribution factors (1, 0, 0.5). Therefore, $\tau_{c,d,s} \in (1, 0, 0.5)$.
$\beta_{c,m,t,d}$ is the proportion in country c, of method m, in year t, that is supplied by sector d. The sector supply shares are accessed using Demographic and Health Surveys [87]. The contraceptive supply-share market can be broken down into three main sectors: Public, private commercial medical and private other.

Let $\delta_{c,m,t,s}$ be the inverse of $\lambda_{c,m,t,s}$, and the private sector adjustment factor in country c, for method m, in year t, that is captured by service statistics data type s,

$$\delta_{c,m,t,s} = \frac{1}{\lambda_{c,m,t,s}}. \tag{7.5}$$

Therefore, the number of users after adjusting for the potentially missing private sector contribution is given by,

$$\phi_{c,m,t,s} = \eta_{c,m,t,s}\delta_{c,m,t,s}. \tag{7.6}$$

Where, $\phi_{c,m,t,s}$ is the estimated total number of users after accounting for the private sector adjustment in country c, of method m, in year t, service statistics data type s, across all three supply sectors.

For each sector, this step considers its contribution to the overall contraceptive supply market and it's contribution to the service statistics data records. If a method does not have sector supply share information (for example, in the case of emergency contraception), the best practice approach is to refrain from scaling up the service statistics data for that method [80].

Step 3: Calculate the estimated number of modern users

This step calculates the total number of modern contraceptive users across all methods captured by service statistics type s, in year t. Let,

$$E_{c,t,s} = \sum_{m=1}^{22} \phi_{c,m,t,s}, \tag{7.7}$$

where, $E_{c,t,s}$ is the total number of modern contraceptive users across all 22 modern contraceptive methods, in country c, in year t, captured by service statistics data type s.

Step 4: Calculate the EMU

Estimated modern use (EMU) capture the proportion of women aged 15-49 that are using any modern method of contraception [79]. However, not all countries collect data on modern contraceptive use among unmarried women. Therefore, during the initial stages of service statistics data preparation the user will define what group of women the service statistics reflect. This informs the population estimates used in the denominator of the final EMU. EMUs are the ratio of the estimated number of modern contraceptive users across all methods to the population of (married or all) women aged 15-49 in country c, in year t, captured by service statistics type s.

Let,

$$EMU_{c,t,s} = \frac{E_{c,t,s}}{N_{c,t}^{pop.}}, \tag{7.8}$$

where,

$EMU_{c,t,s}$ is a proportion of all women using modern contraceptives in country c, in year t, captured by service statistics data type s.
$N_{c,t}^{pop.}$ is the population of married women or all women (depending on the service statistics) aged 15-49 in country c, year t. The population estimates are supplied by the United Nations Population Division, World Populations Prospects [84].

7.6 Comparison to existing approaches

In the current approach, the private sector adjustment factor calculation fixes the contraceptive method supply shares, $\beta_{c,m,t,d}$, to be the observed level captured by the most recently observed Demographic and Health Survey (DHS) in year t_{DHS}. This means that both the private sector adjustment factor, $\delta_{c,m,t,s}$, and the proportion of users across the public and private sectors, in country c, using method m, captured by service statistics data type s, $\lambda_{c,m,t,s}$, are now time-invariant. Such that,

$$\lambda_{c,m,s}^{DHS} = \sum_{d=1}^{3} \tau_{c,d,s} \beta_{c,m,t_{DHS}}. \tag{7.9}$$

Therefore, the private sector adjustment is,

$$\delta_{c,m,s}^{DHS} = \frac{1}{\lambda_{c,m,s}^{DHS}}. \tag{7.10}$$

where, $\lambda_{c,m,s}^{DHS}$ is the proportion of all users (according to the most recent DHS survey) across the public and private sectors, in country c, using method m, for all years, captured by service statistics data type s.
t_{DHS} is the year index corresponding to the most recent DHS survey in country c. $\beta_{c,m,t_{DHS},d}$ is the observed proportion of method m, according to the most recent DHS carried out in country c, in the year t_{DHS}, supplied by sector d.

Using the most recently observed method supply shares removes the temporal aspect from the private sector adjustment factor, $\delta_{c,m,s}$. This results the estimated yearly number of women before adjusting for the private sector, $\eta_{c,m,s}$, receiving the same private sector adjustment, $\delta_{c,m,s}^{DHS}$.

The proposed update to the private sector adjustment calculation

We propose that rather than a time-invariant private sector adjustment, we utilise a temporally-varying private sector adjustment. This is calculated using a hierarchically estimated vector of posterior samples of $\beta_{c,m,t,d}$, the proportion in country c, of method m, in year t, that is supplied by sector d. The vector of posterior samples, $\boldsymbol{\beta}^*_{c,t,m,d}$, is 2000 samples of $\beta_{c,m,t,d}$.

Let $\boldsymbol{\lambda}^*_{c,m,t,s}$ be the vector of posterior samples for the temporally-varying private sector adjustment factor in country c, for method m, in year t, captured by service statistics data type s. Then,

$$\boldsymbol{\lambda}^*_{c,m,t,s} = \textstyle\sum_{d=1}^{3} \tau_{c,d,s}\boldsymbol{\beta}^*_{c,t,m,d}, \tag{7.11}$$

where,

$$\boldsymbol{\beta}^*_{c,t,m,d} = \left(\beta^{\{1\}}_{c,t,m,d}, \beta^{\{2\}}_{c,t,m,d}, \ldots, \beta^{\{2000\}}_{c,t,m,d}\right). \tag{7.12}$$

Where, $\beta^{\{i\}}_{c,t,m,d}$ is the i^{th} sample of vector of posterior samples for the estimated proportion in country c, of method m, in year t, that is supplied by sector d.

Therefore, the private sector adjustment becomes,

$$\boldsymbol{\delta}^*_{c,m,t,s} = \frac{1}{\boldsymbol{\lambda}^*_{c,m,t,s}}, \tag{7.13}$$

where,
$\boldsymbol{\delta}^*_{c,m,t,s}$ is the vector of posterior samples for private sector adjustment factor in country c, for method m, in year, t, that is captured by service statistics type s.

Consequently, the subsequent steps of the EMU calculation include a vector of 2000 posterior samples for each observation. This allows us to propagate the uncertainty from the posterior samples of $\boldsymbol{\beta}^*_{c,t,m,d}$ into the final EMU estimates, $\boldsymbol{EMU}^*_{c,t,s}$, such that,

$$\boldsymbol{EMU}^*_{c,t,s} = \frac{\boldsymbol{E}^*_{c,t,s}}{N^{pop.}_{c,t}}, \tag{7.14}$$

where, $\boldsymbol{EMU}^*_{c,t,s}$ is the vector of posterior samples for the estimates of modern contraceptive use in country c, in year t, captured by service statistics data type s. $\boldsymbol{E}^*_{c,t,s}$ is the vector of posterior samples for the total number of all modern contraceptive users in country c, in year t, captured by service statistics data type s.

Figure 7.2 compares the time-invariant private sector adjustment factor to the temporally-varying private sector adjustment factor with uncertainty for a case study in Country A. The time-invariant private sector adjustment factor, δ^{DHS}, is plotted as a solid line over time with no associated uncertainty. The private sector adjustment calculated using hierarchically estimated annual contraceptive method supply shares with uncertainty, $\boldsymbol{\delta}^*$, is denoted by the dashed line and the 95% uncertainty interval is represented by the shaded area. From this figure, we can see that the level of δ^{DHS} is fixed over time as it is only informed by the most recent DHS taken in Country A. In contrast, the level of $\boldsymbol{\delta}^*$ changes over time as it is informed by all DHS taken in Country A.



Figure 7.2: The private sector adjustment is on the y-axis. The estimated median of the temporal-varying private sector adjustment factor, $\boldsymbol{\delta}^*$, is denoted by the dashed line with a 95% credible interval indicated by the shaded area for the private sector adjustment factor in country A, for method m, in year t, captured by service statistics type s. The solid line represents the time-invariant private sector adjustment, δ^{DHS} . Time in years is represented on the x-axis. Each of the colours represents a different contraceptive method. The panels capture the private sector adjustment factor for the different types of service statistics data collected in Country A.

Next, we will proceed to a comparative analysis between the current method of private sector adjustment and our newly proposed approach. We will assess the effects on EMU estimates using two specific case study countries: Country A and Country B. It's important to note that while the data in these case studies is authentic, we have omitted the actual country names to preserve data privacy. In Country A, the service statistics pertain to the commodities distributed to clients. In Country B, the service statistics are also obtained from the commodities distributed to clients.

7.7 Case study: Country A

We consider the supply of female sterilisation, implants, injectables, intra-uterine devices (IUDs) and oral contraceptive pills (OC pills), which inform the private sector adjustment factor used to calculate EMUs from family planning service statistics in Country A. Figure 7.3 considers the contraceptive supply share estimates for Country A between 1990 and 2030. Country A has had 5 DHS surveys since 1990, with the most recent survey occurring in 2016. The public sector has consistently dominated the supply of contraceptive methods since 1990. However from 2001 the supply shares of female sterilization and IUDs from the public sector has gradually declined. Injectables and OC pills also experienced a decline in the public sector supply shares between 2001 and 2011, however in 2016 the public sector supply of these methods increased slightly. Each of the contraceptive methods have varying amounts of survey observations in Country A. The supply shares of OC pills and injectables are recorded in 5 surveys, female sterilisation supply shares are recorded in 4 surveys, IUD supply shares were recorded in 3 surveys, and there is no data available for the supply of implants.

For commodities to clients service statistics data collected in Country A, the model-based estimates of method supply shares inform the temporally-varying private sector adjustment factors, and the most recent DHS collected in 2016 (Figure 7.3) informs temporally-invariant private sector adjustment factors (Figure 7.4). The uncertainty of the method supply share estimates has a direct effect on the uncertainty of the private sector adjustment factor. This is clearly seen in the private adjustment factor of OC pills in commodities to clients , $\boldsymbol{\delta}^*_{\text{pills},t,\text{comm.clients}}$, (Figure 7.4), where the uncertainty mirrors that seen in OC pills commercial medical supply shares, $\boldsymbol{\beta}^*_{\text{pills},t,\text{comm.clients}}$ (Figure 7.3). In addition, the shape of the trajectories in the private sector supply shares are mirrored in the private sector adjustment factors. This is clearly seen in the adjustment for IUDs where the increase between 2001 and 2015 and the plateau from approximately 2016 onward is driven by trends seen in the private sector (commercial medical and private other Figure 7.3).



Figure 7.3: These are the estimated and projected method supply shares for Country A between 1990 and 2030 with uncertainty. These observations are used in the private sector adjustment step of the EMU calculation process. Each of the three sectors (public, private commercial medical and private other) contributions for five contraceptive methods are plotted over time. The vertical bars on the observations represent the standard errors calculated using the DHS microdata. The public sector supply shares are marked in blue. The commercial medical sectors, marked in grey, and other sector, marked in gold, make up the total private sector. The median (50^{th} percentile) estimate is represented by the solid line. The associated 80% and 95% credible intervals are denoted by the shaded areas.



Figure 7.4: The private sector adjustments calculated for commodities to clients service statistics data collected in Country A. The y-axis captures the levels of the private sector adjustment factors, $\boldsymbol{\delta}^*$ and δ^{DHS}, for each method. The estimated median of the temporal-varying private sector adjustment factor, $\boldsymbol{\delta}^*$, is denoted by the dashed line with a 95% credible interval indicated by the shaded area for the private sector adjustment factor in Country A, for method m, in year t. The solid line represents the time-invariant private sector adjustment, δ^{DHS} . Time in years is represented on the x-axis. Each of the colours and panel captures represents a different contraceptive method.

In Figure 7.5, EMUs calculated using a temporally-invariant private sector adjustment and a temporally-varying private sector adjustment applied to commodities to clients service statistics data in Country A are plotted over time. From Figure 7.3 between 2014 and 2020 (the EMU observation period) there is only one available DHS survey observation of the supply share, which is in 2016. During this period, the projected private sector supply shares of female sterilisation, injectables and OC pills experience a gradual decline. As such, the EMUs calculated using the temporally-varying adjustment (we will refer to this as $EMU_{\text{temporal adj.}}$) are systematically lower than the EMUs calculated using a temporally-invariant private sector adjustment factor based on the 2016 DHS (we will refer to this as $EMU_{\text{fixed adj.}}$). The EMUs derived using the temporally-invariant adjustment are an average of 0.5 percentage points higher than the median EMU calculated using a temporally-varying adjustment over time. Despite this small average difference, the 95% credible interval of the $EMU_{\text{temporal adj.}}$ do not overlap with the levels estimated by $EMU_{\text{fixed adj.}}$ until shortly after 2018, implying a significant difference between EMU estimates prior to 2018. The width of the uncertainty interval associated with $EMU_{\text{temporal adj.}}$ increases gradually from 2016 onward. This mirrors the behaviour of the model estimates (Figure 7.3), as the uncertainty associated with the annual method supply share projections increase when the time between DHS surveys increases.



Figure 7.5: Plotting the calculated EMU (in %) over time for Country A. The private sector adjustment each EMU is made with is differentiated by colour. The gold EMUs are calculated using a time-invariant private adjustment factor informed by the most recent 2016 DHS estimate in Country A. The grey EMUs are created using hierarchically estimated annual supply shares with uncertainty. The median (50^{th} percentile) is denoted using the solid grey line and the associated 95% credible intervals marked using lighter shaded grey areas.

Next we compare the $EMU_{\text{fixed adj.}}$ and the $EMU_{\text{temporal adj.}}$ levels with mCPR estimates produced by FPET using survey data inputs. From Figure 7.6, we can see that both sets of EMU estimates are lower than the mCPR estimates from FPET. Like the $EMU_{\text{temporal adj.}}$, the width of the uncertainty associated with the mCPR estimates increases post-2016 due to a lack of survey data. The trends observed in the levels of $EMU_{\text{fixed adj.}}$ and $EMU_{\text{temporal adj.}}$ are very similar to one-another.



Figure 7.6: Plotting EMU and mCPR estimates (in %) over time for Country A. The type of estimate is differentiated by colour. Gold represents EMUs calculated using a temporally-invariant private sector adjustment factor (based on the 2019 DHS). Grey represents EMUs calculated using the temporally-varying adjustment based on modelled estimates, with the median (50^{th} percentile) denoted using the solid grey line and the associated 95% credible intervals marked using lighter shaded grey areas. Blue represents mCPR calculated using the Family Planning Estimation Tool with survey data as an input, with the median (50^{th} percentile) denoted using the solid blue line and the associated 95% credible intervals marked using lighter shaded blue areas.

Presently in FPEM, EMUs are not used to inform the level of mCPR. Rather, the rates of change between EMUs are used to inform rates of change between mCPR estimates [10]. When we evaluate the rates of change for differences between EMUs and mCPR estimates from FPET, we see that the rates of change in the $EMU_{\text{temporal adj.}}$ are slightly lower than the rates of change in the $EMU_{\text{fixed adj.}}$ (Figure 7.7). From 2017 onward, the rates of change with uncertainty from the $EMU_{\text{temporal adj.}}$ cover the rates of change estimated in the mCPR levels. The average rate of change in Country A over time is 0.26 percentage points for mCPR, 0.86 percentage points in $EMU_{\text{temporal adj.}}$, and 0.88 percentage points in $EMU_{\text{fixed adj.}}$. This suggests that, in Country A, using a temporally-varying private sector adjustment factor improves the ability of rates of change in EMUs to track rates of change in mCPR estimates.



Figure 7.7: Plotting the rates of change between consecutive years of EMU and mCPR estimates (in %) over time for Country A. The type of estimate is differentiated by colour. Gold represents EMUs calculated using a temporally-invariant private sector adjustment factor (based on the 2019 DHS). Grey represents EMUs calculated using the temporally-varying adjustment based on modelled estimates, with the median (50^{th} percentile) denoted using the solid grey line. Blue represents mCPR calculated using the Family Planning Estimation Tool with survey data as an input, with the median (50^{th} percentile) denoted using the solid blue line.

7.8 Case study: Country B

The next case study will consider Country B. Figure 7.8 considers contraceptive method supply shares over time with uncertainty for Country B between 1990 and 2030. Country B has collected 4 surveys since 1990, with the most recent DHS collected in 2019. There is no data available for the method supply shares of female sterilisation or IUDs. Similar to Country A, the public sector has dominated the supplies of all five contraceptive methods in Country B, but in recent times there has been an uptake in the proportion of injectables and OC pills being supplied by the private sector. The private sector supply shares of both injectables and OC pills in Country B have been growing since 2016, increasing by approximately 25 percentage points in both methods.

The 2019 DHS survey in Country B observes a higher proportion of OC pills and injectables being supplied by the private sector than in previous years (Figure 7.8). Therefore, when comparing the fixed and temporally-varying private sector adjustment factor over time for Country B, we can see that for both OC pills (pink) and injectables (green) the temporally-invariant private sector adjustment factors (solid line) are significantly higher than the temporally-varying private sector adjustment factor (dashed line) (Figure 7.9). This is due to only 2019 DHS observations informing the temporally-invariant private sector adjustment factor, whereas the temporally-varying private sector adjustment factor changes over time and is informed by all DHS surveys collected in Country B. Due to a lack of data for IUDs and female sterilisation, the fixed private sector cannot be calculated for these methods and therefore it is set to 1. In contrast to this, due to the information-sharing between methods within the Bayesian hierarchical model used to estimate the method supply shares, we are able to gain informed estimates for these methods using the temporally-varying private sector adjustment factor. However, the lack of available survey data is reflected in the large uncertainty associated with the private sector adjustment factors for these methods.



Figure 7.8: These are the estimated method supply shares for Country B between 1990 and 2030. These observations are used in the private sector adjustment step of the EMU calculation process. Each of the three sectors contributions for five contraceptive methods are plotted over time. The vertical bars on the observations represent the standard errors calculated using the DHS microdata. The public sector is marked in blue. The commercial medical sector, marked in grey, and other sector, marked in gold, make up the total private sector.



Figure 7.9: Plotting the fixed and temporally-varying private sector adjustment factor over time for Country B. The solid line represents the private adjustment factor when calculated using the 2019 DHS observation. The dashed line represents the temporally-varying private adjustment factor calculated using the contraceptive method supply share model estimates. The 95% credible intervals are presented using the shaded regions. The colours represent the five contraceptive methods considered in this study. The panels capture the private sector adjustment factor for three different types of service statistics data.

In Figure 7.10, we compare the EMUs calculated using either a temporally-invariant private sector adjustment factor based on the 2019 DHS (as before, we will refer to this as $EMU_{\text{fixed adj.}}$) or temporally-varying adjustment (the $EMU_{\text{temporal adj.}}$) with mCPR estimates produced by FPET using survey data inputs. In Country B, the $EMU_{\text{temporal adj.}}$ is systematically lower than the $EMU_{\text{fixed adj.}}$ by approximately 3 to 5 percentage points over time. This is the private sector adjustment associated with $EMU_{\text{temporal adj.}}$ and is larger than that of $EMU_{\text{temporal adj.}}$ (Figure 7.9), resulting in a larger scale-up of the service statistics data and larger final EMU estimates.



Figure 7.10: Plotting EMU and mCPR estimates (in %) over time for Country B. The type of estimate is differentiated by colour. Gold represents EMUs calculated using a temporally-invariant private sector adjustment factor (based on the 2019 DHS). Grey represents EMUs calculated using the temporally-varying adjustment based on modelled estimates, with the median (50^{th} percentile) denoted using the solid grey line and the associated 95% credible intervals marked using lighter shaded grey areas. Blue represents mCPR calculated using the Family Planning Estimation Tool with survey data as an input, with the median (50^{th} percentile) denoted using the solid blue line and the associated 95% credible intervals marked using lighter shaded blue areas.

For the reasons discussed in the Introduction, EMUs are not used as direct estimates of mCPR within FPEM. Rather, rates of change in EMUs inform rate of change in model estimates of mCPR [10]. Figure 7.11 considers the median estimated rates of change year on year for these EMUs and FPET estimates of mCPR. The rates of change calculated from the $EMU_{\text{fixed adj.}}$ tend to be larger than those calculated using the $EMU_{\text{temporal adj.}}$. While the level of the $EMU_{\text{temporal adj.}}$ is further from the mCPR estimates (Figure 7.10), from this figure we can see that the rates of change of the $EMU_{\text{temporal adj.}}$ are closer to the rates of change in mCPR estimates than the rates of change calculated from the $EMU_{\text{temporal adj.}}$.



Figure 7.11: Plotting the rates of change between consecutive years of EMU and mCPR estimates (in %) over time for Country B. The type of estimate is differentiated by colour. Gold represents EMUs calculated using a temporally-invariant private sector adjustment factor (based on the 2019 DHS). Grey represents EMUs calculated using the temporally-varying adjustment based on modelled estimates, with the median (50^{th} percentile) denoted using the solid grey line. Blue represents mCPR calculated using the Family Planning Estimation Tool with survey data as an input, with the median (50^{th} percentile) denoted using the solid blue line.

7.9 Discussion

This chapter introduces a revised methodology for calculating EMUs within the existing framework. For a considerable period, the field of family planning has heavily relied on comprehensive national surveys like the DHS to gauge progress towards family planning objectives at the country level. Service statistics present an exciting opportunity for the family planning community to access annual data characterized by high geographical granularity, minimal data collection costs, and consistent collection practices. Notably, service statistics are already playing a pivotal role in the Family Planning Estimation Model. Within this framework, they inform the rates of change in mCPR, enabling data-driven estimates and projections that extend beyond the latest available national survey data [10] [11] [2]. Yet, the utilization of service statistics for deriving FP indicators is not devoid of challenges. They can exhibit errors, leading to potential issues related to both bias at the level of FP indicator measurement and variance. Furthermore, service statistics often exhibit gaps in capturing the contribution of the private sector to the contraceptive market within a country [49] [91]. Consequently, the calculation of the family planning indicator EMU involves a sequence of adjustments aimed at mitigating these challenges. One such adjustment is the "private sector adjustment," which scales up service statistics data to account for the potentially underrepresented private sector [80]. Presently, the private sector adjustment draws from the latest DHS survey to estimate the market share of contraceptive supply in a given country [80]. This chapter's core focus revolved around proposing a refined methodology for calculating the private sector adjustment within the EMU calculation process.

Implementing a more dynamic temporally-varying private sector adjustment factor, illustrated in Figure 7.2, enhances the accuracy of EMUs in reflecting shifts in contraceptive supply share markets. Notably, in Country A, the EMU levels computed with the dynamic private sector adjustment factor don't agree with those generated using a fixed factor until after 2018. In Country B there is a notable distinction in the 2019 DHS survey compared to preceding years (Figure 7.8). Here, the private sector supply shares for OC pills and injectables underwent a marked increase, leading to a decline in public sector supplies. This specific case study of Country B underscores that using a recent DHS survey that deviates from established trends can introduce an inflation to the adjustment factor and adjusted service statistics. As depicted in Figure 7.9, anchoring a fixed, time-invariant private sector adjustment factor to the 2019 DHS survey triggers disproportionate scaling of service statistics data predating 2019. Consequently, we deduce that EMUs derived from an unchanging adjustment factor, especially one based on DHS surveys marked by rapid shifts in method supply shares, will consistently differ from

EMUs calculated employing a temporally evolving adjustment factor.

In Countries A and B, we can see that the EMUs produced using a temporally-varying adjustment factor are further from the observed mCPR levels (Figure 7.6 and Figure 7.10). However, currently within FPET, the observed annual changes in EMU level estimates inform changes in FPET estimates of mCPR [10]. When we consider the rates of change between EMU estimates, we see that despite any issues with level-bias, EMUs calculated using a temporally-varying private sector adjustment are closer to the rates of change observed in the mCPR estimates than those calculated from EMUs derived using a single DHS survey (Figure 7.7 and Figure 7.11). In this instance we conclude that in both Country B and Country A, the overall quality of the EMU is improved as it more closely tracks the rates of change in mCPR estimates. The proposed update also has the ability to estimate private sector adjustment factors for methods without any DHS data being available (Figure 7.4, Implants). Previously, this was not possible and private sector adjustment factors were set to 1 for methods without any data. Due to cross-method correlations utilised within the Bayesian hierarchical model producing the annual contraceptive method supply share estimates and projections, methods without any DHS observations may still be informed by DHS observations in other methods to produced data-driven informed estimates even in the absence of survey data.

Finally, EMUs currently calculated using a temporally-invariant private sector adjustment factor are point estimates with no associated uncertainty. In the proposed update, given the probabilistic nature of the method supply share estimates, the associated uncertainty can be propagated into the EMU calculations to quantify a measure of uncertainty associated with each EMU, improving their potential usefulness within larger models such as FPEM.

7.10 Conclusions

In summary, the presented update introduces hierarchically estimated Bayesian model estimates for contraceptive supply share markets across time, along with their associated uncertainties, into the EMU calculation process through the ”private sector adjustment” step. The proposed dynamic private sector adjustment, which varies temporally, allows EMUs to flexibly accommodate shifts in the contraceptive supply shares over the years. Our findings have underscored how this proposed temporal adjustment can enhance the quality of derived EMUs. It achieves this by enhancing precision in tracking rates of change within mCPR estimates and effectively propagating uncertainty. An understanding of the uncertainty enveloping EMUs enhances their value for integration into comprehensive family planning indicator models like the Family Planning Estimation Model. As we look ahead, our future investigations aim to extend the scope of analysis to encompass a broader range of case study countries at the national level. Additionally, we intend to expand upon this proposed update by integrating subnational EMUs into the analysis. This expansion will involve evaluating the influence of subnational method supply variations within the EMU calculation process, focusing on case-study countries at the subnational level.

8
Conclusions

In this thesis, we have introduced a modelling approach for estimating modern contraceptive supply shares at the national and subnational administration level using Demographic and Health Survey data, with an application to the calculation of estimated modern contraceptive use. Quantifying the role of the public and private sectors in the supply of contraceptive methods within countries is vital for effective and sustainable family-planning delivery [8] [55]. However, many low- and middle-income countries quantify contraceptive supply using out-of-date Demographic Health Surveys. Just under half of the countries considered in this thesis have DHS data available at the national or subnational level after 2015. Therefore, a need exists for annual estimates of these method supply shares with uncertainty. They provide key insights into the stability of the family planning market and allow for its critical evaluation.

The applications of method-supply shares are not limited to evaluating family planning market stability and sustainability. Method supply shares also serve a purpose in the calculation of estimated modern use (EMUs), a family planning indicator that is derived from family planning service statistics [79]. Service statistics are a routinely collected data source that is available annually in every country participating in FP2030. They are collected as a by-product of carrying out family planning service delivery, and so have low costs and high geographic detail associated with them [49]. EMUs have been used in the past as a supplemental data source for the Family Planning Estimation Model (FPEM). FPEM is a Bayesian hierarchical model used to produce annual estimates with uncertainty of key family planning indicators [2] [85]. In the absence of data from a large-scale national survey, such as the DHS, EMUs are used to inform trends in modern contraceptive prevalence within FPEM [11]. Therefore, EMUs and the components involved in their derivation, such as the method supply shares, play a pivotal role in evaluating the success of family planning programmes within individual countries, including those that have made commitments to FP2030. In this final chapter, we briefly revisit the multi-country national-level model proposed in Chapter 2, the mcmsupply R package used to disseminate this work in Chapter 4, and the application and impact of using the proposed model estimates to derive EMUs from service statistics in Chapter 7.

In Chapter 2, we proposed a Bayesian hierarchical penalised spline model, with DHS survey input, to estimate the proportion of modern contraceptives supplied by the public and private sectors at the national administration level. Our approach shares information across countries, accounts for survey observational errors and produces probabilistic projections informed by past changes in supply shares, as well as correlations between supply-share changes across different contraceptive methods. The case studies presented consider five countries with varying amounts of DHS data available. They illustrated the strength and flexibility of the modelling approach in its ability to capture the evolving nature of the contraceptive supply share over time. The hierarchical setup of the model and the imposed cross-method correlation structure allows the model to produce informed estimates with uncertainty, even in cases where very limited data are available. We validated our model against simpler modelling alternatives, including a Bayesian hierarchical penalised spline model where the cross-method correlation structures are set to 0 and a Bayesian hierarchical linear model. For full details of these validation results see Chapter 3. The model results of each country in the dataset can be found in Chapter 9. In both instances, the Bayesian hierarchical penalised spline model model described in Chapter 2 outperforms these modelling alternatives. In future work, we would like to focus our analyses on incorporating relevant covariates to try and explain any potential differences in supply shares across countries and within countries over time.

In Chapter 4, we presented the *mcmsupply* R package. This R package is an effective way for us to disseminate our work and encourage the use of our models where estimates of modern contraceptive method supply shares are required. The package implements four types of models. These models vary by the administration level of their estimates (national or subnational estimates) and dataset type utilised in the estimation (multi-country or single-country datasets). Each of the functions contained within *mcmsupply* is presented and explained using examples for each instance of model fitting (national or subnational and multi-country or single-country). The use-case where a user may wish to incorporate custom-data into the estimation process is also presented. Flow diagrams explaining the set of R functions required for each modelling instance, as well as flow diagrams summarising and linking the modelling description of the national models are given to aid the reader in their understanding of the package. A complete mathematical description of each model is given in Chapter 5 and the out-of-sample validation results for the subnational and single-country models are found in Chapter 6. The model results for each subnational province in the data are presented in see Chapter 9. In future work, we hope to extend this R package to include functionality to incorporate the calculation of EMUs from service statistics, using annual estimates of method supply shares with uncertainty estimated by the *mcmsupply* R package to inform the private sector adjustment step (see Chapter 7 for a full explanation of this process). Lastly, we understand that a limitation of this package is the computational speed when running multi-country national and subnational models. These models take many hours of computing to complete and so, are not ecologically friendly. An area of future work in this package concerns the implementation of the JAGS models. The multi-country national and subnational JAGS models have not been optimised. Hence, improvements such as matrix operations rather than for-loops would greatly improve the computation efficiency of this package, making it more energy efficient and minimizing it's environmental impact.

Finally to conclude this thesis, in Chapter 7 we proposed an update to the existing estimated modern use (EMU) derivation, which incorporates national-level annual estimates of the method supply shares into the private-sector adjustment step of the EMU calculation. Using posterior samples for the annual method supply share estimates promotes the propagation of uncertainty into the final EMUs. This chapter presents the mathematical methodology of the EMU calculation process and compares and contrasts the existing approach of using temporally invariant private sector adjustments to the proposed updated approach using temporally-varying private sector adjustments with uncertainty. In this chapter, we evaluate the impact of the proposed update on the resulting EMUs using two case studies in Country A and Country B. In future work, we wish to extend this proposed update to include subnational EMUs and evaluate the impact of the subnational method supply shares within the EMU calculation process in some case-study countries. We remark here that there are other aspects of the EMU calculation process that would greatly benefit from annual estimates with uncertainty derived from Bayesian estimation, such as the estimation of method continuation rates (see section 7.5, Step 1), and so this is another area of future work.

9
Appendix D: Model results

9.1 National multi-country model results

Below are the country estimates produced by the national level multi-country model for the 30 countries we evaluated on.



Figure 9.1: The projections for the proportion of modern contraceptives supplied by each sector in Benin. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.2: The projections for the proportion of modern contraceptives supplied by each sector in Burkina Faso. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.3: The projections for the proportion of modern contraceptives supplied by each sector in Cameroon. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.4: The projections for the proportion of modern contraceptives supplied by each sector in Congo. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.5: The projections for the proportion of modern contraceptives supplied by each sector in Cote d'Ivoire. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.6: The projections for the proportion of modern contraceptives supplied by each sector in Ethiopia. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.7: The projections for the proportion of modern contraceptives supplied by each sector in Ghana. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.8: The projections for the proportion of modern contraceptives supplied by each sector in Guinea. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.9: The projections for the proportion of modern contraceptives supplied by each sector in India. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.10: The projections for the proportion of modern contraceptives supplied by each sector in Kenya. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.11: The projections for the proportion of modern contraceptives supplied by each sector in Liberia. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.12: The projections for the proportion of modern contraceptives supplied by each sector in Madagascar. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.13: The projections for the proportion of modern contraceptives supplied by each sector in Malawi. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.14: The projections for the proportion of modern contraceptives supplied by each sector in Mali. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.15: The projections for the proportion of modern contraceptives supplied by each sector in Myanmar. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.16: The projections for the proportion of modern contraceptives supplied by each sector in Niger. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.17: The projections for the proportion of modern contraceptives supplied by each sector in Nigeria. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.18: The projections for the proportion of modern contraceptives supplied by each sector in Pakistan. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.19: The projections for the proportion of modern contraceptives supplied by each sector in Philippines. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.20: The projections for the proportion of modern contraceptives supplied by each sector in Rwanda. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.21: The projections for the proportion of modern contraceptives supplied by each sector in Senegal. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.22: The projections for the proportion of modern contraceptives supplied by each sector in Sierra Leone. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.23: The projections for the proportion of modern contraceptives supplied by each sector in Tanzania. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.24: The projections for the proportion of modern contraceptives supplied by each sector in Togo. The median estimates are shown by the continuous line with the 95% and credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.



Figure 9.25: The projections for the proportion of modern contraceptives supplied by each sector in Uganda. The median estimates are shown by the continuous line with the 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, grey for commercial medical and gold for other private.

9.2 Subnational multi-country model results

Below, the method supply shares over time with uncertainty are plotted for each subnational province and country included in the subnational multi-country data.



Figure 9.26: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.27: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.28: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.29: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.30: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.31: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.32: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.33: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.34: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.35: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.36: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.37: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.38: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.39: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.40: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.41: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.42: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.43: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.44: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.45: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.46: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.47: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.48: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.49: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.50: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.51: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.52: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.53: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.54: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.55: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.56: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.57: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.58: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.59: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.60: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.61: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.62: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.63: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.64: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.65: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.66: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.67: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.68: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.69: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.70: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.71: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.72: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.73: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.74: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.75: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.76: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.77: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.78: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.79: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.80: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.81: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.82: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.83: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.84: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.85: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.86: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.87: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.88: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.89: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.90: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.91: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.92: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.93: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.94: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.95: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.96: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.97: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.98: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.99: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.100: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.101: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.102: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.103: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.104: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.105: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.106: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.107: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.108: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.109: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.110: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.111: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.112: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.113: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.114: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.115: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.116: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.117: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.118: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.119: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.120: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.121: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.122: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.123: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.124: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.125: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.126: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.127: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.128: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.

Figure 9.129: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.130: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.131: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.132: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.133: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.134: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.135: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.136: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.137: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.138: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.139: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.140: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.141: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.142: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.143: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.144: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.145: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.146: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.147: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.148: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.149: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.150: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.151: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.152: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.153: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.154: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.155: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.156: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.157: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.158: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.159: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.160: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.161: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.162: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.163: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.164: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.165: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.166: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.167: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.168: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.169: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.170: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.171: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.172: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.173: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.174: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.175: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.176: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.177: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.178: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.179: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.180: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.181: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.182: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.183: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.184: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.185: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.186: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.187: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.188: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.189: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.190: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.191: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.192: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.193: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.194: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.195: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.196: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.197: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.



Figure 9.198: The projections for the proportion of modern contraceptives supplied by each sector. The median estimates are shown by the continuous line with the 80% and 95% credible intervals marked by the shaded coloured areas. The DHS data point is signified by a point on the graph with error bars displaying the standard error associated with each observation. The sectors are coloured blue for public, gold for commercial medical and grey for other private sectors.

Bibliography

[1] M. Alexander and L. Alkema. A Bayesian Cohort Component Projection Model to Estimate Women of Reproductive Age at the Subnational Level in Data-Sparse Settings. *Demography*, 59(5):1713–1737, 10 2022.

[2] L. Alkema, V. Kantorova, C. Menozzi, and A. Biddlecom. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: A systematic and comprehensive analysis. *The Lancet*, 381(9878):1642–1652, 2013.

[3] M. Ayad, M. Wilkinson, and M. McNiff. Sources of Contraceptive Methods. *DHS Comparative Studies*, 11, 1994.

[4] J. J. Azose and A. E. Raftery. Estimating large correlation matrices for international migration. *Annals of Applied Statistics*, 12(2):940–970, 2018.

[5] D. A. Binder. On the Variances of Asymptotically Normal Estimators from Complex Surveys. *International Statistical Review / Revue Internationale de Statistique*, 51(3):279, 1983.

[6] J. Bongaarts. The Evolution of Family Planning Programs. *Studies in Family Planning*, 50(4), 12 2019.

[7] T. J. BOSSERT and J. C. BEAUVAIS. Decentralization of health systems in Ghana, Zambia, Uganda and the Philippines: a comparative analysis of decision space. *HEALTH POLICY AND PLANNING*, 17(1):14–31, 2002.

[8] S. E. K. Bradley and T. Shiras. Roles of the public and private sectors in providing contraception and how they can best collaborate to expand contraceptive access and choice. Technical report, Sustaining Health Outcomes through the Private Sector Plus Project, Abt Associates., Rockville, MD, 2020.

[9] J. Bremner, S. Scoggins, Y. Bai, S. Farid, E. Sonneveldt, P. Emmart, and J. Stover. FP2030 Measurement Report 2021. Technical report, FP2030 & United Nations Foundation, 2021. Accessed: 2023-03-30.

[10] N. Cahill, E. Sonneveldt, P. Emmart, J. Williamson, R. Mbu, A. B. F. Yetgang, I. Dambula, G. Azambuja, A. A. M. Govo, B. Joshi, S. Felix, C. Makashaka, V. Ndaruhutse, J. Serucaca, B. Madzima, B. Muzavazi, and L. Alkema. Using family planning service statistics to inform model-based estimates of modern contraceptive prevalence. *PLoS ONE*, 16(10 October):1–14, 2021.

[11] N. Cahill, E. Sonneveldt, J. Stover, M. Weinberger, J. Williamson, C. Wei, W. Brown, and L. Alkema. Modern contraceptive use, unmet need, and demand satisfied among women of reproductive age who are married or in a union in the focus countries of the Family Planning 2020 initiative: a systematic analysis using the Family Planning Estimation Tool. *The Lancet*, 391(10123):870–882, 3 2018.

[12] O. M. Campbell, L. Benova, D. Macleod, C. Goodman, K. Footman, A. L. Pereira, and C. A. Lynch. Who, What, Where: An analysis of private sector family planning provision in 57 low- and middle-income countries. *Tropical Medicine and International Health*, 20(12):1639–1656, 2015.

[13] G. Casella and R. L. Berger. *Statistical Inference*. Duxbury, second edition, 2002.

[14] W. J. Chen and N. Walker. Fertility of HIV-infected women: insights from Demographic and Health Surveys. *Sexually Transmitted Infections*, 86(Suppl_2):ii22, 2010.

[15] C. R. Cisek, K. Klein, S. Koseki, and R. Wood. Strengthening family planning stewardship with a total market approach: Mali, Uganda, and Kenya experiences. *Public Administration and Development*, 39(1):47–56, 2 2019.

[16] H. Comiskey, L. Alkema, and N. Cahill. Estimating the proportion of modern contraceptives supplied by the public and private sectors using a Bayesian hierarchical penalized spline model. *Arxiv*, 12 2023. Accessed: 2022-08-31.

[17] H. Comiskey, L. Alkema, and N. Cahill. Package 'mcmsupply', 2023. Accessed: 2023-08-01.

[18] T. N. Croft, A. M. J. Marshall, and C. K. Allen. Guide to DHS Statistics DHS-7. `https://dhsprogram.com/data/Guide-to-DHS-Statistics/index.cfm`, 2018. Accessed: 2022-08-31.

[19] Data For Impact Project. Contraceptive Continuation rates. `https://www.data4impactproject.org/prh/family-planning/fp/contraceptive-continuation-rates/`. Accessed: 2022-08-31.

[20] Data For Impact Project. Long-Acting and Permanent Methods. `https://www.data4impactproject.org/prh/family-planning/long-acting-permanent-methods/`. Accessed: 2022-08-31.

[21] Data For Impact Project. Method mix. `https://www.data4impactproject.org/prh/family-planning/fp/method-mix/`. Accessed: 2022-08-31.

[22] Data for Impact Project. Source of supply (by method). https://www.data4impactproject.org/prh/family-planning/fp/source-of-supply-by-method/. Accessed: 2023-03-30.

[23] Demographic and H. Surveys. The DHS Program Final Reports. https://www.dhsprogram.com/search/index.cfm?bydoctype=publication&bypubtype=5. Accessed: 2022-08-31.

[24] Department for International Development United Kingdom. Family planning: London summit, 11 july 2012. https://www.gov.uk/government/news/family-planning-london-summit-11-july-2012, Jul 2012. Accessed: 2023-03-30.

[25] T. Q. Dong and J. Wakefield. Space-time smoothing models for subnational measles routine immunization coverage estimation with complex survey data. *https://doi.org/10.1214/21-AOAS1474*, 15(4):1959–1979, 12 2021.

[26] Family Planning 2030. About FP2030. https://fp2030.org/about, Mar 2022. Accessed: 2023-03-30.

[27] R. E. Fay III and R. A. Herriot. Estimates of Income for Small Places: An Application of James-Stein Procedures to Census Data. *Journal of the American Statistical Association*, 74(366):269, 6 1979.

[28] FP2020. Additional Users and mCPR — FP2020 The Way Ahead 2016-2017. http://2016-2017progress.familyplanning2020.org/en/measurement-section/fp2020-and-the-pace-of-progress-core-indicators-1-2-additional-users-and-mcpr, 2017. Accessed: 2022-08-31.

[29] FP2030. Family Planning 2030. https://fp2030.org/about, 2021. Accessed: 2022-08-31.

[30] FP2030. Rights and Empowerment Principles for Family Planning. Technical report, United Nations Foundation, 2021. Accessed: 2021-12-14.

[31] A. Gelman. Prior distributions for variance parameters in hierarchical models(Comment on Article by Browne and Draper). *Bayesian Analysis*, 1(3):515–534, 2006.

[32] A. Gelman, J. B. Carlin, H. S. Stern, D. B. Dunson, A. Vehtari, and D. B. Rubin. *Bayesian Data Analysis*. Chapman and Hall/CRC, 2015.

[33] G. Guranich, N. Cahill, and L. Alkema. Fpemlocal: Estimating family planning indicators in R for a single population of interest. *Gates Open Research*, 5, 2021.

[34] F. Harrell. *Cubic Spline Functions*, chapter 2, page 23–28. Springer, 2016.

[35] E. Heger Boyle, M. King, and M. Sobek. IPUMS-Demographic and Health Surveys: Version 9 [dataset], 2022.

[36] Z. W. Htay, J. Kiriya, J. L. Sakamoto, and M. Jimba. Association Between Women's Empowerment and Unmet Family Planning Needs in Low- and Middle-Income Countries in Southeast Asia: A Cross-Sectional Study. *https://doi.org/10.1080/23293691.2023.2174822*, pages 1–16, 2 2023.

[37] D. Hubacher and J. Trussell. A definition of modern contraceptive methods. *Contraception*, 92(5):420–421, 2015.

[38] ICF. The DHS Program STATcompiler. `https://www.statcompiler.com/en/`, 2012. Accessed: 2021-12-14.

[39] M. Jain, M. Chauhan, and B. Talwar. Role of private sector in family planning programme in Rajasthan, India - a rapid assessment. *International Journal of Community Medicine and Public Health*, pages 869–874, 2016.

[40] E. Kennedy, N. Gray, P. Azzopardi, and M. Creati. Adolescent fertility and family planning in East Asia and the Pacific: a review of DHS reports. *Reproductive health*, 8(1):11, 5 2011.

[41] V. Knutson, S. Aleshin-Guendel, A. Karlinsky, W. Msemburi, and J. Wakefield. Estimating global and country-specific excess mortality during the Covid-19 pandemic. *Annals of Applied Statistics*, 17(2):1353–1374, 6 2023. Accessed: 2022-08-31.

[42] P. Lavrakas. Taylor Series Linearization (TSL). *Encyclopedia of Survey Research Methods*, 2013.

[43] D. Lee. A comparison of conditional autoregressive models used in Bayesian disease mapping. *Spatial and Spatio-temporal Epidemiology*, 2:79–89, 2011.

[44] Q. Li, T. A. Louis, L. Liu, C. Wang, and A. O. Tsui. Subnational estimation of modern contraceptive prevalence in five sub-Saharan African countries: A Bayesian hierarchical approach. *BMC Public Health*, 19(1), 2019.

[45] D. A. Linzer and J. B. Lewis. Journal of Statistical Software poLCA: An R Package for Polytomous Variable Latent Class Analysis.

[46] F. Liu, M. J. Bayarriy, and J. O. Berger. Modularization in Bayesian analysis, with emphasis on analysis of computer models. *Bayesian Analysis*, 4(1):119–150, 2009.

[47] T. Lumley. Package 'survey' Title Analysis of Complex Survey Samples. Technical report, CRAN, 2021. Accessed: 2023-03-30.

[48] D. Lunn, N. Best, D. Spiegelhalter, G. Graham, and B. Neuenschwander. Combining MCMC with 'sequential' PKPD modelling. *Journal of pharmacokinetics and pharmacodynamics*, 36(1):19–38, 2 2009.

[49] R. J. Magnani, J. Ross, J. Williamson, and M. Weinberger. Can family planning service statistics be used to track population-level outcomes? *Global Health Science and Practice*, 6(1):93–102, 3 2018.

[50] Y. Marhuenda, I. Molina, and D. Morales. Small area estimation with spatio-temporal Fay-Herriot models. *Computational Statistics and Data Analysis*, 58(1):308–325, 2 2013.

[51] MEASURE DHS & ICF International. Sampling and Household Listing Manual, Demographic and Health Surveys Methodology. Technical report, U.S. Agency for International Development (USAID), 2012. Accessed: 2022-08-31.

[52] Measure Evaluation: Family Planning and Reproductive Health Indicators Database. Percent of contraceptives available from the private sector. `https://www.measureevaluation.org/prh/rh{_}indicators/health-systems/ps/percent-of-target-population-using-fp-rh-or-hiv`, jul 2017. Accessed: 2023-03-30.

[53] D. Meekers and R. V. Rossem. Explaining inconsistencies between data on condom use and condom sales. *BMC Health Services Research*, 5:1–14, 1 2005.

[54] L. D. Mercer, F. Lu, and J. L. Proctor. Sub-national levels and trends in contraceptive prevalence, unmet need, and demand for family planning in Nigeria with survey uncertainty. *BMC Public Health*, 19(1), 12 2019.

[55] A. Moazzam. Ensuring contraceptive security through effective supply chains. Technical report, World Health Organization, United Nations Population Fund, 2015. Accessed: 2023-03-30.

[56] M.-F. Munoz and M. Ali. Commitment to FP2030. `https://cdn.who.int/media/docs/default-source/reproductive-health/who-srh-fp2030.pdf?sfvrsn=780d62cb_3`, 2022. Accessed: 2022-08-31.

[57] J. R. New, N. Cahill, J. Stover, Y. P. Gupta, and L. Alkema. Levels and trends in contraceptive prevalence, unmet need, and demand for family planning for 29

states and union territories in India: a modelling study using the Family Planning Estimation Tool. *Lancet Global Health*, 5:350–58, 2017.

[58] I. Park and H. Lee. Design Effects for the Weighted Mean and Total Estimators Under Complex Survey Sampling . *Statistics Canada*, 30(2):183–193, 2004.

[59] M. Plummer. JAGS: A Program for Analysis of Bayesian Graphical Models Using Gibbs Sampling. Technical report, 3^{rd} International Workshop on Distributed Statistical Computing, 2003. Accessed: 2023-03-30.

[60] M. Plummer. Cuts in Bayesian graphical models. *Statistics and Computing*, 25(1):37–43, 1 2015.

[61] M. Plummer, A. Stukalov, and M. Denwood. Package 'rjags'. `https://mcmc-jags.sourceforge.io.`, 2022. Accessed: 2023-03-30.

[62] D. F. I. Project. Source of supply (by method). `https://www.data4impactproject.org/prh/family-planning/fp/source-of-supply-by-method/`, 2023.

[63] G. Ramakrishnan and S. Callahan. Factors Influencing the Private Sector's Contributions to Family Planning Market Growth. Technical report, Sustaining Health Outcomes through the Private Sector Plus Project, 2021.

[64] H. Rue, A. Riebler, S. H. Sørbye, J. B. Illian, D. P. Simpson, and F. K. Lindgren. Bayesian Computing with INLA: A Review. 2017.

[65] M. Salama. Green computing, a contribution to save the environment. `https://www.lancaster.ac.uk/data-science-of-the-natural-environment/blogs/green-computing-a-contribution-to-save-the-environment`, 2020. Accessed: 2022-08-31.

[66] D. Sharrow, L. Hug, D. You, L. Alkema, R. Black, S. Cousens, T. Croft, V. Gaigbe-Togbe, P. Gerland, M. Guillot, K. Hill, B. Masquelier, C. Mathers, J. Pedersen, K. L. Strong, E. Suzuki, J. Wakefield, and N. Walker. Global, regional, and national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation. *Lancet Global Health*, 10:195–206, 2022. Accessed: 2022-08-31.

[67] J. D. Shelton and C. Finkle. Leading with LARCs in Nigeria: The stars are aligned to expand effective family planning services decisively. *Global Health Science and Practice*, 4(2):179–185, 2016.

[68] P. L. Speckman and D. Sun. Fully Bayesian Spline Smoothing and Intrinsic Autoregressive Priors. *Biometrika*, 90(2):289–302, 2003.

[69] SPSS. SPSS Tutorials: Pearson Correlation. https://libguides.library.kent.edu/SPSS/PearsonCorr, 2023. Accessed: 2022-08-31.

[70] Y.-S. Su and M. Yajima. R2jags: Using R to Run 'JAGS', 2021. Accessed: 2022-08-31.

[71] H. Susmann, M. Alexander, and L. Alkema. Temporal Models for Demographic and Global Health Outcomes in Multiple Populations: Introducing a New Framework to Review and Standardise Documentation of Model Assumptions and Facilitate Model Comparison. *International Statistical Review*, 90(3):437–467, 12 2022.

[72] Sustaining Health Outcomes through the Private Sector (SHOPS) Plus. Total Market Approach Compendium . https://shopsplusproject.org/tmacompendium, 2016. Accessed: 2022-08-31.

[73] The BMJ. Correlation and regression. https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression, 2023. Accessed: 2022-08-31.

[74] The DHS Program. The DHS Program - Demographic and Health Survey (DHS). https://dhsprogram.com/methodology/survey-Types/dHs.cfm. Accessed: 2022-08-31.

[75] The Global Health Observatory. Contraceptive prevalence. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/5. Accessed: 2023-03-30.

[76] The RESPOND Project. New Developments in the Calculation and Use of Couple-Years of Protection (CYP) and Their Implications for the Evaluation of Family Planning Programs. Technical report, United States Agency for International Development (USAID), Washington, D.C., 9 2011. Accessed: 2022-08-31.

[77] Track20. Track20: Who we are. https://www.track20.org/pages/about_us/who_we_are/Track20.php. Accessed: 2022-08-31.

[78] Track20. Monitoring Progress in Family Planning The Family Planning Estimation Tool (FPET) How does FPET forecast the future? Technical report, Avenir Health, Glastonbury, Conneticut, 2015. Accessed: 2022-08-31.

[79] Track20. Monitoring Progress in Family Planning Estimated Modern Use (EMU): A New Service Statistics-Based Family Planning Indicator. Technical report, Avenir Health, Glastonbury, Conneticut, 2017. Accessed: 2022-08-31.

[80] Track20. SS to EMU Tool: Process Guide SS to EMU Process Guide. Technical report, Avenir Health, Glastonbury, Conneticut, 2017. Accessed: 2022-08-31.

[81] M. D. Ugarte, T. Goicoa, and A. F. Militino. Spatio-temporal modeling of mortality risks using penalized splines. *Environmetrics*, 21(3-4):270–289, 5 2010.

[82] M. D. Ugarte, T. Goicoa, A. F. Militino, and M. Durbán. Spline smoothing in small area trend estimation and forecasting. *Computational Statistics and Data Analysis*, 53:3616–3629, 2009.

[83] J. I. Ugaz, M. Chatterji, J. N. Gribble, and S. Mitchell. Regional trends in the use of short-acting and long-acting contraception accessed through the private and public sectors. *International Journal of Gynecology and Obstetrics*, 130:E3–E7, 2015.

[84] United Nations Department of Economic and Social Affairs. World Population Prospects 2022, Online Edition. `https://population.un.org/wpp/Download/Standard/Population/`, 2022. Accessed: 2022-08-31.

[85] United Nations Population Division. Making Family Planning Count. `https://www.un.org/development/desa/pd/content/making-family-planning-count`, 2023. Accessed: 2022-08-31.

[86] United Nations Statistics Division. Methodology, Standard country or area codes for statistical use (M49). `https://unstats.un.org/unsd/methodology/m49/overview/`, 2022. Accessed: 2022-08-31.

[87] U.S. Agency for International Development (USAID). The Demographic and Health Surveys (DHS) Program. `https://dhsprogram.com/Methodology/Survey-Process.cfm`, 2022. Accessed: 2023-03-30.

[88] A. Vehtari, A. Gelman, D. Simpson, B. Carpenter, and P.-C. Bürkner. Rank-normalization, folding, and localization: An improved $\hat{R}$ for assessing convergence of mcmc (with discussion). *Bayesian analysis*, 16(2):667–718, 2021.

[89] Z. Wang, M. J. Fix, L. Hug, A. Mishra, D. You, H. Blencowe, J. Wakefield, and L. Alkema. Estimating the stillbirth rate for 195 countries using a bayesian sparse regression model with temporal smoothing. *The Annals of Applied Statistics*, 16(4):2101–2121, 2022.

[90] M. Weinberger and S. Callahan. The Private Sector: Key to Achieving Family Planning 2020 Goals. Technical report, Bethesda, MD: Sustaining Health Outcomes through the Private Sector Project, 2017.

[91] M. B. Weinberger, K. Fry, T. Boler, and K. Hopkins. Estimating the contribution of a service delivery organisation to the national modern contraceptive prevalence

rate: Marie Stopes International's Impact 2 model. *BMC Public Health*, 13(SUPPL 2):1–17, 6 2013.

[92] H. Wickham. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York, 2016.

[93] M. D. Wilkinson, M. Dumontier, I. J. Aalbersberg, G. Appleton, M. Axton, A. Baak, N. Blomberg, J. W. Boiten, L. B. da Silva Santos, P. E. Bourne, J. Bouwman, A. J. Brookes, T. Clark, M. Crosas, I. Dillo, O. Dumon, S. Edmunds, C. T. Evelo, R. Finkers, A. Gonzalez-Beltran, A. J. Gray, P. Groth, C. Goble, J. S. Grethe, J. Heringa, P. A. t Hoen, R. Hooft, T. Kuhn, R. Kok, J. Kok, S. J. Lusher, M. E. Martone, A. Mons, A. L. Packer, B. Persson, P. Rocca-Serra, M. Roos, R. van Schaik, S. A. Sansone, E. Schultes, T. Sengstag, T. Slater, G. Strawn, M. A. Swertz, M. Thompson, J. Van Der Lei, E. Van Mulligen, J. Velterop, A. Waagmeester, P. Wittenburg, K. Wolstencroft, J. Zhao, and B. Mons. Comment: The FAIR Guiding Principles for scientific data management and stewardship. *Scientific Data*, 3, 3 2016.

[94] T. Williamson, S. Duvall, A. A. Goldsmith, K. Hardee, and R. Mbuya-Brown. The Effects of Decentalization on Family Planning: A Framework for Analysis. Technical report, Futures Group, Health Policy Project., Washington, DC, 2014.

[95] S. N. Wood. *Smoothers*, chapter 5, pages 204–207. Chapman and Hall/CRC, 2017.

[96] b. Yunhan Wu, Z. Richard Li, B. K. Mayala, H. Wang, P. A. Gao, J. Paige, G.-A. Fuglstad, C. Moe, J. Godwin, R. E. Donohue, B. Janocha, T. N. Croft, and J. Wakefield. Spatial Modeling for Subnational Administrative Level 2 Small-area Estimation. Technical report, U.S. Agency for International Development (USAID), 2021.